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Abstract 
The University of Manchester 
Duncan Matthew Forster 
Doctor of Philosophy (PhD) 
Investigation of a transgenic model of Alzheimer's Disease, the  
TASTPM mouse, using magnetic resonance spectroscopy and  
matrix assisted laser desorption imaging 
2010 
There is currently no definitive biomarker for Alzheimer’s Disease (AD), 
confirmation of diagnosis is only possible post-mortem. Magnetic resonance 
spectroscopy (MRS) has potential in aiding diagnosis, an MRS scan can be 
performed during an MRI scan, only adding around 10 minutes to scan time. 
Use of data from the two scans may allow more accurate diagnosis of AD. This 
thesis investigates a transgenic mouse model of AD, the TASTPM mouse using 
in vitro and in vivo MRS as well as matrix assisted laser desorption ionisation 
mass spectrometry imaging (MALDI MS Imaging). The first aim of the study 
was to search for a biomarker of AD that may allow better diagnosis or further 
our understanding of the pathology of the disease. The second aim was to 
evaluate the TASTPM mouse as a model of AD for use in preclinical testing of 
amyloid lowering agents. The third aim was to investigate a thalamic pathology 
in the TASTPM mice using MALDI MS Imaging. Metabolically, we found 
differences between the brains of TASTPM mice and their wild type base strain 
in both in vitro and in vivo scans. These differences may be exploited in the 
preclinical testing of novel amyloid lowering therapies. We also found 
similarities with human AD and other mouse models, lower N-acetylaspartate, 
lower glutamate and higher myo-inositol are all observed in human AD, as well 
as the TASTPM mice in vivo. We also found further evidence of impaired 
neuronal energy metabolism in TASTPM mice, such as lower succinate. 
Cerebral hypometabolism is a symptom of human AD. The TASTPM mouse 
seems to be a fairly good approximation of the human disease, sharing several 
traits. In our investigation of the thalamic pathology, we discovered a peptide 
which was strongly localised to the regions of the pathology and isolated it, but 
were unable to identify it, the work in this area will continue. 
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Chapter 1. Introduction 
1.1. Aims of Thesis 
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative 
disease associated with β-amyloid (Aβ) neuritic plaques, neurofibrillary tangles 
and neuronal and synaptic degeneration (Selkoe, 2001; Blennow et al., 2006). 
There is a need to develop a biomarker for AD, to aid in drug development, 
treatment monitoring, diagnosis and patient monitoring. An ideal biomarker 
must be easy to measure, non-invasive, related to disease progression and 
specific for AD. There is currently no definitive biomarker for AD. Magnetic 
resonance imaging (MRI) observation of AD patients has found atrophy, 
increasing in severity with disease progression (Frisoni et al., 2010), however 
brain atrophy is not specific to AD. A proton magnetic resonance spectroscopy 
(1H MRS) scan could be performed during the same session as an MRI scan, 
only adding approximately 10 mins to scan time. If a 1H MRS biomarker could 
be found, a more robust diagnosis could potentially be made. Disease 
progression could also be monitored more closely. A metabolic biomarker for 
AD could also be invaluable in treatment monitoring. If the 1H MRS spectrum 
from an AD patient could be normalized by application of a therapeutic agent, 
this could give an early, non-invasive indication of drug efficacy. Our 1H MRS 
work with the transgenic mouse strain TASTPM will be carried out with this in 
mind, specifically to look for a robust biomarker of disease progression in the 
mice that could be exploited during the drug discovery process and possibly 
give us a better understanding of human AD. 
 
Significant age dependent thalamic pathology has been observed in TASTPM 
mice (Evans et al., 2007), any insights gained into this phenomenon may be 
invaluable. The work will complement longitudinal MRI investigations carried 
out by GlaxoSmithKline in collaboration with University of London, as well as 
other pathophysiological studies of TASTPM mice. Hopefully this will give 
further insight into the relevance of amyloid deposition in the pathology of AD. 
The TASTPM mouse has potential as a transgenic model of AD to be used in 
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drug discovery. Again, we aim to identify a specific, robust disease-related 
neurometabolic difference between the TASTPM mouse and its wild type base 
strain, which may allow the model to be validated for testing disease modifying 
therapies. It could then become a valuable tool for evaluating new therapies. 
This could potentially speed up drug discovery in AD research, allowing new 
drugs on to the market faster and improving the standard of care and quality of 
life for AD patients (and their carers) everywhere. 
 
The thalamic pathology observed in the TASTPM (and other) mice is worthy of 
further investigation, due to the presence of observable neurodegeneration, 
and thus a similarity with human AD. Therefore matrix assisted laser desorption 
ionisation (MALDI) Imaging experiments will be initiated on TASTPM brains, to 
look for protein and/or peptide moieties specific to the thalamic lesions and 
attempt to identify any differences observed. Any proteomic information 
gleaned from this process may provide valuable insight into the underlying 
pathology behind the lesion. 
This chapter contains an introduction to Alzheimer’s disease with a description 
of the biochemical and pathological which accompany the disease, followed by 
a review of current and potential therapies. The magnetic resonance methods 
used in the thesis are introduced with a description of the underlying physical 
principles followed by a review of applications in Alzheimer’s disease. The use 
of mouse models to study the disease is reviewed and the strain used in this 
work –the TASTPM mouse – is described. Finally there is a description of an in 
vitro imaging technique (MALDI) which is used to investigate neuropathology in 
the TASTPM model in this thesis. 
 
1.2.1. Alzheimer’s Disease 
AD is the leading cause of dementia among the elderly. It is characterised by 
progressive cognitive decline and memory loss, eventually leading to death. 
Death normally occurs within 7-10 years of the clinical diagnosis of symptoms. 
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As medical science advances, the population in general are living to a more 
advanced age. Consequently, the problem of AD (and other forms of dementia) 
is likely to become much more significant as time goes on, and will ultimately 
lead to huge cost implications for society. Currently, there is no definitive 
biomarker for AD and therefore, examination of biopsy or autopsy tissue is 
currently the only way to ensure a correct diagnosis of AD.    
 
The aim of this introduction is to give an overview of the current understanding 
of AD, current therapies and potential novel drug targets, followed by an 
overview of the use of cerebral 1H MRS, its potential uses in the study of AD 
and the reasons for carrying out the proposed project. 
 
1.2.2. Amyloid β Peptide and the Amyloid Cascade Hypothesis 
There are many hypotheses about the causes underlying the pathogenesis of 
AD. The amyloid cascade hypothesis is currently the most widely accepted of 
these hypotheses. Central to this hypothesis is amyloid precursor protein 
(APP). which is a membrane bound protein residing on chromosome 21 (Kang 
et al., 1987). APP is widely expressed in tissues throughout the body. 
Metabolism of APP is carried out by the secretase enzymes, α, β and γ. The 
amyloidogenic pathway is mediated by β and γ-secretases, whereas the non-
amyloidogenic pathway involves α and γ-secretases (Blennow et al., 2006). α-
Secretase activity is mediated by a disintegrin and metalloprotese (ADAM), the 
main form is ADAM-10 (Lammich et al., 1999).  The enzyme responsible for β-
secretase activity is β-site APP cleaving enzyme (BACE) (Vassar et al., 1999). 
γ-Secretase activity is mediated by a membrane bound protein complex 
comprised of presenilin, nicastrin, Aph-1 and Pen-2, in which presenilin is 
thought to form the active site (Kimberly et al., 2003; Chyung et al., 2005). 
Firstly cleavage by α or β-secretase occurs, releasing the majority of the 
extracellular domain of APP in soluble form as α-APP or β-APP  (Newman et 
al., 2006). The remainder of the protein is then cleaved by γ-secretase. In the 
non-amyloidogenic pathway p3 peptide is released. In the amyloidogenic 
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pathway amyloid β (Aβ) protein is released (Fig.1). The most common forms of 
the protein are 40 and 42 amino acid residues in length (Aβ40 and Aβ42), of the 
two Aβ42 appears to accumulate more rapidly into amyloid plaques (Jarrett et 
al., 1993). The Aβ42 protein is widely thought to be central to the pathology of 
AD, mainly as familial mutations leading to early onset AD almost invariably 
increase prevalence of Aβ42 in the CNS (see below for more detail and 
references). 
 
Fig.1 Diagram representing the cleavage of APP, first by either α- or β-
secretase, release of the resulting extracellular domain, then further cleavage 
by γ-secretase, releasing either P3 or Aβ, depending upon whether initial 
cleavage was by α- or β-secretase (diagram sourced from http://www1.tu-
darmstadt.de/fb/ch/Fachgebiete/OC/AKSchmidt/Research.htm) 
 
The amyloid cascade hypothesis states that an imbalance in the production and 
degredation/clearance of Aβ in the brain is the initiating event in a cascade 
ultimately leading to neuronal degeneration, dementia and death (Hardy and 
Selkoe, 2002). This hypothesis is supported by the fact that causal mutations in 
familial AD are located on the genes for APP (Goate et al., 1991) and the 
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presenilin genes (part of the γ-secretase complex)(Esler et al., 2000). When Aβ 
builds up it is thought to undergo a conformational change to high β-sheet 
content, leading to aggregation initially as soluble oligomers, then larger, 
insoluble fibrils and plaques (Blennow et al., 2006). The Aβ plaques were 
initially thought to be the cause of the neurotoxicity, but a study (Dahlgren et al., 
2002) suggested that soluble Aβ oligomers might be to blame, since oligomeric 
species were shown to inhibit neuronal viability to a much greater degree than 
fibrillar species. Other studies have suggested that oligomers interfere with 
hippocampal long term potentiation (memory) and synaptic plasticity (Walsh 
and Selkoe, 2004). 
 
Aβ clearance is mediated by both enzymatic degradation and a balance 
between efflux and influx to and from the CNS (Blennow et al., 2006). Some of 
the enzymes responsible for Aβ degradation are neprilysin (NEP), insulin-
degrading enzyme (IDE), endothelin-converting enzyme (ECE 1 and 2) and 
plasmin (Ledesma et al., 2000; Eckman and Eckman, 2005). Plasmin levels 
have been found to be reduced in the brains of AD patients, especially in the 
hippocampus (Ledesma et al., 2000). NEP levels have been found to decrease 
with age in both normal subjects and AD patients (Hellstrom-Lindahl et al., 
2006). Membrane bound (but not cytosolic) IDE concentration and activity were 
found to be significantly reduced in the hippocampus of mild (or moderate) 
cognitive impairment (MCI) patients at high risk of developing AD (Zhao et al., 
2007). The IDE levels continued to decrease during conversion from MCI to 
AD, the occipital cortex was also examined but no such effect was seen (Zhao 
et al., 2007). ECE 2 gene expression was found to be significantly 
downregulated in AD patients (Weeraratna et al., 2007). Clearance of Aβ from 
the brain by efflux at the blood-brain barrier (BBB) appears to be mediated 
largely by low density lipoprotein (LDL) receptor-related protein-1 (LRP-1) 
(Shibata et al., 2000). 
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1.2.3 The Role of Tau 
Tau is a protein found in neurons which binds to microtubules and assists in 
microtubule assembly and stability (Iqbal et al., 2005). In AD tau becomes 
hyperphosphorylated (Grundke-Iqbal et al., 1986; Kopke et al., 1993), leading 
to sequestration of normal tau and other microtubule-associated proteins by the 
hyperphosphorylated tau (Alonso et al., 1994; Alonso et al., 1997). As a 
consequence microtubules disassemble (Iqbal et al., 1986; Alonso et al., 1997) 
and axonal transport is disrupted, normal neuronal and synaptic function are 
thus compromised, leading to loss of synapses and death of neurons (Iqbal et 
al., 2005). Loss of functional tau may also increase expression of tau protein by 
way of a compensatory mechanism. Hyperphosphorylated tau also polymerises 
by association with normal tau, resulting in the formation of paired helical 
fragments and neurofibrillary tangles (NFT) (Fig.2) (Alonso et al., 1996). These 
formations are not directly toxic to the neuron but as the disease progresses 
they may grow to a size whereupon the affected cell is physically choked to 
death (Iqbal et al., 2005). The end product of both these processes is dementia.  
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Fig.2 Diagram illustrating the hyperphosphorylation of tau protein, microtubule 
depolymerisation and aggregation of phosphorylated tau into paired helical 
fragments, the precursor to neurofibrillary tangles (Diagram sourced from 
http://www.mpasmb-hamburg.mpg.de/mandelkow2/taubilder.htm) 
 
In AD tau levels in the brain are around eightfold higher than in age-matched 
controls, with the increase being in the form of the abnormally phosphorylated 
protein (Khatoon et al., 1992). Whether the hyperphosphorylation of tau and 
subsequent tangle formation are one of the causes of AD or a consequence of 
the disease is not currently known. 
 
An in vitro study using cultured neuronal cells transfected with a mutant tau 
fragment showed that abnormal tau aggregation was cytotoxic, a toxicity that 
could be prevented by inhibition of aggregation or by proteolysis (Wang et al., 
2007).  
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A possible link between tau hyperphosphorylation and reduced glucose 
metabolism has been postulated. O-glycosylation, a process regulated by 
glucose metabolism, has been shown to correlate negatively with tau 
hyperphosphorylation. A four-fold decrease in O-glycosylation was observed 
when compared to non-hyperphosphorylated tau (Liu et al., 2009).  
 
 
1.2.4. Symptoms and Disease Progression 
AD is a slowly progressive disease characterised by increasing impairment of 
episodic memory with instrumental signs including aphasia, apraxia and 
agnosia (Blennow et al., 2006). Other general cognitive symptoms also 
manifest themselves, such as impaired judgement, orientation and decision 
making (Blennow et al., 2006). The initial neurodegenerative changes occur in 
the medial temporal lobe, with the entorhinal cortex and hippocampus among 
the first areas affected (Braak et al., 1999). 
 
The underlying pathology and neurodegeneration behind AD has been 
estimated to begin between 20 and 30 years before symptoms allow clinical 
diagnosis (Blennow et al., 2006). In this phase, it is thought that plaque and 
tangle load increase to a certain threshold level where symptoms start to 
appear. The initial observable phase of AD is often described as mild cognitive 
impairment (MCI). 
 
MCI is a term used to describe subclinical complaints of memory impairment in 
the elderly. There is thought to be a high risk of patients with MCI progressing 
to AD (Ritchie and Touchon, 2000). MCI can be seen as a precursor for 
dementia, however some people with MCI may remain stable for many years or 
even return to normal over time (Gauthier et al., 2006). Amnestic (memory 
impaired) MCI is thought to be a potential intermediate stage between normal 
aging and AD (Gauthier et al., 2006). Pathologically speaking it may in many 
cases just be the early stages of AD where symptoms start to become 
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detectable. A study found that approximately 12% of patients with MCI 
progressed to clinical dementia each year (Petersen, 2004).  
 
There is considerable research currently ongoing into potential neural 
compensatory mechanisms which allow pre-clinical AD patients to remain 
cognitively normal while much of the neurodegeneration leading to AD takes 
place (Smith et al., 2007). Potential compensatory mechanisms include 
upregulation of neurotransmitters such as Ach, use of redundant memory 
systems and recruitment of other neural networks as ones in current use are 
damaged (Smith et al., 2007). In a recent study using positron emission 
tomography (PET) 5-HT1A receptor binding was found to be significantly higher 
in patients with MCI compared with controls, whereas AD patients had 
significantly lower receptor binding (Truchot et al., 2007). This provides further 
evidence of potential compensatory mechanisms prior to the onset of clinically 
detectable AD. 
 
 
1.2.5. Familial Predisposition 
Familial AD (FAD) is caused by mutations in the genes coding for APP and 
presenilin 1 and 2 (PS1 and PS2). The known APP mutations (chromosome 
21) are all located either immediately before the β-secretase cleavage site, 
after the α-secretase cleavage site or on the C-terminal side of the γ-secretase 
site (Selkoe, 2001). In APP mutations have increased overall Aβ production or 
increased Aβ42:Aβ40 ratio as a consequence (Selkoe, 1994). Onset of 
symptoms with the APP mutation can be as early as age 50 (Selkoe, 2001). 
The PS mutations – PS1 (chromosome 14q) and PS2 (chromosome 1) seem to 
selectively increase the ratio of Aβ42:Aβ40 (Scheuner et al., 1996), while some 
seem to reduce Aβ40 production along with other PS-dependent actions (Shen 
and Kelleher, 2007). New evidence is emerging that most PS mutations result 
in an overall loss of function and a reduction in overall Aβ production (loss of 
function), but somehow favour release of Aβ42 over Aβ40 (gain of function) 
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(Wolfe, 2007). In PS mutation FAD symptoms may manifest as early as in the 
patients 30’s (Selkoe, 2001).  
 
The apolipoprotein E4 (ApoE4) ε4 allele is a genetic risk factor for late onset 
AD (LOAD) (Strittmatter et al., 1993). The frequency of the ε4 allele has been 
found to be significantly greater in LOAD patients compared with age matched 
controls (Strittmatter et al., 1993). ApoE4 has been shown to be a ligand for 
LRP-1 and may affect Aβ clearance across the BBB, according to a study done 
in transgenic mice (Shibata et al., 2000). 
 
Another genetic candidate linked with increased risk of LOAD is sortilin-related 
receptor, also known as LR11 or SORLA (SORL1). Six single nucleotide 
polymorphisms in SORL1 have been linked with LOAD in well-defined samples 
from different populations (Katzov, 2007). In younger patients with AD, plaque 
and tangle load are strongly correlated with dementia severity, whereas with 
increasing age this correlation disappears (Prohovnik et al., 2006), which could 
be of clinical significance.  
 
1.2.6. Brain Hypometabolism 
Cognitive decline and AD have been linked with metabolic deficiencies in the 
brain. PET studies have found reduced cerebral glucose metabolism in AD 
patients, in areas central to AD, such as the posterior cingulate (Herholz et al., 
2007). A multicentre PET study found that monitoring regional cerebral glucose 
metabolism allowed differentiation between AD and other dementias, as well as 
MCI (Mosconi et al., 2008). A PET study showed that ApoE4 ε4 allele carriers 
had reduced glucose metabolism in the lateral temporal lobe (LTL) and the 
superior temporal gyrus compared with non-carriers (de Leon et al., 2001). 
Glucose metabolism in the LTL was also found to decline faster over time in ε4 
carriers than in non-carriers (de Leon et al., 2001). Anomalies in glucose 
metabolism have been observed in patients with MCI, with reductions in areas 
such as the hippocampus and middle temporal cortex (Drzezga et al., 2003). 
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The severity of these reductions has been found to correlate with progression 
from MCI to AD over the course of a year (Drzezga et al., 2003).  
 
The posterior cingulate cortex in AD patients has been shown to have reduced 
cytochrome oxidase (CO) activity (Valla et al., 2001), CO is a mitochondrial 
enzyme essential for aerobic energy metabolism. This reduction appears to be 
progressive, greater in women and linked to disease duration (Valla et al., 
2001).  
 
Two mitochondrial markers, CO-1 and lipoic acid were increased in the 
neuronal cytoplasm of AD patients compared with controls, lipoic acid was also 
found in autophagic vacuoles and lipofuscin of neurons in AD patients (Moreira 
et al., 2007). These data suggest that mitochondria undergo increased 
autophagic degredation in AD sufferers. This may be due to either increased 
turnover or mitochondrial numbers within neurons may be reduced, leading to 
reduced respiration and cellular dysfunction.  
 
A recent study has shown expression of subunits of the mitochondrial electron 
transport chain to be significantly lower in the posterior cingulate cortex, 
hippocampus and entorhinal cortex in AD patients, compared with controls 
(Liang et al., 2008). These regions are some of the first affected by AD, these 
differences may be a causal factor in the reduced glucose metabolism seen in 
AD. 
 
Reproducible defects have been observed in mitochondria from the brains of 
AD sufferers, with deficiencies in two enzymes of the tricarboxylic acid cycle – 
pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (Gibson et al., 
1998) and in CO (Cottrell et al., 2001). Mitochondrial function is reliant upon 
structural integrity and there is considerable evidence of mitochondrial damage 
in AD (Zhu et al., 2004; Moreira et al., 2007). Damaged mitochondria are less 
able to utilise oxygen in the respiratory process and thus produce more reactive 
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oxygen species (ROS), leading to oxidative damage (see next section) (Zhu et 
al., 2007).  
 
There is thus strong evidence linking defects in energy metabolism with 
symptoms of AD. 
 
Glucose hypometabolism has also been observed in a transgenic mouse model 
of AD, which has been shown to be independent of amyloid deposition and to 
correlate with memory impairment (Dodart et al., 1999).  
 
Reduced cerebral energy usage may well be a factor in causing the symptoms 
of AD, it may also contribute to, or be a symptom of both neuronal dysfunction 
and eventual neuronal death. This is discussed later in the context of the 
findings presented in this thesis. 
 
1.2.7. Oxidative Stress and Inflammation 
Oxidative stress has long been thought to play a role in AD neurodegeneration. 
This is borne out by evidence of elevated protein and lipid oxidation in AD 
brains (Hensley et al., 1995; Lovell et al., 1995), along with evidence of 
decreased antioxidant activity in AD patients (Gsell et al., 1995). There are a 
number of postulated sources of the observed oxidative stress, some of these 
are iron (and other redox-active metals) redox cycling, mitochondrial 
dysfunction and inflammation. Iron has been found to accumulate in both 
amyloid plaques and NFTs, this iron was found to be redox-active (Smith et al., 
1997). Aβ42 has been demonstrated to increase the solubility of iron, allowing it 
to remain in its redox-active form longer and potentially generate more reactive 
oxygen species (ROS) via the Fenton reaction (Khan et al., 2006). Aβ produces 
hydrogen peroxide in vitro via a mechanism which reduces iron or copper 
(Huang et al., 1999). In vitro testing has also shown that the neuronal toxicity of 
Aβ can be attenuated by pre-treatment with an iron chelator and restored by 
incubation with excess free iron (Rottkamp et al., 2001). NFTs have also been 
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shown to produce hydrogen peroxide when in the presence of redox metals 
(iron or copper) (Sayre et al., 2000).  
 
It is postulated that Aβ deposition actually occurs due to oxidative stress and 
this has a protective effect against neuronal damage. In both in vitro and in vivo 
testing oxidative stress has been shown to increase production of APP and Aβ 
by neuronal cells (Yan et al., 1995). Oxidative damage has been demonstrated 
to be greatest in the early stages of AD, increases in Aβ deposition correlating 
with decreases in oxidative damage (Nunomura et al., 2001). Histologically a 
negative correlation has been seen between amyloid burden and oxidation 
levels, it has been postulated that the high levels of zinc within amyloid plaques 
interact with Aβ to give robust antioxidant properties (Cuajungco et al., 2000). 
 
Inflammation in AD is mediated by both microglia (cerebral macrophages) and 
astrocytes (Akiyama et al., 2000a). The activated forms of both cell types have 
been found to be associated with Aβ (Eikelenboom and Veerhuis, 1996; Mrak 
et al., 1996). In vitro Aβ enhances ROS production and release from microglia 
(Klegeris and McGeer, 1997). Microglia are involved in the removal and 
breakdown of Aβ in the brain, however it appears that soluble Aβ is taken up 
and does not cause activation of the microglia, whereas the aggregated form is 
phagocytosed and does result in activation (Akiyama et al., 2000a).  
 
 
 
1.2.8. The Presenilin Hypothesis 
An alternative to the amyloid cascade hypothesis has recently been put 
forward. It proposes that a loss of PS function in AD may be the primary event 
triggering neurodegeneration, for detail on supporting evidence see (Shen and 
Kelleher, 2007). This hypothesis is potentially important as if it is true then 
some of the new potentially disease modifying therapies in development may 
actually worsen the disease rather than having a beneficial effect. 
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1.2.9. Intraneuronal Aβ as a possible risk factor 
Recent studies have suggested an important role of intracellular Aβ in the 
pathogenesis of AD. In an APP/PS1 model (APP/PS1KI), correlation between 
intraneuronal Aβ accumulation and loss of hippocampal CA1 neurons has been 
demonstrated (Casas et al., 2004). No such correlation was seen with 
extracellular Aβ deposits. Reduced short- and long-term synaptic plasticity and 
poor performance in working memory tests were also observed in these mice 
(Bayer et al., 2008). Co-incidence of intracellular Aβ build up and behavioural 
changes has also been shown elsewhere (Knobloch et al., 2007). In various AD 
mouse models, behavioural changes have been seen to occur prior to 
significant Aβ plaque deposition (Bayer and Wirths, 2008). These findings 
indicate the potential for an important role of intracellular Aβ in the 
pathogenesis of AD, possibly as the disease-triggering event. 
 
1.2.10. Other Potential Risk Factors  
Old age and genetic predisposition are the only well researched risk factors for 
AD, however a number of physiological and psychosocial factors may also play 
a role. Vascular and dietary factors such as hypertension, obesity, diabetes 
mellitus, heart disease, cerebrovascular disease, hyperlipidaemia, heavy 
alcohol consumption, cigarette smoking and high saturated fat intake are all 
thought to increase risk of AD (Qiu et al., 2007). In contrast, light to moderate 
alcohol consumption has been associated with a reduction in the risk of 
dementia (Stampfer et al., 2005). High fish intake has also been linked to 
reduced risk of dementia, which is thought to be related to increased plasma 
levels of docosahexaenoic acid (Schaefer et al., 2006). 
 
There is evidence to suggest a poor education increases the risk of developing 
AD (Karp et al., 2004). Longitudinal lifestyle studies have linked social 
disengagement with increased AD risk, whereas subjects with greater 
engagement in mentally and/or physically stimulating activities seemed to be at 
reduced risk of the disease (Fratiglioni et al., 2004).  
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Elevated occupational magnetic field exposure has been associated with an 
increased risk of AD (Davanipour et al., 2007). In this study AD (and suspected 
AD) patients and controls were classified by occupation as having low, medium 
or high magnetic field exposure. High exposure was classified as average 
exposure over 10 milligauss (or regular intermittent exposure over 100 
milligauss). Medium exposure was classified as average exposure between 2 
and 10 milligauss (or regular intermittent exposure over 10 milligauss). The 
study found that subjects with medium or high exposure were 2.1 times as 
likely to have AD, in the high exposure group alone, subjects were found to be 
2.9 times as likely to have AD (Davanipour et al., 2007). 
 
1.3. Current Therapies 
 
1.3.1. Acetylcholinesterase inhibitors 
Due to consistent findings of damage to cholinergic neurons in the basal 
forebrains (associated with memory and attention) of AD sufferers, enhancing 
cholinergic transmission is thought to have potential in alleviating symptoms 
(Terry and Buccafusco, 2003). The acetylcholinesterase inhibitors 
(rivastigmine, donepezil and galantamine) are the drugs of choice for this 
purpose, increasing acetylcholine (Ach) levels by preventing its metabolism in 
the synaptic cleft (Blennow et al., 2006). Modest improvements in cognitive 
symptoms have been observed with these drugs. A mean treatment effect of 
2.7 points on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale 
(ADAS-Cog) and 1.4 points on the mini-mental state exam (MMSE) (Birks, 
2006). Due to their mechanism of action these treatments only temporarily 
alleviate some of the symptoms of AD however, and are not thought to be 
disease modifying. 
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1.3.2 Memantine 
The major excitatory neurotransmitter in the brain is glutamate. Glutamate and 
the N-methyl-D-aspartate (NMDA) receptor are important in the processes of 
learning and memory. In AD increased glutamatergic activity can result in 
sustained low-level NMDA receptor activation, potentially impairing neuronal 
function and leading to excitotoxic effects (Areosa et al., 2005). Memantine is a 
non-competitive antagonist at the NMDA receptor which is thought to reduce 
overstimulation of the receptor caused by abnormally high glutamate levels. 
The intent is to restore normal physiological function and reduce potential for 
excitotoxicity (Wilcock, 2003). Memantine has been shown to have beneficial 
effects in patients with moderate to severe AD (MMSE score <15), however 
there are currently no data to suggest that it will have beneficial effects in mild 
AD (Areosa et al., 2005). Although memantine may be neuroprotective, it is not 
specific for AD and the current trials are too short to assess potential disease 
modifying effects (Areosa et al., 2005). 
 
1.4.1. Potential Novel Therapies 
Due to a better understanding of AD pathology and of the underlying 
processes, a number of potential new therapeutic targets have been developed 
many of which could potentially have disease-modifying activity. In addition, 
based on epidemiological studies, several drugs/chemicals already in use are 
being investigated for any possible clinical benefit. Some of the novel therapies 
being investigated are described below. 
 
1.4.2. Potential Aβ Therapies 
 
1.4.3. Targeting Aβ Production 
All three secretases are potential targets for pharmacological intervention. β-
Secretase knockout mice have been proved to be viable and have reduced Aβ 
production (Cai et al., 2001; Luo et al., 2001). Thus if an inhibitor for β-site 
APP-cleaving enzyme (BACE), the enzyme responsible for β-secretase 
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cleavage of APP (Hussain et al., 1999; Vassar et al., 1999; Yan et al., 1999) 
can be synthesised it could be of great benefit in lowering Aβ and slowing 
amyloid pathology in AD. So far it has proven to be a difficult pharmacological 
target, but it is likely that effective β-secretase inhibitors will be developed 
within a few years (Golde, 2006). Another problem is that β-secretase knockout 
mice while overtly normal, may have a harmful phenotype (Dominguez et al., 
2005). Disruptions in hippocampal synaptic plasticity and in cognitive and 
emotional tests have been reported (Laird et al., 2005). Thus there could be 
problems with long term β-secretase inhibition and it remains to be seen 
whether any inhibitors which are produced are well tolerated. 
 
Inhibitors targeting PS have been developed and have entered into phase I 
clinical trials (Siemers et al., 2005). There are potential problems with these 
compounds too, as γ-secretase doesn’t just cleave APP, it is important in other 
areas such as the notch signalling pathway. Blocking γ-secretase could thus 
have toxic effects due to disruption of notch signalling (De Strooper et al., 
1999). Non-steroidal anti inflammatory drugs (NSAIDs) have potential use in 
selectively modulating γ-secretase action, shifting cleavage away from the Aβ42 
form to shorter peptides (Weggen et al., 2001). A selective Aβ42 lowering agent 
R-flurbiprofen is currently undergoing clinical trials (Black et al., 2006). 
 
Whereas inhibitors of β and γ-secretases are sought, an inducer of α-secretase 
activity could also be of therapeutic benefit. Metalloprotease disintegrins have 
been shown to be responsible for α-secretase cleavage of APP, namely ADAM-
10 and ADAM-17 (Buxbaum et al., 1998; Fahrenholz et al., 2000; Kojro and 
Fahrenholz, 2005). In an APP transgenic mouse model upregulation of α-
secretase activity was found to decrease production of Aβ peptides and 
formation of plaques, as well as alleviating cognitive symptoms (Postina et al., 
2004). ADAM-10 and ADAM-17 are involved in a number of signalling 
pathways and long term upregulation may not be without its side effects.  
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1.4.4. Targeting Aβ Aggregation 
In its soluble, non-aggregated form Aβ is not thought to be toxic (Golde, 2006). 
Which particular species of Aβ is the main contributor to neurotoxicity is 
unknown, but it is quite possible that many different Aβ aggregates interact and 
contribute to overall neurotoxicity (Walsh and Selkoe, 2004). Nevertheless 
preventing Aβ aggregation (and lysing already aggregated formations) is likely 
to have disease modifying effects. A compound which seems to have a 
promising future is curcumin, a component of the curry spice turmeric. 
Curcumin has been shown to inhibit formation of Aβ oligomers and fibrils in 
vitro (Yang et al., 2005). In vivo, curcumin crosses the blood brain barrier, binds 
plaques and reduces amyloid load in a mouse model (Yang et al., 2005). On 
top of this curcumin has anti-inflammatory, cholesterol lowering, antioxidant and 
metal chelating properties, all of which have the potential to be protective 
against AD neuropathology (Ringman et al., 2005).  
 
1.4.5. Enhancing Aβ Clearance 
A number of enzymes are known to be involved in degradation of monomeric 
Aβ, including insulin degrading enzyme (IDE), neprilysin (NEP) and endothelin 
converting enzyme (ECE) (Eckman and Eckman, 2005). Transgenic 
overexpression of IDE and NEP has been shown to lower brain Aβ levels and 
reduce or prevent plaque formation in APP transgenic mice (Leissring et al., 
2003). Due to their mechanism of action, upregulation of these proteases would 
likely be more useful in prevention of AD rather than treatment of the disease 
once it is established.  
 
Increasing efflux of Aβ from the brain through the BBB to the circulation is 
another potential way of lowering brain amyloid burden. One transporter which 
has been studied and is involved in the transport of Aβ across the BBB  is p-
glycoprotein (Lam et al., 2001). There are known pharmacologic activators of 
this protein and these may have therapeutic benefit in prevention or treatment 
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of AD, but more research and proof of concept studies are needed (Golde, 
2006). 
 
1.4.6. Immunotherapy 
A study using APP transgenic mice has revealed that immunisation against 
Aβ42 attenuates Aβ plaque formation in young animals and reduced the extent 
and progression of AD like neuropathologies in older animals where plaque 
build up was already significant (Schenk et al., 1999). The first active 
immunisation trial in humans was stopped due to 6% presentation of patients 
with meningioencephalitis (Nicoll et al., 2003; Orgogozo et al., 2003). This was 
unexpected and whilst the precise mechanism is unknown, one hypothesis is 
that it was caused by an autoreactive T-cell response against Aβ (Nicoll et al., 
2003). However a cohort of 30 patients who participated in the study were 
followed up for 1 year and it was found that those patients who produced 
antibodies against Aβ showed slower rates of decline in cognitive function and 
daily living activities compared to patients who produced no such antibodies 
(Hock et al., 2003). Tests used included MMSE, Disability Assessment for 
Dementia and the Visual Paired Associates Test of delayed recall. These 
results indicate that the presence of antibodies against Aβ can slow the 
progress of AD. An MRI study of cerebral volumes in the patients who 
produced antibodies and showed slower rates of decline in cognitive function 
compared to the placebo group gave unexpected results (Fox et al., 2005). The 
antibody responders had significantly greater overall brain volume decrease, 
along with greater ventricular enlargement and a nonsignificant greater 
hippocampal volume decrease (Fox et al., 2005). This indicates a dissociation 
between brain volume loss and cognitive function in the antibody responders in 
this study (Fox et al., 2005). Potential reasons for this include removal of 
deposited Aβ and associated cerebral fluid shifts however, further work is 
required to fully elucidate the reason. Due to these (and other) results work 
continues into both active and passive immunisation methods targeting Aβ. The 
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details of these are beyond the scope of this report, for a review see (Weiner 
and Frenkel, 2006). 
 
A study in vitro found that opsonisation of Aβ with anti-Aβ antibodies enhances 
Aβ clearance but also increases release of toxic inflammatory mediators 
(Strohmeyer et al., 2005). This means care should be taken with 
immunotherapy as there may be a balance to be struck between Aβ clearance 
and release of toxic mediators causing side effects, as seen above. 
 
1.4.7. Potential Tau Modifying Therapies 
 
1.4.8. Tau Production 
Mice expressing a repressible human tau variant were shown to develop 
progressive NFTs, neuronal loss and memory impairments. The neuronal loss 
and memory decline were stabilised by suppression of the transgenic tau, but 
NFTs continued to accumulate (Santacruz et al., 2005). These results suggest 
potential therapeutic benefit could be achieved by decreasing tau expression 
while also questioning the role of NFTs in related toxicity. Tau knockout mice 
survive and seem to have a relatively mild phenotype for a complete deficiency 
in what is thought to be an essential protein (Harada et al., 1994), thus tau 
could potentially be downregulated without serious side effects. New agents 
targeting tau production are predominantly in the conceptual stage (Golde, 
2006). 
 
1.4.9. Tau Phosphorylation 
As tau phosphorylation is under the control of multiple kinases (Golde, 2006), 
inhibition of any one is unlikely to have a significant therapeutic impact. An 
agent which could inhibit multiple kinases may be of some benefit. In a study 
using a mixed kinase inhibitor treatment was found to reduce soluble 
aggregated hyperphosphorylated (64kDa) tau and delay or prevent typical 
motor impairments in JNPL3 tau transgenic mice (Le Corre et al., 2006). 
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Partially inhibiting multiple kinases may be advantageous in the inhibition of tau 
induced neurodegeneration. Preclinical study has been carried out with lithium 
and another inhibitor of glycogen synthase kinase 3 (GSK3) in tau transgenic 
mice. The study showed reduced levels of both phosphorylated tau and 
aggregated, insoluble tau. This reduction correlated with a reduction in the level 
of axonal degeneration (Noble et al., 2005). Although further studies are 
needed, it can be seen that there is potential in modulating tau phosphorylation 
for the treatment of AD. 
 
 
 
1.4.10. Other Tau Targets 
Other potential strategies to reduce tau related toxicity in AD include the 
inhibition of tau aggregation and tau chaperone upregulation. Both of these 
targets need further research before suitable inhibitors can be identified (Golde, 
2006). One interesting compound is the microtubule binding agent paclitaxel, 
usually used as an anticancer agent. This compound was found to restore fast 
axonal transport and increase microtubule numbers in the spines of tau 
deficient mice while also having a beneficial effect on observed motor 
impairments (Zhang et al., 2005).  
 
1.4.11. Alternative Strategies 
The exact mechanism of neuronal death in AD is still unknown, both chronic 
inflammation and oxidative stress are thought to be contributing factors 
(Akiyama et al., 2000b). Thus a wide range of compounds which may influence 
these processes are under investigation for their potential efficacy in treating 
AD (Golde, 2006). Due to the potential role of redox active metals in AD 
pathology, the use of metal chelating therapy could be disease modifying and 
some promising results have already been reported (Crouch et al., 2007). 
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Summary 
While our knowledge of the pathology of AD is expanding all the time, we still 
do not know the root cause of the neurodegeneration. In spite of this, there are 
now several inviting drug targets such as tau and Aβ. Up until now we have 
been relying on purely symptomatic treatments, the new targets present a 
strong possibility of disease-modifying therapies being on the market in the 
near future.  
 
Disease-modifying treatments will be most effective if AD can be diagnosed as 
early as possible. The effects of the disease-modifying therapies will need to be 
monitored during treatment to assess efficacy. For these reasons we need a 
reliable biomarker of AD, preferably one that is non-invasive, 1H MRS has the 
potential to provide this biomarker by monitoring differences in cerebral 
metabolite levels, for this reason 1H MRS forms the basis of much of this thesis. 
 
1.5. Nuclear Magnetic Resonance and MRS Theory 
The following references were consulted in writing this piece (Gadian, 1995; de 
Graaf, 1998) 
 
1.5.1. The Basis of NMR 
Nuclear magnetic resonance takes advantage of a property of certain atomic 
nuclei known as spin. Examples of nuclei which possess spin are hydrogen 
(1H), carbon-13 (13C), and phosphorus (31P). Hydrogen is the nuclei this thesis 
is concerned with so this will be the focus of this section. Hydrogen has a spin 
quantum number ½. In the absence of an applied magnetic field, the spinning 
hydrogen nuclei take up random orientations (Fig.3). When hydrogen nuclei are 
placed in a static magnetic field B0, they take up one of two orientations with 
respect to the applied magnetic field, parallel or antiparallel (Fig.3).  
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Fig.3 The left hand side of the diagram shows protons in the absence of 
magnetic field, with spins in random directions. The right hand side of the 
diagram illustrates the behaviour of the spins in the presence of an applied 
magnetic field, oriented parallel or antiparallel to the field (Diagram sourced from 
http://physiology-physics.blogspot.com/2010/06/understanding-basic-principles-of.html) 
 
The two spin states are at different energy levels, the difference is proportional 
to the strength of B0 and is given by the equation: 
∆E = hv0 
Where h is the Planck constant and v0 is the resonant frequency, given by: 
v0 = (γ/2π)B0 
 where B0 is the magnitude of the applied magnetic field and γ is the 
gyromagnetic ratio of the nucleus (42.58MHz/T in the case of hydrogen) 
The distribution of nuclei in the two spin states is given by the Boltzmann 
distribution: 
n2/n1 = e(-∆E/kT) 
where n1 is the number of nuclei at the lower energy level, n2 is the number of 
nuclei at the higher energy level, k is the Boltzmann constant and T is 
temperature in Kelvin. In practical situations, the difference between the two 
spin populations is very small, for example, around 1 part in 42000 for a 7T 
magnet. 
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The spinning protons precess around the axis of the applied field B0, the 
frequency of precession is proportional to the field strength and is given by the 
equation: 
ω0 = γB0 
ω0 is known as the Larmor frequency. The application of a radiofrequency (RF) 
pulse, B1 at the Larmor frequency will cause the protons to absorb energy, 
inducing transitions between energy states. This causes the net magnetization 
to tilt away from the B0 direction (z axis). The angle of the tilt θ is given by the 
equation: 
θ = γB1tp 
Where tp is is the time that the RF pulse is applied for. Prior to the RF pulse, the 
net magnetisation in the xy plane is zero, thus no signal is observed. After B1 is 
turned off the net magnetisation has been tilted away from the z axis, toward 
the xy plane. This magnetisation then rotates around B0 at frequency ω0, 
inducing an electromotive force in the receiver coil. Following the RF pulse, 
signal decreases as magnetisation in the xy plane returns to zero with a time 
constant T2*.  The signal generated by this process is known as a free 
induction decay or FID (Fig.4) 
 
The FID is a time dependent signal, it can be converted by a mathematical 
manipulation known as Fourier transformation to a spectrum of frequency and 
amplitude (Fig.4). 
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Fig.4 An FID on the left, in the time domain, converted by Fourier transform to 
an amplitude signal in the frequency domain (image sourced from 
http://chemistry.umeche.maine.edu/CHY431/NMR/NMR-4.html) 
 
1.5.2. Magnetic Resonance Spectroscopy (MRS) 
NMR signal is dependent on a number of physical and chemical effects, 
including chemical shift, spin-spin coupling and relaxation.  
 
1.5.3. Chemical shift 
The applied magnetic field B0, causes the electrons around nuclei to generate 
their own magnetic field, opposing B0. This effect is known as shielding. The 
magnetic field produced is proportional to B0 and is also sensitive to the 
chemical environment surrounding the nuclei. Due to this, nuclei in different 
chemical environments produce signals with differing frequencies. The net 
magnetic field the protons experience is given by the equation: 
Beff = B0(1-σ) 
 
Where σ is the shielding constant and is dependent on the chemical 
environment of the nuclei. Shielding can arise from electrons surrounding the 
nucleus in question, but may also arise from electrons on different atoms in the 
same molecule.  The separation of resonance frequencies from a reference 
frequency is called the chemical shift (δ). Chemical shift is usually measured 
relative to a reference compound and is expressed in the dimensionless units 
of parts per million (ppm). If the reference compound is either added to, or 
intrinsic to the sample it is called an internal reference, when it is unfeasible to 
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add a reference compound, an external reference may be used. Internal 
references are preferable as the reference compound will be contained in the 
same material as the sample. This is more desirable as the local magnetic field 
experienced by a nucleus is altered by shielding produced by the surrounding 
medium, this is known as bulk shielding. In the case of an internal reference, 
bulk shielding effects should be equal, and so not responsible for any 
differences observed. In the case of an external reference, differences in bulk 
shielding must be taken into account.  
 
1.5.4. Spin-spin Coupling 
Neighbouring nuclear spins often interact with each other, causing resonances 
produced by the nuclei to split into two or more components. This phenomenon 
is known as spin-spin coupling, the separation of the components is given by 
the coupling constant, J in Hz. Spin-spin coupling can be an interaction 
between nuclei which share a direct bond, or nuclei which are separated by 
more than one bond. J tends to decrease as the number of separating bonds 
increases. 
 
Spin-spin coupling can produce first- and second-order spectra. In first order 
spectra the frequency difference between the nuclear resonances involved is 
much greater than the magnitude of J. In nuclei on an equivalent group (i.e. the 
protons of a CH3 group) the spin-spin coupling produces no observable 
splitting. In basic terms for first-order spectra, if a nucleus is coupled to one 
nucleus of spin ½ the resulting resonance will be a doublet with relative 
intensities 1:1. If the nucleus is adjacent to 2 spin ½ nuclei, the resonance will 
split into a triplet, with relative intensities 1:2:1 and if the nucleus is adjacent to 
3 spin ½ nuclei the resonance will split into a quartet with relative intensities of 
1:3:3:1. In second order spectra the frequency difference and J are not far 
apart, in this case splitting can be more complicated and difficult to interpret. 
More information on spin-spin coupling can be found in (Gadian, 1995).  
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1.5.5. Relaxation 
At equilibrium, net magnetisation along the z (B0) axis is equal to M0, at the 
same time the net magnetisation in the xy plane Mxy is zero. After an excitatory 
RF pulse, some of the net magnetisation is shifted into the xy plane (Fig.5). 
Relaxation describes the processes by which magnetisation returns to its 
equilibrium state. 
The return of magnetisation along the z axis (Mz) to its equilibrium value is 
known as spin-lattice relaxation. This process is characterised by the time 
constant T1, or the longitudinal relaxation time. 
 
Fig.5 Initial transfer of magnetisation from the Mz  to the Mxy plane, 
magnetisation returns to the Mz direction, the time taken is dependent on the 
time constant T1 (diagram sourced from Gadian, 1995) 
 
The loss of magnetisation in the xy plane (Mxy) (in addition to the loss through 
T1 relaxation) is called spin-spin relaxation (Fig.6). This comes about by the 
gradual dephasing of Mxy caused by interactions between neighbouring nuclear 
spins and inhomogeneities in B0. Spin-spin relaxation is characterised by the 
time constant T2, or transverse relaxation time. 
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Fig.6 a – As magnetisation is initially switched from Mz to Mxy, all the spins are 
in phase and the signal is strong. b and c – gradually the spins lose phase with 
each other as they precess at slightly different frequencies until net Mxy = 0 
(diagram sourced from (Gadian, 1995) 
 
1.5.6. MRS Pulse Sequences 
Spectroscopy pulse sequences consist of a combination of timed 
radiofrequency pulses and pulsed magnetic field gradients designed to produce 
a signal from a specific region of interest (or voxel), while editing out signal from 
the surrounding regions. Separate pulse sequences have been developed with 
the sole purpose of suppressing the signal from water, as water signal is ~105 
times more abundant than the signal from metabolites. MRS experiments 
generally combine a spectroscopy sequence with a water suppression 
sequence to obtain the best possible spectrum.  
 
1.5.7. PRESS 
PRESS, or point-resolved spectroscopy (Bottomley, 1987) uses the following 
pulse sequence: 
 
900 – TE1/2 – 1800 – (TE1 + TE2)/2 – 1800 – TE2/2 – Acquire 
 
As can be seen in Fig 7, the three RF pulses are slice selective, along the x, y 
and z-axes respectively.  
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The 900 – 1800 pulses generate an echo at TE1/2 from the 1800 pulse from the 
spins inhabiting the column selected by the two slices, this echo is not 
collected. The collected echo is formed TE2/2 following the second 1800 pulse, 
this echo corresponds to the voxel defined by the intersection of the three 
selected slices, in which spins have been excited by all three RF pulses. 
 
Fig.7 PRESS pulse sequence (Bottomley, 1987) showing RF pulses, gradients 
in the three planes, Gx, Gy and Gz and echo generation. TE is the time between 
the original 900 pulse and the echo generated following the second 1800 pulse. 
(diagram sourced from (Gadian, 1995) 
 
Slice selection is achieved by use of gradients and RF pulses of specific 
frequencies. A gradient is applied, along the x-, y- or z-axis which alters B0 
depending upon the position along the axis. An RF pulse of a certain frequency 
or band of frequencies will then only excite protons which have resonance 
frequencies which coincide with the RF pulse. Protons in other slices will not be 
excited, as their resonance frequencies are different due to the presence of the 
gradient. Signal from spins in regions which only experience one or two RF 
pulses can be removed by spoiler gradients. 
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The PRESS sequence gives a relatively high signal detection and good SNR. 
One potential problem with the sequence is that TE is required to be quite long 
in order to accommodate the RF pulses and spoiler gradients, thus it is not 
optimal for detection of metabolites with short T2 values or complex coupling 
patterns as there is significant signal loss at longer TE. Modern magnet and 
gradient systems overcome these problems so that PRESS can be used at 
short echo times for detection of coupled spin systems. 
 
1.5.8. Water Suppression 
Metabolite concentrations in the brain are several orders of magnitude smaller 
than the concentration of water in the brain. Due to this, water signal will 
overwhelm the signal from metabolites of interest if nothing is done about it.  
Water suppression is carried out in order to decrease the amplitude of the 
water peak in the spectrum, allowing easier visualisation of metabolite signals.  
One method of water suppression is chemical shift selective excitation 
(CHESS), this involves excitation at the frequency of water, followed by a 
crusher gradient to dephase the resulting magnetization (Haase et al., 1985). 
This results in a system where there is a large reduction (>1000-fold) in water 
magnetisation, but the components which resonate at different frequencies are 
unaffected.  
 
The CHESS sequence only gives good water suppression over a relatively 
narrow range of water T1 values and RF (B1) values. Thus alternative 
sequences were developed using multiple suppression pulses with optimised 
flip angles and delays. The result is effective water suppression over a range of 
T1 and B1 values. One of these methods is called volume localized, solvent 
attenuated, proton NMR VAPOR (Griffey and Flamig, 1990; Tkac et al., 1999), 
and it is our method of choice for water suppression. 
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1.5.9. Data processing method 
Interpretation of an in vivo 1H MRS spectrum must be done with care. Many 
factors must be taken into account in order to obtain accurate metabolic 
information.  
 
Strong overlapping of metabolite peaks occurs, low SNR, broad background 
resonances originating from macromolecules and lipids with short T2 values, 
line broadening and peak overlap caused by magnetic field inhomogeneities 
and the residual water signal must all be taken into account during 
quantification. This precludes manual peak integration. Various semi- and fully 
automated methods have been developed, for a review see (Poullet et al., 
2008).  
 
There are two types of method involved in MRS quantification – interactive and 
noninteractive (Vanhamme et al., 1997). Noninteractive methods are 
computationally efficient and potentially fully automatic, however very little prior 
knowledge can be imposed on these models (Vanhamme et al., 1997). 
Interactive methods incorporate more user-involvement and allow inclusion of 
prior knowledge, but can be less computationally efficient (Vanhamme et al., 
1997). Prior knowledge is the only way of increasing the accuracy of fitted 
model parameters for a given dataset (de Graaf, 1998). Prior knowledge can 
also reduce unknown model parameters, reducing calculation time (de Graaf, 
1998). 
 
For the in vivo part of this thesis we have chosen to use a time-domain method 
of quantification. This offers several advantages, the time-domain is the 
measurement domain in MR, consequentially missing initial and/or final data 
points do not greatly hamper quantification so such points may be omitted 
(Higinbotham and Marshall, 2001). Time-domain methods also allow automatic 
processing of water (de Beer et al., 1992) and background signals (Ratiney et 
al., 2005). 
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The method we used is known as QUEST (quantitation based on quantum 
estimation) (Ratiney et al., 2005). This is part of a software package known as 
jMRUI. This method is based upon extensive prior knowledge, in our case 
obtained by quantum mechanical simulation. The metabolite basis set will be 
created using a program called NMR SCOPE (Graveron-Demilly et al., 1993). 
 
The quantification process involves initial zero-order phasing to correctly phase 
the water peak, followed by use of Hankel-Lanczos singular value 
decomposition (HLSVD) to remove the residual water peak, then (if necessary) 
first-order correction to phase the peaks of interest. Quantification can then be 
carried out using the pre-generated metabolite basis set to obtain metabolite 
levels based on peak amplitudes. 
 
1.6.1. 1H MRS in Alzheimer’s Disease 
There is increasing evidence suggesting that the symptoms of AD only manifest 
themselves in a clinically detectable way once the underlying pathology of the 
disease has progressed significantly (Golde, 2003). There is evidence from 
imaging studies that brain atrophy and neuronal dysfunction may precede the 
onset of symptoms by years or even decades (Fox et al., 2001). One study 
using an amyloid imaging agent recently showed significant amyloid deposition 
in cognitively normal subjects (Fagan et al., 2006). 
 
The lack of a definitive biomarker is a problem for both clinical diagnosis of AD 
and also drug discovery in animal models. 1H MRS is a non-invasive method 
and is sensitive to changes in metabolite concentrations in vivo of around 1mM 
(Brooks et al., 1999). Using 1H MRS, differences in metabolite levels in both 
pathologic and healthy brain tissue can thus be assessed and potentially 
quantified in vivo. The non-invasive nature of 1H MRS is a considerable 
advantage, along with the fact that it does not involve any ionising radiation, as 
with some other scanning techniques.  
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MRS metabolic studies were initially carried out using 31P MRS as it is less 
complex than 1H MRS. 1H MRS has been used in cerebral studies as it allows 
non-invasive monitoring of several potentially important CNS metabolites. 1H 
MRS is more technically complex than 31P MRS as large signals from both 
water and fats need to be suppressed. In addition the chemical shift range of 
the various metabolites of interest is relatively narrow, leading to interpretive 
difficulties (Gadian, 1995). Advancements in solvent suppression techniques 
and spectral editing, as well as improvements in field homogeneity have 
allowed spectroscopy to be carried out even at clinical field strengths (1.5T). 
The fact that the brain generates very little signal from fats is also a great 
advantage of using 1H MRS in the brain, as opposed to other tissues where the 
fat signal presents a problem (Gadian, 1995).  
 
The high sensitivity of the 1H nucleus when compared with other nuclei is 
another advantage of 1H MRS as it potentially allows detection of low 
concentrations of metabolites. The signal from metabolites at low 
concentrations can however, be masked by signals from metabolites at higher 
concentrations. Due to this, the higher sensitivity of the 1H nucleus is exploited 
by trading signal-to-noise ratio for spatial resolution. Smaller volume elements 
can therefore be used and adequate signal-to-noise ratios obtained (Gadian, 
1995).  
 
A parameter known as echo time (TE) is the delay between radiofrequency 
excitation and detection of the signal (echo). As different metabolites have 
different T2 relaxation times, altering the TE alters the appearance of the 
spectrum. Short echo times (20-40ms) give spectra containing contributions 
from a large set of different metabolites, thus they contain more information. 
This information can be difficult to obtain however, as the spectra are often 
difficult to interpret. Longer echo times (120-300ms) give spectra with a flatter 
baseline and only containing contributions from creatine, choline, N-
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acetylaspartate, myo-inositol, lactate and lipids. Information is generally easier 
to obtain from these spectra. 
 
1.6.2. Major Detectable Metabolites 
Several major metabolites can be detected by in vivo 1H MRS, the main 
metabolites seen are: N-acetylaspartate (NAA), choline (Cho) compounds, 
myo-inositol (MI), creatine and phosphocreatine (Cr) and glutamate/glutamine 
(Glx) (Gadian, 1995). A brief overview of each of these metabolites is given 
below. Following that their potential significance with respect to AD will be 
discussed. 
 
NAA (chemical shift [δ] = 2.02 and 2.6 ppm) is present in the brain at 
concentrations of about 10mM, thus it is the second most prevalent free amino 
acid derivative in the central nervous system after glutamate (Demougeot et al., 
2004). NAA concentrations in all other body tissues are minute. Studies using 
lesioning (Koller et al., 1984), immunohistochemical analysis (Moffett et al., 
1991) and NMR/HPLC (Urenjak et al., 1992) have shown that NAA is mainly 
confined to neurones in the adult brain. Loss of NAA has been attributed to 
either loss of neurones or neuronal damage. Various studies have found that 
NAA concentration in the brain correlates with either overall neuronal loss or 
temporary neuronal dysfunction (Demougeot et al., 2004). A strong correlation 
has been shown between estimates of NAA concentration in vitro and data 
derived from MRS estimates in rats (Burri et al., 1990). The exact function of 
NAA in the brain is still being investigated. One report has linked NAA with 
myelination processes in adult humans (Bhakoo and Pearce, 2000). 
 
Significant correlation between left occipitoparietal white matter NAA/Cr and 
intellectual performance has been seen in young healthy volunteers (Jung et 
al., 1999a). A stronger association has also been made between NAA 
concentration and performance in neuropsychological timed tests (Jung et al., 
1999b). 
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Choline compounds (δ = 3.2ppm). Choline itself is a precursor in the synthesis 
of both cell membrane phosphatidylcholine and the neurotransmitter 
acetylcholine (Ach), in the case of Ach it is rate-limiting. The MRS peak for 
choline measures mobile forms of choline, including choline, Ach, 
glycerophosphorylcholine (GPC) and phosphocholine. Due to its immobility, 
phosphatidylcholine is invisible to MRS (Valenzuela and Sachdev, 2001). 
Choline concentration has been shown to increase with age (Moats et al., 
1994). Elevated choline levels may mark cellular proliferation (neoplasia) or 
myelin breakdown (Lazeyras et al., 1998). 
 
Myo-inositol (δ = 3.6 and 4.0 ppm) is a sugar alcohol with a structure similar to 
that of glucose, its function is uncertain (Valenzuela and Sachdev, 2001). Of 
the visible peak for MI, approximately 70% comes from free MI and 15% from 
MI phosphate (Ross, 1991). Potential functions of MI include osmoregulation, 
acting as an intracellular messenger and acting as a detoxification agent in the 
brain/liver (Ross, 1991). Elevated MI could represent gliosis, cytoskeletal 
abnormalities or membrane dysfunction (Lazeyras et al., 1998).  
 
Creatine and phosphocreatine (δ = 3.0 and 3.9 ppm). Cellular ATP/ADP ratios 
are buffered by the phosphocreatine-creatine equilibrium reaction, which acts 
as a reserve for high energy phosphates (Miller, 1991). As a consequence the 
combined Cr signal reflects the state of energy use and storage within a 
system. The Cr signal can be used as a reference metabolite in quantification 
of other neurochemicals (Valenzuela and Sachdev, 2001). Cr has been shown 
not to vary significantly between different people or between normal subjects 
and AD patients (Moats et al., 1994). White matter disease causes decreased 
Cr levels (Oppenheimer et al., 1995), whereas Cr levels increase in the grey 
matter with age (Chang et al., 1996). 
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Glutamate/glutamine (δ = 2.1-2.4 ppm). Glutamate is the most abundant neural 
amino acid, with approximate concentrations in the brain of 12mM. The function 
of glutamate is as an excitatory neurotransmitter. Glutamine is thought to be 
important to normal cerebral function, acting as a detoxifying agent and 
regulating the excitatory activity of its precursor (glutamate) (Ross, 1991). The 
chemical structures of glutamate and glutamine give a highly coupled and 
complex MRS spectrum with low individual peak intensities (Ross, 1991).  
 
1.6.3. Metabolic Differences in AD Detected by 1H MRS 
The use of 1H MRS in studying AD has produced some interesting results. 1H 
MRS of perchloric acid exctracts from post-mortem AD brains showed 
increases in MI and aspartate, among others. It also showed decreases in NAA 
and phosphoethanolamine (Klunk et al., 1996). While in vivo techniques cannot 
detect the same number of metabolites as spectra from extracts, potentially 
useful information has been gathered. 
 
The most striking feature of the various in vivo 1H MRS studies in AD subjects 
has been a decrease in NAA in AD sufferers. Reduction in NAA has been seen 
in a number of different neurological disorders (Jessen et al., 2000). Due to this 
efforts must be made to focus on areas of the brain known to be the site of 
neuronal injury in AD, for instance the medial temporal lobe, which is the 
earliest site of neuronal loss (Braak and Braak, 1991). Exact brain locations 
studied have varied, but reduced NAA has been found in parieto-occipital 
regions (Huang et al., 2001; Waldman and Rai, 2003), hippocampus (Dixon et 
al., 2002; Ackl et al., 2005), medial temporal lobes (Chantal et al., 2004), 
posterior cingulate (Kantarci et al., 2000), occipital cortex (Shonk et al., 1995), 
anterior temporal lobes (Frederick et al., 2004) and parietal lobes (Schuff et al., 
2002) among others. NAA decrease has been shown in over 20 papers as 
correlating with AD pathology. This reproducibility is encouraging, as is the 
magnitude of the observed decrease of around 10-15% in various studies 
observing different brain regions and using different protocols.  NAA depletion 
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seems to be greater in grey matter than white matter. Furthermore, in AD 
atrophy of various regions of the brain is known to occur. In a study which 
corrected for hippocampal atrophy, reduced NAA levels were still observed in 
AD subjects compared with controls (Schuff et al., 1997).  
 
The other major finding of the continued research has been elevation of MI 
levels in AD subjects. Increases have been seen in various brain regions, 
including the parietal lobe grey matter (Ackl et al., 2005; Zhu et al., 2006), 
occipital lobes (Dixon et al., 2002), medial temporal lobes (Kantarci et al., 
2000), occipital cortex (Shonk et al., 1995) and parieto-occipital region 
(Waldman and Rai, 2003). However, a study using spectral acquisition and 
data evaluation techniques similar to Shonk et al. 1995 found reduced NAA but 
no change in MI (Heun et al., 1997). Elevated MI in AD could represent reactive 
gliosis following neurodegeneration (Lazeyras et al., 1998). Also, severe 
deficits in phosphoinositide signalling are thought to occur in AD (Pacheco and 
Jope, 1996). Abnormal activation of phospholipase C and associated metabolic 
dysfunctions could also play a role in the increased MI signal seen in AD 
(Kanfer et al., 1998). 
Study of changes in MI may be confounded by the presence of other diseases 
which also affect the brain, such as hepatic encephalopathy (Kreis et al., 1992), 
diabetes mellitus (Kreis and Ross, 1992) and metachromatic leucodystrophy 
(Kruse et al., 1993). 
 
Choline levels do not appear to be affected by AD. Creatine signal (which also 
seems fairly constant in AD subjects compared with controls), along with water 
is often used to quantify levels of MI and NAA seen in spectra.  
 
One study in the cingulate region points to reduced ratios of glutamate and 
glutamine (Glx) to creatine in AD subjects (Antuono et al., 2001). Decreased 
glutamate could lead to less efficient neuronal signalling, which could be a 
factor contributing to the symptoms seen in AD. Glx ratios in AD sufferers were 
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also seen to be correlated with MMSE scores (Antuono et al., 2001), this could 
aid in the diagnosis of the disease, this will be discussed in more detail later. A 
potential flaw with this study however; is that the data were obtained from 
clinically diagnosed probable AD sufferers, and not histologically verified cases. 
Also the number of patients included in the analysis was small; therefore further 
work is needed before any final conclusions can be drawn. 
 
1.6.4. Potential Uses of 1H MRS in AD 
The data obtained so far by 1H MRS have a number of potential uses. Use of 
metabolite ratios in diagnosis of AD, preferably at an earlier stage than with 
current clinical practice is a possibility. Some correlation has been seen 
between metabolite ratios and cognitive test scores, this could be a useful 
marker of disease progression. Prediction of progression from MCI to AD may 
also be possible, as well as differentiating between different forms of dementia. 
If definitive biomarkers of the disease and their role in the disease are verified, 
they may be of use in treatment monitoring. Transgenic animal models of AD 
with similar metabolic profiles to human AD sufferers could be of great benefit 
in drug discovery if they can be validated.  
 
1.6.5. Diagnosis 
A number of studies have demonstrated differences in metabolite ratios 
between AD subjects and age matched controls. Decreased NAA and 
increased MI are the most common findings (Miller et al., 1993; Moats et al., 
1994; Rose et al., 1999; Catani et al., 2001; Jessen et al., 2009). Absolute 
concentrations and creatine ratios have both been used in these studies. These 
findings have been largely reproducible between laboratories, with some 
exceptions (Stoppe et al., 2000). The potential diagnostic applications of these 
differences could be very useful. If they can be used to reliably diagnose AD it 
could allow earlier diagnosis and better treatment. The location of the volume(s) 
of interest varies between studies. If different laboratories could obtain spectra 
from the exact same regions and demonstrate genuinely reproducible results it 
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could go a long way toward providing proof that 1H MRS can be used as a 
diagnostic tool in AD. 
 
1.6.6. Disease Progression 
Disease progression measured by cognitive test performance could also 
potentially be monitored by 1H MRS. Significant correlation between MMSE 
score and NAA/MI, MI/Cr and absolute NAA has been reported (Rose et al., 
1999). This study also showed a correlation between metabolite levels and 
brain atrophy (measured by comparing cerebrospinal fluid and grey matter 
compositions of the spectroscopy voxel). Similar results for NAA (but not 
always MI) have been reported to correlate with MMSE score elsewhere 
(Huang et al., 2001; Waldman and Rai, 2003). Another study, measuring NAA 
content of the whole brain (WBNAA) found it to be a good predictor of MMSE 
score (Falini et al., 2005). The same study found that normalised brain volume 
(NBV) was a good marker of overall brain damage, but found only moderate 
correlation between NBV and WBNAA. Verbal fluency in AD subjects was 
reported to positively correlate with parietal MI/NAA (Ackl et al., 2005). 
Correlation was found between both NAA/Cr and MI/NAA with MMSE in a 
single voxel study, the study also indicated that a single voxel MRS 
examination only added about 10 mins to a routine MRI scan (Doraiswamy et 
al., 1998).  
 
If 1H MRS can be reliably used to chart disease progression it could prove very 
valuable, especially in treatment monitoring of any new potentially disease 
modifying therapy. 
 
 
1.6.7. Differentiation –AD/MCI 
MCI is a term used to describe subclinical complaints of memory impairment in 
the elderly. There is thought to be a high risk of patients with MCI progressing 
to AD (Ritchie and Touchon, 2000). 1H MRS measurements have potential use 
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in differentiating between the two and predicting likelihood of progression from 
MCI to AD. In the case of differentiation there is some disagreement between 
studies. One study showed significantly lower NAA/Cr ratios in AD subjects 
compared with MCI subjects (Kantarci et al., 2000), whereas another showed 
increased MI/H2O ratios in AD subjects compared with MCI subjects (Chantal 
et al., 2004). A third paper found no significant difference in metabolite ratios 
between the two (Catani et al., 2001). Clearly more work is required to evaluate 
whether or not exploitable differences exist in 1H MRS detectable 
neurometabolite profiles between AD and MCI.  
 
Prediction of progression from MCI to AD has potential clinical benefit, 
especially when disease modifying drugs become available as patients at high 
risk could be started on appropriate therapy before full onset of symptoms. One 
study gathered data on subjects with MCI then followed them up on average 3 
years later. It found that NAA/Cr ratio in the occipital cortex predicted dementia 
at 100% sensitivity and 75% specificity. Positive predictive value was 83% and 
negative predictive value was 100%, with an overall, cross validated accuracy 
of 88.7% (Modrego et al., 2005). Another study found that Cho/Cr ratios 
declined in stable MCI patients compared with patients who progressed to 
clinical AD (Kantarci et al., 2006). These results show some promise, however 
due to the lack of correlation between results, and the different protocols used 
in the studies no conclusions can be drawn. Add this to the difficulties 
experienced in using 1H MRS to differentiate between MCI and AD and it is 
clear further work is required to determine whether there is a practical use for 
the technique in this particular area. 
 
 
1.6.8. Differentiation – AD/Other Dementias 
1H MRS has potential uses in differentiating between different forms of 
dementia, which may be of use in choosing the correct therapy. Differentiation 
between vascular dementia (VD) and AD seems possible and appears to be a 
 58
matter of location in the brain. One study found fairly similar changes in 
metabolite ratios between AD and VD, but the distribution of metabolic 
differences was different. AD followed a temporo-parietal pattern, whereas VD 
followed a global, subcortically pronounced pattern (Herminghaus et al., 2003). 
The same study also found a difference in Cho/Cr ratios (Cho was referred to 
as trimethylamines in the paper), with increases in VD not seen in AD. Another 
study differentiated the two diseases by claiming that similar changes in 
metabolites are seen between the two diseases, but in VD it is predominantly 
the white matter affected, whereas in AD it is the grey matter (Jones and 
Waldman, 2004). This study also showed a higher MI/NAA ratio in AD from 
mesial parieto-occipital spectra, using a short echo time. Another study also 
showed significant differences in the mesial parieto-occipital lobes between VD 
and AD, showing correlation with MMSE for AD but not VD (Waldman and Rai, 
2003). A further study found differences in the posterior cingulate gyrus in 
NAA/MI, MI/Cr and Cho/Cr between AD and VD (Martinez-Bisbal et al., 2004). 
 
Differentiation between AD and frontotemporal dementia (FTD) was achieved 
using 1H MRS. The differences were seen in the frontal lobe, with an altered 
metabolic profile seen in FTD but not in AD. Using these data a linear 
discriminant analysis correctly differentiated 92% of FTD patients from AD 
patients (Ernst et al., 1997).  
 
The results of another study indicate that 1H MRS metabolic profiles could be 
used to differentiate between AD, VD, FTD and dementia with lewy bodies. 
This paper indicates that further testing with longitudinal studies and 
therapeutic trials is necessary in order to be confident of accurate differentiation 
(Kantarci et al., 2004).  
 
1.6.9. Treatment Monitoring 
In a treatment monitoring study using the anticholinesterase donepezil on AD 
patients, changes were observed by 1H MRS in vivo. Treatment caused an 
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increase in NAA and NAA/Cr ratio in the parietal lobe. ADAS-Cog scores were 
found to correlate with changes in both NAA and NAA/Cr in the left parietal lobe 
after 3 months of treatment. Parietal NAA/Cr ratio was also found to be 
predictive of treatment response, patients with lower initial NAA/Cr benefited 
more from the treatment (Jessen et al., 2006). One potential weakness of this 
study is that no placebo group was included for ethical reasons. This means 
changes seen might be unrelated to cholinergic treatment.  
 
Another study used a different anticholinesterase, rivastigmine, and showed an 
increase in NAA/Cr ratio in the frontal cortex only. Some improvements in 
cognitive test scores were seen but these were not statistically significant. No 
effect on MI/Cr levels was seen (Modrego et al., 2006). As anticholinesterase 
treatment only produces modest and transient benefit in AD patients these 
results are not surprising.  
 
A third study using the selective muscarinic (M1) cholinergic agonist 
xanomeline showed a decreased in the Cho/Cr ratio caused by xanomeline 
treatment (Satlin et al., 1997). This study was limited in that only a small 
number of subjects were included (10 xanomeline, 2 placebo) and no age-
matched control subjects without AD were included. 
 
Despite some weaknesses, these three studies are relatively encouraging for 
the potential use of 1H MRS in treatment monitoring. However, the levels of the 
metabolites of interest can potentially be modified at many points in their 
metabolic pathways. Thus any changes seen may not be caused by a disease 
modifying effect of treatment, but by an interaction of the drug with the 
metabolite at an unrelated point in its metabolism, this would be a global effect, 
not restricted to a specific region. The reproducibility of the spectroscopic 
measurements used must also be extensively tested to ensure that changes 
seen are caused by the drug administered. As MRS systems and techniques 
improve effects of treatments on other metabolites which may play a role in 
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neurodegeneration may also be possible. These include glutamate and the 
endogenous antioxidant glutathione. 
 
In monitoring both treatment and disease progression MRI scans can be used 
to observe volumetric changes in the brain as a measure of disease 
progression, with atrophy occurring as the disease progresses (Fearing et al., 
2007), most notably in the medial temporal lobe, including the hippocampus, 
entorhinal cortex and the amygdala (Petrella et al., 2003). The addition of 1H 
MRS to this protocol adds only about 10 mins to scan time and allows 
assessment of both brain structure and chemistry. Using the two in tandem 
could make interpretation of results easier and/or more accurate. As neuronal 
dysfunction is likely to occur before neuronal death, metabolic changes 
detectable by 1H MRS may occur before observable brain volume loss in 
disorders such as AD. An observable increase in NAA (or slowing of decline) 
along with clinical markers of delayed disease progression may support a claim 
for neuroprotective properties of a drug. Interpretation of volume measures may 
also be difficult if neuronal loss is counterbalanced with gliosis or subtle 
oedema (Doraiswamy et al., 2000). 
 
1.7. Magnetic Resonance Imaging in AD 
MRI has been used extensively to study AD patients. Common findings include 
atrophy of cortical grey matter, temporal lobes and hippocampi, along with 
ventricular enlargement (Wahlund, 1996; Xanthakos et al., 1996). Some 
correlation between MMSE and hippocampal/temporal lobe atrophy has also 
been found (Wahlund, 1996; Xanthakos et al., 1996).  
 
Medial temporal lobe structures, including the hippocampus, parahippocampal 
gyrus and amygdala have been investigated using volumetric MRI (Jack et al., 
1997). Volumes were found to decrease with age in AD patients and age-
matched controls, however the volumes of the structures were significantly 
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smaller in AD patients than controls. Loss of hippocampal volume was also 
shown to correlate with disease progression (Jack et al., 1997).  
 
Overall brain atrophy has been shown to be greater in AD patients than age-
matched controls (Fox et al., 1996a) with no overlap between groups. 
Accelerated hippocampal volume loss has also been shown to correlate with 
onset of AD symptoms (Fox et al., 1996b). Although atrophy has been 
observed, rates and sites of atrophy corresponding to a diagnosis of AD have 
not been sufficiently validated for MRI to be used as a diagnostic tool (Frisoni et 
al., 2010).  
 
Amyloid plaques often contain iron (Smith et al., 1997), this means the plaques 
can have paramagnetic properties. This is a potential reason that some plaques 
are visible to MRI without the use of contrast agents (Benveniste et al., 1999). 
 
1.8. Investigation of Animal Models 
The development of transgenic mouse models of AD is a way of studying 
disease mechanisms and testing potential new therapeutics. Many different 
transgenic mice have been developed in order to study AD pathogenesis. 
These have human mutant variants of the genes coding for APP, the 
presenilins and tau expressed singly and in various combinations. Most of 
these mice develop amyloid plaques in their lifetimes (Higgins and Jacobsen, 
2003). Pathological changes seen in these mice include deficits in synaptic 
transmission (Hsia et al., 1999), learning deficits (Holcomb et al., 1998), 
impaired long-term potentiation (Moechars et al., 1999) and reduced brain 
volume (Van Broeck et al., 2008). 
 
To date, three different types of AD mouse model have been studied using 1H 
MRS. These are the APP, APP-PS1 and PS2APP. In APP mice, mutated 
human amyloid-β precursor protein (APP) is expressed. The APP-PS1 mouse 
coexpresses mutated human presenilin 1 (PS1) and APP. The PS2APP mouse 
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overexpresses mutated human presenilin 2 (PS2) and APP. Presenilin 1 and 2 
are thought to be part of the catalytic site of γ-secretase, an enzyme involved in 
the pathogenesis of AD (Esler et al., 2000). APP is a membrane bound protein 
which is cleaved by β- and γ-secretases to give amyloid-β protein, this protein 
aggregates in the CNS and is thought to be the main causal factor behind the 
neuronal damage seen in AD.  
 
The three mice strains all develop amyloid plaques, the APP at 10 months, the 
PS1-APP at 3 months and the PS2APP at 8 months. All three strains have also 
shown memory deficits which correlate with AD symptoms. 1H MRS studies 
have been performed on all 3 strains of mice.  The APP mice were found to 
have decreases in NAA/Cr, glutamate/Cr and glutathione/Cr in the cerebral 
cortex compared with wild type.  An increase in the amino acid taurine/Cr was 
also seen. Taurine is known to be predominantly present in the glia (Dedeoglu 
et al., 2004). This scenario seems similar to the human situation, with taurine 
replacing MI as a marker of glial proliferation. No attempt was made during the 
study to test for correlation between plaque load and neurochemical changes.  
 
For PS2APP mice, age dependent reductions in NAA/Cr and glutamate/Cr, 
were observed. There was no concurrent increase in either taurine or MI.  The 
NAA and glutamate levels were found to correlate well with plaque load in the 
frontal cortex. At 20 months a diagnostic test obtained results with 92% 
sensitivity and 82% specificity in differentiating PS2APP mice from wild type 
(von Kienlin et al., 2005). 
 
The APP-PS1 mice have been the most extensively studied with 1H MRS. In a 
study looking at APP-PS1 mice of varying ages, a reduction in NAA/Cr and 
glutamate/Cr was observed with advancing age (Marjanska et al., 2005). This 
effect has also been seen in wild type mice, but to a much lesser extent and 
with a later age of onset (von Kienlin et al., 2005). There is some concordance 
between the 3 mouse AD models and the human condition in the reduction of 
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NAA levels. The APP-PS1 mice also showed a dramatic, age dependent 
increase in MI/Cr levels (Marjanska et al., 2005). This differs from the other two 
mouse models. This increase was attributed to microglial activation in these 
mice. Thus, according to current evidence, the APP-PS1 mouse most closely 
resembles the human condition in that it mimics the decrease in NAA as well as 
the increase in MI. Activated microglia accumulate around amyloid plaques in 
both humans and APP-PS1 mice. Concern is expressed by the authors of the 
study that the increase in MI may be a consequence of plaque load rather than 
genotype, which could limit the use of this model (Marjanska et al., 2005).  
 
In a study using multivariate data analysis, MI/Cr was found to be important for 
group separation (transgenic/wild type) in younger mice, while NAA/Cr, 
glutamate/Cr and macrolipids were more important in older animals (Oberg et 
al., 2007). This study only used animals up to 9 months old. In a study 
comparing memory differences (measured by the object recognition test) with 
metabolite levels from brain extracts, measurable memory deficits were first 
observed at 35 weeks. At this point the mice were sacrificed and NMR spectra 
acquired from extracts from various brain regions. Increased MI was found in all 
tested brain regions, a small decrease in NAA was found in the temporal cortex 
(Woo et al., 2010). It would appear that increased MI precedes NAA decrease 
in this model, except in the temporal cortex, one of the areas in which 
pathology surfaces in early human AD. 
 
Of the 3 strains APP-PS1 appears to be the most attractive model to be used in 
drug discovery. Due to the similarities in the 1H MRS profile of the APP-PS1 
mice and human AD subjects, disease-modifying therapies could potentially be 
investigated using these mice, and thus accelerate the process of developing 
new therapies. This in turn would result in new therapies being available to AD 
patients much sooner. 
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In summary, 1H MRS has many potential applications in the study and 
treatment of AD. The changes in NAA and MI seen are now fairly widely 
accepted and as techniques/instrumentation improve other metabolites may be 
studied in more detail. The potential use of 1H MRS as a diagnostic tool and in 
monitoring disease progression/therapy is demonstrated, however further 
development and optimisation is required. The use of animal models for drug 
discovery is an increasingly important area of research, particularly for the 
novel therapeutic targets currently under investigation. Use of these animal 
models allows disease-modifying actions to be studied in detail before clinical 
trials begin in humans.  
 
1.9. TASTPM Mouse 
The TASTPM mouse was developed from two transgenic mouse strains. The 
first was TAS-10, overexpressing hAPP695swe (Swedish familial mutant APP) 
under the control of the neuronal promoter Thy-1. The second is TPM, 
overexpressing the PS1 M146V mutation, also under the control of Thy-1. Both 
mice have C57BL/6 mice as the background strain (Howlett et al., 2004). TAS-
10 mice were backcrossed onto C57BL/6 and the resulting offspring were 
crossed with TPM mice to produce heterozygote double mutant mice 
(TASTPM) (Howlett et al., 2004). Thus the TASTPM expresses both human 
mutant APP and PS1 genes, both under the control of the neuronal promoter 
Thy-1 (Howlett et al., 2004). These mice begin to develop cerebral Aβ42 
deposits as early as 3 months of age, female TASTPM mice exhibit more 
immunolabelled Aβ deposits than their male counterparts. They also exhibit an 
age-dependent cognitive impairment as measured by the object recognition 
test, indicating that these mice could not distinguish between familiar and novel 
objects. The observed impairment can be detected from 6 months of age 
(Howlett et al., 2004). Dystrophic neurites were observed by electron 
microscopy in the cortex of TASTPM from 6 months of age. This suggests an 
age-related degenerative change (Howlett et al., 2004). The dystrophic neurites 
were invariably associated with extracellular Aβ deposits, suggesting that the 
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observed neuronal toxicity involves Aβ or something associated with it (Howlett 
et al., 2004).  
 
In a study examining Aβ deposition in TASTPM mice (Howlett et al., 2008), Aβ 
deposition was observed from 2-4 months of age. The amyloid plaques were 
found to contain both human Aβ and endogenous rodent amyloid. Aβ42 was 
found to be more prevalent than Aβ40 in these plaques. Inflammatory cells were 
found in close proximity to amyloid deposits, from 2-4 months of age glial 
fibrillary acidic protein (GFAP) positive astrocytes were found associated with 
plaques and microglia and astrocytes were found surrounding plaques (Howlett 
et al., 2008).  
 
Histopathologically, neuronal loss in the brains of TASTPM mice, particularly in 
the cell layers of the hippocampus, appears very similar to that occurring in the 
human AD brain (Howlett et al., 2008). Hyperphosphorylated tau was also 
observed from 4 months of age and increased with age, this tau appeared to be 
associated with dystrophic neuritis (Howlett et al., 2008). In a study on brain 
volume changes in TASTPM and C57BL/6 (WT) mice numerous differences 
were observed (James et al., 2007). An overall increase in brain volume was 
observed in both strains, but the increase was greater in the TASTPM mice and 
appeared to be continuous. The volume increase levelled off after 11 months in 
the WT. In absolute terms the majority of TASTPM brain regions increased in 
volume over time (James et al., 2007).  
 
When normalised to whole brain volume (WBV) several brain regions could be 
seen to be affected by the genetic difference over time. The hippocampal 
formation reduced in size over time in WT mice, while it increased relative to 
WBV in TASTPM mice (James et al., 2007). The normalisation process 
suggests that the transgenes elicit one of two responses. The first group 
includes the corpus callosum, corticospinal tract, hypothalamus, midbrain-
hindbrain and fornix system. In this group TASTPM brain regions are smaller 
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than WT, which suggests a negative early effect of the transgenes. These 
regions still increase in volume with age along similar lines to the WT. The 
second group includes the thalamus, cerebellum, cerebral cortex and 
caudoputamen. In this group regions are initially larger in TASTPM than WT, 
but reduce in size more rapidly with age (except for the cerebellum and 
cerebral cortex). The early increase in size in this second group is indicative of 
the effect of early Aβ deposition and inflammatory processes, leading to grey 
matter loss with age and thus a decrease in size (James et al., 2007). Early 
volume increases could also be a result of large amounts of intracellular APP 
being present, increasing cell size. Later volume loss could be offset by 
increased gliosis. 
 
In most areas of the TASTPM brain Aβ deposition is accompanied by astro- 
and microgliosis (Howlett et al., 2008). Significant thalamic pathology has been 
observed in TASTPM mice by MRI, micro-CT and histology (Evans et al., 
2007). The pathology (which is visible on MRI scans as signal hypointensity in 
the thalamus) starts to become visible at around 7 months. Although Aβ 
deposits are found in all areas of the brain with histology, only in the thalamus 
are they co-localised with calcium and ferrous iron deposits (Evans et al., 
2007). The thalamic plaques are also the only plaques visible with MR and CT, 
suggesting that the observed signal loss may be caused by a process unique to 
the thalamus or connected regions (Evans et al., 2007). Similar thalamic 
pathology has been observed in other transgenic mouse models of AD 
(Dhenain et al., 2009). There are several possible reasons for this, one is 
potential haemodynamic disruption. It has been shown in rats that transient 
middle cerebral artery occlusion leads to Aβ and APP deposition in the 
ventroposterior medial and ventroposterior lateral nuclei of the thalamus (van 
Groen et al., 2005).  
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1.10. MALDI Imaging 
The thalamic hypointensity detected in the TASTPM mouse has not been 
extensively characterised by histology and, in particular, there has been no 
proteomic analysis of the lesions. In this thesis Matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI MS) is used to probe peptides 
present in the hypo-intense regions to try to identify any peptide/protein 
markers of the lesions. 
 
Mass spectrometry (MS) measures the mass to charge ratio of charged 
particles. It is used to determine the mass of molecules and also to determine 
their elemental composition and chemical structure, in this case we are mainly 
interested in peptides and proteins. The specific type of mass spectrometer 
which is interfaced to the MALDI instrument we used is a time of flight (TOF) 
mass spectrometer. This instrument determines mass to charge ratio by time 
measurement, ions are accelerated by an electric field of known strength, 
resulting in the kinetic energy of ions with the same charge being equal. The 
velocity of the ion is dependent on the mass to charge ratio (with heavier 
molecules travelling at slower speeds). The time taken for the ion to reach a 
detector at a known distance is measured and allows the mass of the ion to be 
determined if the charge is known. 
 
 MALDI is a technique which works by co-crystallising the sample of interest 
(typically small molecules, peptides or proteins) with an organic compound, 
called a matrix. The matrix facilitates ionisation of molecules from the sample 
when it is bombarded with a laser (e.g. N2, Nd-YAG) (Karas et al., 1987; Karas 
and Hillenkamp, 1988). The ions generated then enter the TOF mass 
spectrometer. 
 
The most commonly used matrices are α-cyano-4-hydroxycinnamic acid 
(alpha-cyano) and 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid). 
Matrix compounds are dissolved in a mixture of water and an organic solvent 
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such as acetonitrile or ethanol, Trifluoroacetic acid is often added to provide 
protons to aid ionisation.  
 
In MALDI MS the sample to be analysed is mixed with matrix in a ratio of 
around 1:1 and deposited on a target plate. The mixture is allowed to dry, 
during which time the matrix co-crystallises with sample molecules. The sample 
is then bombarded with short laser pulses, resulting in desorption and ionisation 
of the sample molecule. Intact, protonated molecules from the sample are then 
analysed, usually in a TOF mass analyser, allowing the mass of the parent 
molecule to be deduced. 
 
MALDI imaging involves profiling and imaging the distribution of endogenous 
components e.g. proteins, directly from thin tissue sections. Thin sections of 
tissue (10 – 20 µm thick) are cut in a cryostat and mounted on indium tin oxide 
coated glass slides. Matrix is then applied to the slide in a homgenous manner 
(e.g. airspray deposition) to get an even coating. The slide is then placed in the 
MALDI TOF instrument and the laser irradiates discrete spots over the surface 
of the tissue, covering the surface of the section at intervals which define the 
resolution of the image that will be generated. In this way, distribution of 
proteins/peptides throughout the tissue can be visualised in two dimensions. 
MALDI imaging was used in this thesis to evaluate TASTPM brain sections, 
looking for different amyloid fragments and any variations in comparison to wild 
type mice. 
 
Summary 
Thus, it can be seen that further study on the TASTPM mouse, and specifically 
its neurobiology may lead to: discovery of a novel biomarker of AD; validation of 
the TASTPM mouse as an AD model for preclinical testing; or insight into the 
pathological processes behind the neurodegeneration. 
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The experimental part of the thesis is presented in four chapters, followed by a 
final conclusion. The first two experimental chapters deal with an extraction 
study carried out on the brains of the TASTPM mice, performing MRS on the 
aqueous and organic fractions respectively. The third chapter discusses a 
spectroscopic study performed in vivo on the brains of the TASTPM mice. The 
fourth chapter discusses the MALDI investigation carried out on the brains of 
TASTPM mice. 
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Chapter 2. Longitudinal in vitro 1H MRS of chloroform-methanol extracts 
from the brains of TASTPM mice 
 
2.1. Introduction 
There is a need to develop a biomarker for AD to aid in drug development, 
treatment monitoring, diagnosis and patient management. An ideal biomarker 
must be easy to measure non-invasively, related to disease progression and 
specific for AD. There is currently no such definitive biomarker for AD. Magnetic 
resonance imaging (MRI) observation of AD patients has found atrophy, 
increasing in severity with disease progression (Frisoni et al., 2010), however 
brain atrophy is not specific to AD. A proton magnetic resonance spectroscopy 
(1H MRS) scan could be performed during the same session as an MRI scan, 
only adding approximately 10 mins to scan time. If a 1H MRS biomarker could 
be found, a more robust diagnosis could potentially be made. Disease 
progression could also be monitored more closely. A metabolic biomarker for 
AD could also be invaluable in treatment monitoring. If therapeutic intervention 
caused normalisation of the 1H MRS spectrum from an AD patient this could 
give an early, non-invasive indication of drug efficacy. 
 
Decreased N-acetylaspartate (NAA) and increased myo-inositol (MI) has been 
noted in the brains of AD patients (Shonk et al., 1995; Dixon et al., 2002; Ackl 
et al., 2005). NAA is thought to be a neuronal marker (Urenjak et al., 1992), MI 
is thought to be a marker of gliosis or microglial activation (Lazeyras et al., 
1998), based on observations on cultured glial tumour cells (Brand et al., 1993). 
Some of these results have suggested 1H MRS might be used for both 
diagnosis of AD and distinguishing between different dementias. AD was 
differentiated from frontotemporal dementia (FTD) by analysing spectra 
acquired from midfrontal grey matter, decreased NAA was found in FTD but not 
AD (Ernst et al., 1997). This regional differentiation may be present in the early 
stages of neurodegeneration, but may be lost as the diseases progress and 
neurodegeneration spreads throughout the brain (Kantarci et al., 2004; Garrard 
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et al., 2006). NAA/Creatine was found to be lower in white matter of patients 
with vascular dementia than AD (Kattapong et al., 1996). Several studies have 
shown positive correlation between neuropsychological cognitive test scores 
and NAA/Cr, MI/Cr and NAA/MI ratios (Rose et al., 1999; Jessen et al., 2000; 
Huang et al., 2001; Kantarci et al., 2002), suggesting 1H MRS could be used to 
monitor disease progression. Decreased NAA can be seen in many 
neurological disorders, especially those involving neurodegeneration. 
Differentiation has been achieved by examining different regions. This may only 
be useful in early stage disese, before neurodegeneration becomes 
widespread. If another metabolic marker for AD could be discovered it could 
make differentiation using 1H MRS easier and more accurate. 
 
Understanding the underlying pathology behind AD has improved greatly in 
recent years. This is due in part to the study of mouse models of the disease, 
improving our understanding of deposition of Aβ and links to 
neurodegeneration (Moechars et al., 1999; Bayer and Wirths, 2008). 
Improvements in mouse models have also occurred, leading to models which 
are a closer approximation of human AD (Howlett et al., 2004; Bayer et al., 
2008). The most widely accepted current hypothesis about AD pathology is the 
amyloid cascade hypothesis (Hardy and Selkoe, 2002). This states that an 
imbalance in the production and degradation/clearance of amyloid beta peptide 
(Aβ) in the brain is the initiating event in a cascade ultimately leading to 
neuronal degeneration, dementia and death (Hardy and Selkoe, 2002). 
Therapies influencing Aβ production/degradation/clearance are all being 
developed and there is hope that these therapies can slow or halt the progress 
of AD once diagnosed. With ongoing research into new therapies, animal 
models are required to test efficacy before clinical trials. The object of this study 
is one such mouse, the TASTPM mouse. 
 
In this study the transgenic mouse TASTPM, which overexpresses both a 
mutant form of the amyloid precursor protein (hAPP695swe) and a mutant 
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presenilin-1 variant (M146V) (Howlett et al., 2004) was investigated. TASTPM 
mice first show amyloid deposits at 3 months and cognitive impairment is seen 
from 6 months (Howlett et al., 2004). Here, the aim was to investigate metabolic 
changes occurring over time in the brains of TASTPM mice compared to their 
base strain (C57/BL6). In order to accomplish this, chloroform-methanol 
extractions of the brains were performed and in vitro 1H MRS was performed on 
the resulting extracts. In vivo studies of different AD transgenic mice have 
shown a decrease in NAA and glutamate, and increases in MI and taurine 
(Dedeoglu et al., 2004; Marjanska et al., 2005; von Kienlin et al., 2005). A 
greater number of metabolites can be investigated in vitro and other 
metabolites which are of interest included markers of energy usage and 
neurotransmission, such as succinate and glutamate. 
 
2.2. Methods 
Chloroform-methanol extractions (Le Belle et al., 2002) were performed on 
frozen whole brains of both strains of mice at 3, 6, 9, 12, 15 and 18 months of 
age, with 5 - 9 mice in each group (Table.1).  
 Strain  
Age Group Wild Type TASTPM 
3 5 7 
6 9 8 
9 5 7 
12 9 8 
15 7 8 
18 5 8 
Table.1 Group sizes for TASTPM and wild type mice 
Mice were killed by cervical dislocation, brains were removed immediately and 
flash frozen in liquid N2. Brains were kept at -800C until use. During the 
extraction procedure, the whole frozen brains were kept under liquid nitrogen, 
adding chloroform and methanol (4oC) in a ratio of 1:2 (v/v; 3 ml/g tissue) and 
grinding the frozen reagents and brain tissue to a fine powder with a pestle and 
mortar. The tissue-solvent mixture was then allowed to thaw before being 
transferred to Teflon centrifuge tubes and sonicated. After 15 mins in contact 
with the first solvent mix, a 1:1 mix of chloroform and distilled water was added 
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(1ml/g tissue) to form an emulsion. This was followed by centrifugation at 
13000rpm for 20 min. The upper (aqueous) phase was then separated from the 
lower (organic) phase and both fractions were dried under a stream of nitrogen 
gas. The aqueous fraction was then redissolved in 650µl D2O (GOSS Scientific, 
UK) and the organic fraction in deuterated chloroform. The samples were 
adjusted to pH 7.0 with DCl and/or NaOD. A known concentration of deuterated 
trimethylsilylproprionate (TSP) was then added to each aqueous sample as an 
internal standard. Except where specified, reagents were obtained from Sigma, 
Aldrich UK. 
 
 1H MRS was performed at 25oC with a 9.4T Bruker Avance vertical bore 
magnet. 80-90% relaxed, one-dimensional spectra with a spectral width of 
20.55ppm were acquired with water presaturation using a pulse-acquire 
sequence with the following parameters: repetition time = 6.4s, central 
frequency = 400MHz, number of averages = 128, sweep width = 8223.7Hz, 
number of data points = 32768, dwell time 60.8µs, flip angle 30o. Resonance 
assignments were based on published chemical shifts and coupling patterns of 
known compounds. Peak areas were integrated using NUTS NMR Utility 
Transform Software (Acorn NMR, California, USA) with baseline flattening 
around each integration region (Fig.8). Water suppressed spectra were used 
for integration due to the flatter baseline. 
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Fig.8 Example of integration of spectrum, integrated peaks, from left to right: 
NAA, GABA, alanine, lactate 
 
Absolute quantification of metabolite levels was achieved by using a known 
concentration of the internal standard (157mg TSP dissolved in 10ml D2O, 10µl 
added to each sample = 0.912 µmoles in each sample) in each sample. 
Metabolite integrals were converted to concentrations by comparison to the 
TSP integral, taking into account numbers of equivalent protons making up the 
integral in question. Prior to statistical analysis, all values were normalised to 
individual brain weights to prevent brain size being a contributory factor. 
 
2-way ANOVA (age by genotype) was performed on the metabolite integrals 
using Graphpad Prism version 3.00 for Windows (GraphPad Software, San 
Diego, California, USA). Metabolites investigated were acetate, aspartate, 
alanine, choline, creatine, γ-aminobutyric acid (GABA), glutamate, glutamine, 
glycerophosphocholine (GPC), MI, lactate, NAA, phosphocholine, succinate 
and taurine. 
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2.3. Results 
High quality spectra, with good signal-to-noise (>10000:1 for the NAA 
resonance) were acquired from all samples, examples of which are given in 
Fig. 9 and 10, together with the assignments of the analysed peaks. All 
metabolite data are summarised in Table.3. 
 
 
Fig.9 Example spectrum obtained from an extract of an 18 month old wild type 
mouse brain. 1 – TSP, 2 – lactate, 3 – alanine, 4 – GABA, 5 – NAA, 6 – GABA, 
7 – glutamate, 8 – succinate, 9 – glutamine, 10 – aspartate, 11 – creatine, 12 – 
choline containing compounds, 13 – taurine, 14 – MI 
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Fig.10 Example spectrum obtained from an extract of an 18 month old 
TASTPM mouse brain. 1 – TSP, 2 – lactate, 3 – alanine, 4 – GABA, 5 – NAA, 6 
– GABA, 7 – glutamate, 8 – succinate, 9 – glutamine, 10 – aspartate, 11 – 
creatine, 12 – choline containing compounds, 13 – taurine, 14 - MI 
 
15 metabolites were quantified and analyzed by a 2-way ANOVA (age and 
genotype). Due to the high number of variables being compared, a Bonferroni 
correction was performed on the standard significance level of p<0.05, as 15 
variables were tested a final significance level of p<0.0033 was used. 
Significant effects of age alone were identified for creatine (p<0.001), glutamine 
(p<0.0001) and total choline-containing compounds (the sum of  
glycerophosphocholine (GPC), phosphocholine and choline levels - p<0.0001).  
Creatine was fairly stable and at similar levels in both groups until 15 months, 
when there was a marked increase in the TASTPM mice (Fig.11). Despite this 
change, there was neither an overall effect nor an interaction of genotype on 
creatine concentration. A significant effect of genotype alone was only identified 
for myo-inositol (Fig.12), which was generally higher in TASTPM mice at all 
timepoints (Fig. 18). Though the difference appeared greater in the older age-
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groups there was no significant interaction with, or main effect of, age.  
Succinate, GPC and choline all showed significant effects of both age and 
genotype. Succinate concentration fell continuously from a lower starting point 
in the TASTPM mice (Fig. 17), whereas it increased in wild type mice up until a 
fall at 15 months. Succinate was lower in TASTPM mice at all time points 
(Fig.13). Choline levels fluctuated over time, but this was much more 
pronounced in the TASTPM mice, with choline much lower than in the wild type 
at 6 – 12 months (Fig.14 + 19). GPC increased over time in both strains, but 
was slightly higher in TASTPM mice (Fig.15). No significant effect of age or 
strain was seen on NAA levels (Fig.16) 
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Fig.11 Creatine levels in TASTPM and wild type mice. Values shown are mean 
± S.E.M. 
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Fig.12 MI levels in TASTPM and wild type mice. Values shown are mean ± 
S.E.M. 
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Fig.13 Succinate levels in TASTPM and wild type mice. Values shown are 
mean ± S.E.M. 
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Fig.14 Choline levels in TASTPM and wild type mice. Values shown are mean 
± S.E.M 
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Fig.15 GPC levels in TASTPM and wild type mice. Values shown are mean ± 
S.E.M 
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Fig.16 NAA levels in TASTPM and wild type mice. Values shown are mean ± 
S.E.M 
 
Metabolite Age Genotype Interaction 
Succinate <0.0001 <0.0001 ns 
Choline <0.0001 0.0007 <0.0001 
MI ns <0.0001 ns 
GPC <0.0001 0.0030 ns 
Creatine 0.0008 ns ns 
Glutamine <0.0001 ns ns 
Total Choline <0.0001 ns ns 
 
Table.2 Table showing ANOVA probabilities of significance for metabolites 
where p<0.005. All other metabolite comparisons did not reach statistical 
significance. 
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 3 months 6 months 
Metabolite Mean S.D. CoV Mean S.D CoV 
Inositol Wild Type 4.72 0.70 14.90 5.42 0.86 15.95 
Inositol TASTPM 5.21 1.09 20.99 5.82 1.34 23.08 
Cr2 Wild Type 5.04 0.50 9.82 5.82 0.94 16.21 
Cr2 TASTPM 5.49 0.94 17.10 5.53 0.79 14.26 
Taurine Wild Type 6.63 0.91 13.80 7.34 1.10 14.95 
Taurine TASTPM 7.02 1.43 20.30 7.28 1.22 16.72 
GPC Wild Type 0.71 0.09 12.92 0.82 0.14 16.77 
GPC TASTPM 0.78 0.17 21.84 0.83 0.13 16.15 
PC Wild Type 0.44 0.04 9.29 0.51 0.07 14.54 
PC TASTPM 0.46 0.09 20.42 0.44 0.07 15.44 
Choline Wild Type 0.18 0.05 26.38 0.17 0.06 35.13 
Choline TASTPM 0.17 0.03 19.71 0.11 0.02 16.29 
Cr1 Wild Type 7.05 0.80 11.34 7.74 1.01 13.04 
Cr1 TASTPM 7.47 1.28 17.13 7.53 1.09 14.44 
Aspartate Wild 
Type 2.64 0.38 14.58 2.82 0.51 18.11 
Aspartate TASTPM 2.60 0.45 17.29 2.46 0.45 18.32 
Glutamine Wild 
Type 4.01 0.74 18.51 4.86 1.40 28.85 
Glutamine 
TASTPM 4.05 0.78 19.38 4.12 0.64 15.56 
Succinate Wild 
Type 0.58 0.05 9.19 0.59 0.15 25.58 
Succinate 
TASTPM 0.53 0.10 18.90 0.48 0.07 14.53 
Glutamate Wild 
Type 7.23 0.65 9.02 7.67 1.22 15.85 
Glutamate 
TASTPM 7.07 1.41 19.87 7.09 1.13 15.99 
GABA Wild Type 2.84 0.26 9.07 3.18 0.59 18.41 
GABA TASTPM 3.06 0.56 18.18 2.86 0.45 15.56 
NAA Wild Type 4.52 0.38 8.36 5.02 0.80 15.91 
NAA TASTPM 4.88 0.99 20.33 4.92 0.70 14.20 
Acetate Wild Type 0.29 0.08 28.43 0.28 0.05 19.33 
Acetate TASTPM 0.83 1.52 182.77 0.25 0.06 23.95 
Alanine Wild Type 0.86 0.09 10.22 1.06 0.18 17.16 
Alanine TASTPM 0.95 0.39 41.56 0.92 0.10 10.88 
Lactate Wild Type 10.77 1.13 10.48 13.59 2.03 14.93 
Lactate TASTPM 12.91 3.69 28.59 11.18 1.30 11.67 
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 9 months 12 months 
Metabolite Mean S.D CoV Mean S.D CoV 
Inositol Wild Type 5.07 0.83 16.30 5.37 0.74 13.72 
Inositol TASTPM 5.79 0.44 7.54 5.48 0.77 14.10 
Cr2 Wild Type 5.79 0.59 10.24 5.75 0.56 9.77 
Cr2 TASTPM 6.07 0.64 10.61 5.64 0.42 7.45 
Taurine Wild Type 7.25 1.11 15.31 7.57 0.73 9.70 
Taurine TASTPM 7.62 0.91 11.93 6.76 0.69 10.22 
GPC Wild Type 0.82 0.14 16.57 0.86 0.09 10.09 
GPC TASTPM 0.92 0.08 8.67 0.86 0.11 12.21 
PC Wild Type 0.55 0.06 10.13 0.50 0.06 12.35 
PC TASTPM 0.49 0.04 8.61 0.46 0.04 9.66 
Choline Wild Type 0.15 0.02 16.65 0.18 0.05 26.51 
Choline TASTPM 0.10 0.03 27.16 0.10 0.02 14.92 
Cr1 Wild Type 8.04 0.83 10.28 7.93 0.74 9.28 
Cr1 TASTPM 8.31 0.84 10.05 7.66 0.54 7.08 
Aspartate Wild 
Type 2.75 0.22 7.83 2.67 0.24 9.04 
Aspartate TASTPM 2.70 0.19 7.20 2.64 0.19 7.07 
Glutamine Wild 
Type 5.86 1.39 23.69 4.22 0.52 12.36 
Glutamine 
TASTPM 4.42 0.46 10.37 5.15 1.30 25.26 
Succinate Wild 
Type 0.61 0.09 15.17 0.64 0.12 18.28 
Succinate 
TASTPM 0.45 0.05 12.01 0.43 0.05 12.17 
Glutamate Wild 
Type 7.80 0.62 7.99 7.55 0.78 10.33 
Glutamate 
TASTPM 7.77 0.74 9.53 7.24 0.42 5.76 
GABA Wild Type 3.27 0.46 14.11 3.11 0.39 12.48 
GABA TASTPM 2.87 0.32 11.32 2.69 0.15 5.55 
NAA Wild Type 5.21 0.50 9.52 5.03 0.53 10.48 
NAA TASTPM 5.09 0.45 8.89 4.79 0.31 6.50 
Acetate Wild Type 0.28 0.05 16.58 0.28 0.04 13.22 
Acetate TASTPM 0.22 0.04 18.75 0.20 0.02 10.87 
Alanine Wild Type 1.04 0.10 9.34 1.03 0.14 13.67 
Alanine TASTPM 0.92 0.12 13.27 0.88 0.08 8.60 
Lactate Wild Type 12.95 1.10 8.47 13.57 1.73 12.75 
Lactate TASTPM 11.90 1.66 13.96 11.11 0.94 8.49 
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 15 months 18 months 
Metabolite Mean S.D CoV Mean S.D CoV 
Inositol Wild Type 5.29 0.89 16.88 4.58 0.33 7.26 
Inositol TASTPM 6.57 0.69 10.56 6.70 0.99 14.70 
Cr2 Wild Type 6.05 1.10 18.12 5.60 0.59 10.55 
Cr2 TASTPM 6.84 0.50 7.32 6.91 0.64 9.20 
Taurine Wild Type 7.70 1.48 19.25 7.05 0.48 6.84 
Taurine TASTPM 8.76 0.74 8.40 8.47 0.63 7.47 
GPC Wild Type 0.95 0.16 17.33 0.87 0.10 11.63 
GPC TASTPM 1.08 0.09 8.51 1.07 0.13 12.50 
PC Wild Type 0.51 0.08 15.22 0.47 0.07 14.23 
PC TASTPM 0.53 0.05 8.70 0.53 0.05 8.56 
Choline Wild Type 0.17 0.02 13.92 0.17 0.02 11.62 
Choline TASTPM 0.20 0.02 10.04 0.19 0.01 6.23 
Cr1 Wild Type 8.22 1.53 18.61 7.72 0.82 10.65 
Cr1 TASTPM 9.34 0.66 7.06 9.35 0.89 9.48 
Aspartate Wild 
Type 2.83 0.61 21.53 2.54 0.26 10.31 
Aspartate TASTPM 3.15 0.17 5.43 2.88 0.24 8.48 
Glutamine Wild 
Type 5.02 0.89 17.66 6.10 1.98 32.49 
Glutamine 
TASTPM 6.06 1.13 18.60 6.45 1.25 19.38 
Succinate Wild 
Type 0.48 0.10 20.12 0.47 0.10 20.53 
Succinate 
TASTPM 0.36 0.05 14.29 0.35 0.05 13.22 
Glutamate Wild 
Type 7.63 1.43 18.77 7.10 0.94 13.18 
Glutamate 
TASTPM 8.45 0.50 5.90 8.18 0.64 7.85 
GABA Wild Type 2.90 0.55 19.00 2.76 0.40 14.51 
GABA TASTPM 3.07 0.20 6.54 2.99 0.23 7.84 
NAA Wild Type 5.04 1.00 19.80 4.70 0.59 12.62 
NAA TASTPM 5.15 0.26 4.97 4.96 0.33 6.71 
Acetate Wild Type 0.68 0.12 17.98 0.65 0.11 17.04 
Acetate TASTPM 0.76 0.05 6.88 0.74 0.05 6.42 
Alanine Wild Type 0.90 0.19 21.10 0.72 0.09 12.79 
Alanine TASTPM 0.91 0.10 11.09 0.94 0.09 9.71 
Lactate Wild Type 12.26 2.85 23.21 10.59 1.10 10.40 
Lactate TASTPM 11.36 1.41 12.40 12.12 1.21 9.97 
Table.3 Table of mean, standard deviation and coefficient of variance for all 
metabolites at all time points 
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Fig.17 Comparison of spectra from 18 month wild type (top) and TASTPM mice 
showing differences in succinate signal (1) at 2.41ppm, also showing the 
glutamate C4 pseudo triplet (2) and a GABA triplet (3) 
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Fig.18 Comparison of spectra from 18 month wild type (top) and TASTPM mice 
showing differences in MI signal (1) at 4.06ppm, also showing the creatine peak 
at 3.93ppm (2) and lactate quartet at 4.12ppm (3)  
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Fig.19 Comparison of spectra from 12 month wild type (top) and TASTPM mice 
showing differences in choline signal (1) at 3.20ppm, also showing the 
phosphocholine peak at 3.23ppm (2), the glycerophosphocholine peak at 
3.24ppm (3) and the creatine peak at 3.03ppm (4). These spectra have been 
offset in frequency for clarity 
 
 
 
2.4. Discussion 
Metabolite concentrations are comparable to other studies using in vitro 1H 
MRS on mouse and rat brain extracts (Agrawal et al., 1968; Cerdan et al., 
1985; Arvin et al., 1994; Florian et al., 1996; Chassain et al., 2008). Good 
comparability to studies using HPLC was also achieved (Murai et al., 2001; 
Bogen et al., 2008). The coefficients of variance indicate good reproducibility in 
the results for the most part (Table.3).  
 
The higher levels of MI observed in TASTPM mice are a genotype effect. The 
presence of higher MI in younger TASTPM mice suggests that MI levels are 
independent of amyloid plaque formation. The greater difference at 15 and 18 
months age groups could however, be linked to amyloid deposition. The 
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elevated levels of MI observed in TASTPM mice are in agreement with a 
previous in vivo study showing increased MI in transgenic (APP-PS1) AD mice 
(Marjanska et al., 2005). However, in two other studies of transgenic AD mice 
by 1H MRS, no increase in MI was reported (Dedeoglu et al., 2004; von Kienlin 
et al., 2005). One study found an increase in taurine levels and postulated that 
this may be the equivalent of the MI increase seen in human AD (Dedeoglu et 
al., 2004). The increase in MI could be indicative of glial cell proliferation or 
microglial activation in these mice. Activated microglia have been found to be 
associated with the amyloid plaques in TASTPM mice (Howlett et al., 2004). 
The TASTPM mice and APP-PS1 mice contain the same double mutant 
APPswe (K671N; M671L) mutation (Richardson et al., 2003; Marjanska et al., 
2005). The PS1 mutations incorporated are slightly different, the TASTPM 
contains the M146V variant (Howlett et al., 2004), the APP-PS1 contains the 
M146L variant (Marjanska et al., 2005). The functions of MI in osmoregulation 
and membrane metabolism mean that higher MI levels may cause disruption of 
normal function (Beacher et al., 2005).  MI is also a precursor in the formation 
inositol trisphosphate and therefore can affect neuronal calcium signalling 
(Berridge, 1993). Calcium signalling modulates aspects of brain development 
and function, including neurotransmission, learning and memory (Berridge et 
al., 2000). The presence of elevated MI may be causing some of the problems, 
as opposed to being merely a marker. However, the fact that there was no age-
dependence of the difference in MI suggests that it may be a disease marker 
but would not act as a biomarker of disease progression in this model. 
 
Consistently lower levels of succinate in TASTPM mice could be indicative of 
impaired neuronal energy production or of mitochondrial dysfunction in these 
mice. The effect appears to be a genotype effect, as succinate is lower in 
TASTPM mice at all time points. As amyloid plaques are not detectable at 3 
months, it would appear that lower succinate is independent of amyloid plaque 
formation. There is evidence that intraneuronal Aβ accumulation could be 
responsible for early pathological changes, prior to amyloid plaque formation 
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(Bayer et al., 2008). Mitochondrial dysfunction and impaired neuronal energy 
production have also been observed in human AD (Valla et al., 2001; Zhu et al., 
2004; Moreira et al., 2007). Data from frozen tissue samples has shown that 
the posterior cingulate cortex in AD patients has reduced cytochrome oxidase 
(CO) activity (Valla et al., 2001). CO is a mitochondrial enzyme essential for 
aerobic energy metabolism. This reduction appears to be linked to disease 
duration (Valla et al., 2001). Another study found increased CO and lipoic acid 
in the cytoplasm of neurons of AD sufferers, lipoic acid was also found in 
autophagic vacuoles. This suggests that mitochondria undergo increased 
autophagic degradation in AD sufferers (Moreira et al., 2007). Positron 
emission tomography (PET) has shown reduced cerebral glucose metabolism 
in AD patients as well as patients thought to be at risk of developing AD 
(Drzezga et al., 2003). 
 
Glutamate and glutamine levels were not significantly different between the two 
strains, this does not agree with the in vivo studies, all of which found reduced 
glutamate levels (compared with total creatine) in older mice (Dedeoglu et al., 
2004; Marjanska et al., 2005; von Kienlin et al., 2005). The signal from 
succinate combines with the glutamate signal in vivo due to the broad 
linewidths of in vivo MRS. It is possible that these studies were detecting 
reduced succinate and interpreting this as reduced glutamate levels. It is also 
possible that the specific brain regions observed had reduced glutamate, which 
was masked in this study by whole brain usage. 
 
The slightly higher levels of GPC in the TASTPM mice may indicate differences 
in cell membrane composition. Decreased choline levels in the 6-12 month 
TASTPM mice could indicate problems with acetylcholine neurotransmission, or 
perturbation of phospholipid metabolism or cell membrane changes. Altered 
phospholipid metabolism has been observed in human AD (Kuo et al., 1998; 
Notkola et al., 1998; Roher et al., 1999; Sparks et al., 2000). 
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We did not observe decreased NAA levels in older TASTPM mice, though this 
might be expected on the basis of human data. Although it is possible a 
difference may be masked by the fact that we used whole brains in this study, 
amyloid deposition is extensive throughout the brains of TASTPM mice 
(Howlett et al., 2008). Pathology directly related to amyloid deposition would, 
therefore be expected to occur throughout the brain. Specific brain areas were 
targeted in the in vivo studies which showed a decrease (Dedeoglu et al., 2004; 
Marjanska et al., 2005; von Kienlin et al., 2005). All these studies used creatine 
as the reference metabolite. If creatine is used as the reference metabolite in 
this study, a decrease in NAA is detected in older TASTPM mice and a 
significant effect of strain, age and a strain x age interaction (p<0.0001) are 
detected by ANOVA. As the in vivo studies used creatine as a reference 
metabolite, believing it to be stable across age and strain, there is potential this 
could lead to detection of changes in NAA which may have been influenced by 
increased creatine signal. The sensitivity of the study to detect changes in NAA 
would have produced a significant result given ~20% decrease in TASTPM 
NAA in the 15 and 18 month groups. As the mean NAA actually increased, it is 
safe to say no decrease in NAA occurs in the TASTPM mice with age. 
 
Increased creatine levels in older TASTPM mice were not expected. Although if 
there is extensive glial cell proliferation the relatively higher levels of creatine in 
astrocytes (Urenjak et al., 1993) could be a factor. Increasing creatine levels 
have also been linked with cognitive decline in elderly humans (Ferguson et al., 
2002). A possible reason for the apparent increase could be osmotic stress in 
these mice (Lien et al., 1990). It is possible that, as plaque load increases in 
older TASTPM mice, the huge amount of Aβ interferes with normal 
osmoregulation in the brain. The observed increase indicates that care should 
be taken when using creatine as a reference metabolite. If creatine ratios were 
used in this case the results would have indicated a decrease in NAA in the 
TASTPM mice in the older age group, which could lead to misinterpretation. 
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The potential for this whole brain study to have masked localised changes in 
metabolic levels is highlighted by another in vitro study carried out on dissected 
brains of AD transgenic mice (Salek et al., 2010). In this study, decreases in 
NAA, glutamate, glutamine, taurine, GABA, creatine, choline and succinate 
were observed in the hippocampus, cortex, frontal cortex and midbrain of 
TgCRND8 AD transgenic mice. These results indicate the possibility of 
neurodegeneration as well as disrupted neuronal metabolism in the affected 
areas. 
 
The brains of mice increase in size with age, in contrast to humans 
(Maheswaran et al., 2009). Brain growth over time has been shown to be 
greater in TASTPM mice than their wild type counterparts (Maheswaran et al., 
2009). This is especially evident in grey matter rich areas such as the 
hippocampus and thalamus, in wild type mice there is little or no growth in 
these areas, with white matter and ventricular enlargement being responsible 
for the overall increase in size. As different brain regions contain varying 
concentrations of metabolites, the differential growth of these regions may 
cause some inaccuracy in this study. However, the brain regions displaying 
altered growth show marked amyloidosis and astrogliosis (Maheswaran et al., 
2009). The increased size does not necessarily indicate altered functionality, 
but appears to be an inflammatory response to increasing amyloidosis. 
Additionally, though we observed increasing brain weights right up to the 18 
month time point, there was no significant difference between the brain weight 
of wild type and TASTPM mice. Finally, normalising results to brain weight 
before analysis removes this as a confounding factor. Therefore I do not 
believe the differential brain growth between the two strains has a significant 
effect on the results of this study. 
 
In this study, evidence for a specific disease responsive biomarker was sought. 
Although some findings were encouraging, with succinate levels being the most 
promising, the search for conclusive proof of such a biomarker goes on. 
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Chapter 3. A Comparison of the lipid content of TASTPM and normal 
mouse brain by 1H MRS of chloroform-methanol extracts 
 
3.1. Introduction 
 
There is strong evidence linking phospholipid, and particularly cholesterol 
metabolism and handling to AD which prompted the following study of 
phospholipid profiles in normal and TASTPM mice. This evidence is 
summarised below.  
 
The apolipoprotein E (ApoE) ε4 allele is a genetic risk factor for late onset AD 
(LOAD) (Strittmatter et al., 1993). The major function of ApoE is to redistribute 
lipids and to maintain lipid and cholesterol homeostasis. ApoE mRNA has been 
found at significantly higher levels in the brains of AD patients (Yamagata et al., 
2001). ApoE has been localised by immunohistochemistry to amyloid plaques 
(Harr et al., 1996). Carriers of the ε4 allele have been found to have 
consistently higher serum levels of triglycerides and cholesterol compared to 
peers who carry a different allele (Davignon et al., 1988a). Cholesterol uptake, 
when bound to ApoE4 was found to be less efficient than with other isoforms 
(E2 and E3) in cultured neurons in vitro (Rapp et al., 2006). ApoE4 also 
appears to be the least efficient of the three isoforms in promoting cholesterol 
efflux from neurons in culture (Michikawa et al., 2000).ε4 allele carriers are also 
thought to be at higher risk of coronary artery disease and atherosclerosis 
(Davignon et al., 1988b).  
 
High serum total cholesterol and LDL cholesterol have been found to correlate 
positively with prevalence of AD and amount of Aβ42 in the brain (Kuo et al., 
1998; Notkola et al., 1998).AD patients have been found to have higher total 
and LDL cholesterol, as well as lower HDL levels compared to age-matched 
controls (Roher et al., 1999; Sparks et al., 2000). In cholesterol-fed 
experimental animals, increased production and build up of Aβ has been shown 
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in the brain (Sparks et al., 2000). In humans, use of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors, which lower serum cholesterol have been 
associated with decreased prevalence of AD (Wolozin et al., 2000).  
 
Alterations in cholesterol homeostasis have been implicated as having a direct 
role in the pathogenesis of AD, interference with cholesterol transfer between 
astrocytes and synapses is thought to cause synaptic loss and, eventually 
neurodegeneration (Pfrieger, 2003). In AD brains a reduction in membrane 
cholesterol:phospholipid ratios has been discovered (Shobab et al., 2005; 
Stefani and Liguri, 2009). It is possible that alterations to the structure of the 
lipid membrane bilayer are involved in the pathogenesis of AD. Changes to the 
membrane could have a knock on effect on the activity and catabolism of any 
membrane-bound proteins, including APP. 
 
It is possible that the increased risk of AD associated with ApoE4 is due, in part 
or in full, to inefficient lipid homeostasis. Perturbations of lipid homeostasis 
have the potential to damage synapses and neurons and, if serious enough, 
lead to neurodegeneration. For more detail see (Martins et al., 2009). 
 
Choline, PC and GPC are better reporters of phospholipid metabolism than 
stationary phospholipids. Choline and its related compounds are essential in 
formation of the membrane lipid phosphatidylcholine. They are also released 
when phosphatidylcholine is metabolised. Differences were seen in choline and 
GPC levels between TASTPM and wild type mice in the aqueous fraction of the 
brain extracts. Thus there is potential for differences in lipid metabolism 
between the two strains. 
 
For these reasons, examination of the lipid content of the brains of TASTPM 
AD mice was instigated. Any changes in lipid content could be markers of 
altered membrane composition or lipid homeostasis. If either or both of these 
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effects are present then it would mean the TASTPM model is expressing further 
hallmarks of human AD, further validating it as an AD model. 
 
3.2. Methods 
 
Chloroform-methanol extractions (Le Belle et al., 2002) were performed on 
frozen whole brains of TASTPM and wild type mice at 3, 6, 9, and 12 months of 
age, with 5 - 9 mice in each group. The whole frozen brains were kept under 
liquid nitrogen, adding chloroform and methanol (4oC) in a ratio of 1:2 (v/v; 3 
ml/g tissue) and grinding the frozen reagents and brain tissue to a fine powder 
with a pestle and mortar. The tissue-solvent mixture was then allowed to thaw 
before being transferred to Teflon centrifuge tubes and sonicated. After 15 mins 
in contact with the first solvent mix, a 1:1 mix of chloroform and distilled water 
was added (1ml/g tissue) to form an emulsion. This was followed by 
centrifugation at 13000rpm for 20 min. The upper (aqueous) phase was then 
separated from the lower (organic) phase and both fractions were dried under a 
stream of nitrogen gas. The aqueous fraction was then redissolved in 650µl 
D2O (GOSS Scientific, UK) and the organic fraction in deuterated chloroform. 
The samples were pH adjusted to pH 7.0 with DCl and/or NaOD. Except where 
specified, reagents were obtained from Sigma, Aldrich UK. 
 
 1H MRS was performed at 25oC with a 9.4T Bruker Avance vertical bore 
magnet. Fully relaxed, one-dimensional spectra with a spectral width of 
20.55ppm were acquired using a pulse-acquire sequence with the following 
parameters: repetition time = 6.4s, central frequency = 400MHz, sweep width = 
8223.7Hz, number of data points = 32768, dwell time 121.6µs, flip angle 30o. 
Resonance assignments were based on published chemical shifts and coupling 
patterns of known compounds. Peak areas were integrated using NUTS NMR 
Utility Transform Software (Acorn NMR) with baseline flattening around each 
integration region (Fig.20). Peak assignments were performed based on results 
published in literature (Gunstone, 1995; Kostara et al., 2010). 
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Fig.20 Example of integration of spectrum, integrated peaks, functional groups 
represented from left to right: C=CCH2C=C, CH2CO and CH2C=C 
 
2 way ANOVA was performed on the lipid integrals using Graphpad Prism 
version 3.00 for Windows (GraphPad Software, San Diego California USA). 
Functional groups investigated were CH=CH, CH2OCOR, CH2OPO2-, (CH3)3, 
CH2OR, N+(CH3)3, CH2NH3+, CH2CH2CO, CH=CH-CH2-CH=C, CH2CO, 
CH2C=C, (CH2)n, CH3, Triglyceride terminal methyls and C18/19 cholesterol 
methyls. The (CH2)n peak at 1.3ppm was used as a reference peak as it 
remained fairly constant in all spectra. 
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3.3. Results 
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Fig.21 Peak assignments for lipid integrals. 1 – C18/19 cholesterol methyls, 2 – 
triglyceride terminal methyls, 3 – CH3, 4 – (CH2)n(used as reference peak), 5 - 
CH2CH2CO, 6 - CH2C=C, 7 - CH2CO, 8 – CH=CH-CH2-CH=CH, 9 - CH2NH3+, 
10 - N+(CH3)3, 11 - CH2OR, 12 - (CH3)3, 13 - CH2OPO2-, 14 - CH2OCOR, 15 - 
CH2OCOR, 16 - CH=CH, 17 – chloroform (undeuterated)  
 
 
The biggest resonance detected was from the methylene backbones of the 
lipids. We also detected cholesterol and triglyceride methyl groups, as well as 
phosphorylated, alkylglycerol, ketone and N-methyl head groups. Unsaturated 
groups were also in evidence. 
 
14 functional groups in all were quantified and analyzed by a 2-way ANOVA 
(age and genotype). To reduce the likelihood of false positive results, a 
bonferroni correction was used, giving a significance level of p<0.0035. Of all 
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functional groups investigated, only two approached significance. In the case of 
CH=CH-CH2-CH=C there was an almost significant (p=0.0069) effect of 
genotype, levels were consistently higher in TASTPM mice than wild type 
(Fig.22). Also for CH2OR there was an almost significant (p=0.0044) effect of 
genotype, levels were again consistently higher in TASTPM mice than wild 
type, though the variance was quite high in the TASTPM groups (Fig.23). Two 
other lipid groups showed potential mild genotype effects, (CH3)3 and CH2CO 
both appeared to be higher in 12 month old TASTPM mice compared with wild 
type, the significance level in both cases was p =0.01. 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
3 month 6 month 9 month 12 month
M
ea
n
 
In
te
gr
al
 
Va
lu
e
C=CCH2C=C
Wild Type
C=CCH2C=C
TASTPM
 
Fig.22 CH=CH-CH2-CH=C levels in TASTPM and wild type mice, error bars 
represent S.E.M.  
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Fig.23 CH2OR levels in TASTPM and wild type mice, error bars represent 
S.E.M.  
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  3 month 6 month 
Lipid 
Chemical 
Shift Mean S.D CoV Mean S.D CoV 
Chloroform WT 7.34-7.20 4671 3174 67.9 1829 1530 83.6 
Chloroform T 7.34-7.20 1643 1013 61.6 1626 874 53.7 
CH=CH WT 5.49-5.28 8331 2088 25 7958 1483 18.6 
CH=CH T 5.49-5.28 7916 1444 18.2 8024 865 10.8 
CH2OCOR WT 5.25-5.11 1170 301 25.6 1127 221 19.6 
CH2OCOR T 5.25-5.11 1197 191 15.9 1240 195 15.6 
CH2OCOR WT 4.45-4.01 4818 1203 24.9 5471 978 17.9 
CH2OCOR T 4.45-4.01 5046 1083 21.4 5298 573 10.8 
CH2OPO2- WT 3.99-3.89 2465 589 23.9 2519 445 17.7 
CH2OPO2- T 3.99-3.89 2594 495 19.1 2745 504 18.3 
(CH3)3 WT 3.8-3.7 1432 332 23.1 1569 279 17.7 
(CH3)3 T 3.8-3.7 1667 399 23.9 1750 452 25.8 
CH2OR WT 3.59-3.46 1307 292 22.4 1776 563 31.7 
CH2OR T 3.59-3.46 3991 4222 105.7 3019 2794 92.5 
N+(CH3)3 WT 3.34-3.26 4290 935 21.8 4173 746 17.9 
N+(CH3)3 T 3.34-3.26 4439 915 20.6 4303 628 14.6 
CH2NH3+ WT 3.2-3.11 1482 394 26.6 1344 213 15.9 
CH2NH3+ T 3.2-3.11 1337 243 18.1 1408 273 19.3 
C=CCH2C=C WT 2.92-2.75 4976 1455 29.2 4939 1276 25.8 
C=CCH2C=C T 2.92-2.75 5014 724 14.4 5497 1295 23.5 
CH2CO WT 2.42-2.18 6210 1521 24.5 5942 1125 18.9 
CH2CO T 2.42-2.18 6126 1041 17 6173 856 13.9 
CH2C=C WT 2.13-1.93 7390 1836 24.8 7295 1453 19.9 
CH2C=C T 2.13-1.93 7245 1198 16.5 7515 1100 14.6 
CH2*CH2CO WT 1.64-1.43 8674 1917 22.1 8717 1824 20.9 
CH2*CH2CO T 1.64-1.43 8803 1379 15.7 8895 1421 16 
CH3 WT 1.04-0.97 4180 831 19.9 4198 964 22.1 
CH3 T 1.04-0.97 4122 755 18.3 4107 553 13.4 
Triglyceride 
terminal methyls 
WT 0.95-0.83 15175 3118 20.5 14686 3064 20.9 
Triglyceride 
terminal methyls T 0.95-0.83 14450 2453 17 14665 1853 12.6 
C18/19 cholesterol 
methyls WT 0.71-0.65 1986 446 22.5 2120 551 26 
C18/19 cholesterol 
methyls T 0.71-0.65 1983 454 22.8 1939 346 17.8 
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  9 month 12 month 
Lipid 
Chemical 
Shift Mean S.D CoV Mean S.D CoV 
Chloroform WT 7.34-7.20 1088 384 35.3 2563 2122 82.8 
Chloroform T 7.34-7.20 1639 459 28 2175 786 36.1 
CH=CH WT 5.49-5.28 7361 2301 31.3 7423 1714 23.1 
CH=CH T 5.49-5.28 7551 1304 17.3 6677 1822 27.3 
CH2OCOR WT 5.25-5.11 1114 310 27.8 1077 219 20.4 
CH2OCOR T 5.25-5.11 1171 173 14.8 1015 257 25.2 
CH2OCOR WT 4.45-4.01 5043 2006 39.8 4814 1134 23.6 
CH2OCOR T 4.45-4.01 4829 1091 22.6 4563 1103 24.1 
CH2OPO2- WT 3.99-3.89 2453 808 32.9 2345 490 20.9 
CH2OPO2- T 3.99-3.89 2521 424 16.8 2277 408 17.9 
(CH3)3 WT 3.8-3.7 1558 550 35.2 1446 304 21 
(CH3)3 T 3.8-3.7 1613 352 21.7 1450 256 17.7 
CH2OR WT 3.59-3.46 2254 1143 50.7 1479 418 28.2 
CH2OR T 3.59-3.46 4674 4536 97.1 3041 2780 91.4 
N+(CH3)3 WT 3.34-3.26 4086 1272 31.1 3995 922 23.1 
N+(CH3)3 T 3.34-3.26 4155 786 18.9 3317 1113 33.6 
CH2NH3+ WT 3.2-3.11 1417 304 21.5 1289 359 27.9 
CH2NH3+ T 3.2-3.11 1448 389 26.8 1093 269 24.5 
C=CCH2C=C 
WT 2.92-2.75 4424 1121 25.3 4315 783 18.1 
C=CCH2C=C T 2.92-2.75 5397 1197 22.2 4327 897 20.7 
CH2CO WT 2.42-2.18 5562 1431 25.7 5622 1213 21.6 
CH2CO T 2.42-2.18 6129 1043 17 5589 1374 24.6 
CH2C=C WT 2.13-1.93 6934 1788 25.8 7033 1506 21.4 
CH2C=C T 2.13-1.93 7575 1230 16.2 6511 1585 24.3 
CH2*CH2CO 
WT 1.64-1.43 8168 1787 21.9 8359 1819 21.7 
CH2*CH2CO T 1.64-1.43 9359 1639 17.5 7635 2140 28 
CH3 WT 1.04-0.97 3748 943 25.1 3955 1064 26.9 
CH3 T 1.04-0.97 4135 765 18.5 3763 1101 29.3 
Triglyceride 
terminal 
methyls WT 0.95-0.83 13369 3514 26.3 14160 3460 24.4 
Triglyceride 
terminal 
methyls T 0.95-0.83 14498 2279 15.7 13030 3461 26.6 
C18/19 
cholesterol 
methyls WT 0.71-0.65 1773 540 30.5 1918 609 31.7 
C18/19 
cholesterol 
methyls T 0.71-0.65 1900 450 23.6 1904 580 30.5 
Table 4. Mean Integral values, along with standard deviation and coefficient of 
variance for all measured lipid functional groups at all time points. T – TASTPM 
mice, WT – Wild type mice 
 
 
 
 100
3.4. Discussion 
The use of the methylene peak as a reference appears to compensate well for 
spectrometer variability between spectra. The coefficients of variance for the 
functional groups are, for the most part very good (Table.4), with one notable 
exception, the CH2OR group, this may be an artefact. The detection accuracy 
for most of the functional groups appears to be excellent. 
 
Although no significant differences were found in brain lipid content between 
the two strains of mice, all the groups which approached significance had one 
thing in common. In all cases the lipid signal was higher in the TASTPM mouse 
brains than their wild type counterparts.  
 
The apparent increased lipid signal for unsaturated lipid, alkylglycerol, 
triglyceride methyl groups and ketone groups indicates the possibility of 
alterations either lipid homeostasis or membrane composition, especially in 
older TASTPM mice. If this is the case then the TASTPM mice are displaying 
another of the factors in AD pathology. 
 
A problem arises in that, while appearing to display a trend, the data are not 
significant. There may be several reasons for this. 
 
One reason is that the entire lipid content of the brain was extracted and 
analysed. It is quite possible that any perturbations in membrane composition 
or lipid metabolism would be localised to specific areas such as the 
hippocampus or thalamus. If this is the case then larger, compartmentalized 
changes might not be detected due having been combined with less affected 
areas. 
 
As we can only detect lipid functional groups, rather than whole lipid molecules 
using this technique, it is possible that there are differences which are 
disguised by this shortcoming. HPLC analysis of the samples may yield more 
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useful information. The fact remains that there were differences in choline and 
its related compounds between the two strains. Thus there remains the 
potential for differences to be found in lipid metabolism, along with the potential 
for lipid metabolism being responsible for the pathogenic changes observed in 
the TASTPM mice. 
 
Potential future work could include HPLC analysis of organic samples from 
extracts to determine precise lipid content, as well as isolating more specific 
brain regions to look for regional differences. 
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Chapter 4. Longitudinal 1H MRS of TASTPM and wild type mice in vivo 
with concurrent T1 measurement and behavioural analysis 
 
4.1. Introduction 
There is a need to develop a biomarker for AD, to aid in drug development, 
treatment monitoring, diagnosis and patient management. An ideal biomarker 
must be easy to measure non-invasively, related to disease progression and 
specific for AD. There is currently no such definitive biomarker for AD. Magnetic 
resonance imaging (MRI) observation of AD patients has found atrophy, 
increasing in severity with disease progression (Frisoni et al., 2010), however 
brain atrophy is not specific to AD. A proton magnetic resonance spectroscopy 
(1H MRS) scan could be performed during the same session as an MRI scan, 
only adding approximately 10 mins to scan time. If a 1H MRS biomarker could 
be found, a more robust diagnosis could potentially be made. Disease 
progression could also be monitored more closely. A metabolic biomarker for 
AD could also be invaluable in treatment monitoring. If therapeutic intervention 
caused normalisation of the 1H MRS spectrum from an AD patient this could 
give an early, non-invasive indication of drug efficacy. 
 
Decreased N-acetylaspartate (NAA) and increased myo-inositol (MI) has been 
noted in the brains of AD patients (Shonk et al., 1995; Dixon et al., 2002; Ackl 
et al., 2005). NAA is thought to be a neuronal marker (Urenjak et al., 1992), MI 
is thought to be a marker of gliosis or microglial activation (Lazeyras et al., 
1998), based on observations on cultured glial tumour cells (Brand et al., 1993). 
Some of these results have suggested 1H MRS might be used for both 
diagnosis of AD and distinguishing between different dementias. AD was 
differentiated from frontotemporal dementia (FTD) by analysing spectra 
acquired from midfrontal grey matter, decreased NAA was found in FTD but not 
AD (Ernst et al., 1997). This regional differentiation may be present in the early 
stages of neurodegeneration, but may be lost as the disease progresses and 
neurodegeneration spreads throughout the brain (Kantarci et al., 2004; Garrard 
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et al., 2006). NAA/Creatine was found to be lower in white matter of patients 
with vascular dementia than AD (Kattapong et al., 1996). Several studies have 
shown positive correlation between neuropsychological cognitive test scores 
and NAA/Cr, MI/Cr and NAA/MI ratios (Rose et al., 1999; Jessen et al., 2000; 
Huang et al., 2001; Kantarci et al., 2002), suggesting 1H MRS could be used to 
monitor disease progression. Decreased NAA can be seen in many 
neurological disorders, especially those involving neurodegeneration. 
Differentiation has been achieved by examining different regions. This may only 
be useful in early stage disese, before neurodegeneration becomes 
widespread. If another metabolic marker for AD could be discovered it could 
make differentiation using 1H MRS easier and more accurate. 
 
While the in vitro extract chapter of this thesis dealt with changes in cerebral 
metabolites over time in both TASTPM and wild type mice, it had two 
drawbacks compared with MRS in vivo. The first drawback is the necessary 
death of the animal in order to perform the extract, obviously this has limited 
use in human medicine other than at the post mortem stage. The second is 
related to this, as the animal is killed, cerebral metabolite levels over time in the 
same animal may not be measured. In this study, as the mice recover following 
anaesthesia and scanning, cerebral metabolite shifts in each mouse over time 
may be monitored. Previous studies in vivo of different AD transgenic mice 
have shown a decrease in NAA and glutamate, and increases in MI and taurine 
(Dedeoglu et al., 2004; Marjanska et al., 2005; von Kienlin et al., 2005). 
 
We chose a 3x3x3mm voxel centred on the hippocampus and thalamus for the 
spectroscopy, as the hippocampus is one of the first areas affected in human 
AD, and because of the thalamic lesions present in older TASTPM mice (Evans 
et al., 2007). 
 
Behavioural differences have been reported in both TASTPM mice (Howlett et 
al., 2004) and other transgenic AD mice (Holcomb et al., 1998). These 
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behavioural differences have never been studied along with MRS at the same 
time. We postulate that any behavioural changes may be mirrored by cerebral 
metabolite changes measured by MRS. If this were the case it would lend more 
credence to the link between altered behaviour and metabolic changes in AD.  
 
In our study on brain extracts in vitro from TASTPM mice we found apparently 
increased levels of creatine, along with other metabolites in older TASTPM 
mice. As creatine levels are thought to be stable over time and are often used 
as a reference metabolite for MRS in vivo, this was of some concern as this 
increase might not be detected in vivo. We postulated that a reason for this 
apparent increase might be osmotic stress in the brains of the older mice. It is 
possible that in the brains of the oldest TASTPM mice, the accumulation of 
amyloid may interfere with normal brain osmoregulation. Metabolite levels 
detected by MRS have been found to increase under osmotic stress (Lien et 
al., 1990). As T1 is related to the water content of tissue (Fatouros and 
Marmarou, 1999), T1 measurements of all the brains of the mice at all age 
groups were also undertaken in order to determine if osmotic stress is indeed a 
factor.  
 
During the course of the experiments, it was noted that the amino acid alpha 
proton peak at 3.74 ppm, which usually mostly represents glutamate 
(Govindaraju et al., 2000) was larger than would be expected if just caused by 
glutamate (Fig. 25 and 26). This effect has also been observed in previous 
MRS studies of transgenic AD mice (Marjanska et al., 2005; Oberg et al., 
2007). In order to investigate this, scans using variable repetition times were 
performed to check saturation factors of metabolite peaks. 
 
4.2. Methods 
4.2.1. MR Spectroscopy and T1/T2 Mapping Scans 
TASTPM and wild type mice in 3 age groups were used. Initial ages were 3 
months, 9 months and 15 months. MRS was performed on all groups at 0, 2 
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and 4 month time points, meaning mice in 3 – 19 month age groups were 
scanned at 2 month intervals. Initial group sizes were 8 mice per group, but 
some of the TASTPM mice died over the time so group sizes for the 17 and 19 
month TASTPM were down to 5.  
 
Mice were anaesthetised using a mixture of oxygen and isoflurane. For 
induction the mixture was 5% isoflurane, for maintenance the mixture was 1.5-
2.5% isoflurane. Induction of anaesthesia was carried out in a sealed box with 
tubing delivering and removing the anaesthetic mixture at 1l/min. Once 
anaesthetised the mice were placed on the scanner animal bed in supine 
position with the heads within a nosecone for delivery of anaesthetic within the 
scanner. Respiration rate was monitored constantly using a Graseby Medical 
MR10 respiration monitor (Graseby Medical Ltd, UK). Body temperature was 
monitored constantly throughout scan time using an RS 206-3722 RS 
Components Ltd. UK) temperature monitor, with an RS K coupling and a filter 
built in-house connected to an anally-inserted temperature probe. 
 
MRS was performed on a 7T Magnex 7T/160/AS magnet with a horizontal bore 
(Magnex Scientific Ltd, Oxfordshire, UK) equipped with a 90mm (BGA9-S) 
internal diameter gradient set (maximum gradient strength 740mT/m). A volume 
coil was used for excitation and a rat brain surface coil for signal detection. The 
whole system was run from a Bruker Avance III console (Bruker, Karlsruhe, 
Germany).  
 
Initially a scout was performed to confirm the position of the animal in the 
magnet. This was followed by a FLASH (Fast Low Angle Shot) gradient-echo 
sequence oriented for a series of coronal slices in order to obtain images for 
accurate voxel positioning. The parameters of this sequence were: slice 
thickness 1mm, interslice distance 1mm, No. of slices 9, flip angle 400, TR 
350ms, TE 5.4ms, FOV 3cmx3cm, bandwidth 44642.9Hz. A 3x3x3mm voxel 
was placed so as to be over the hippocampus and thalamus (Fig.24), this voxel 
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was then shimmed using Bruker FASTMAP (Gruetter, 2005), which performs a 
linear shim, followed by a 2nd order shim, then a second linear shim. Shim 
quality was tested by water peak linewidth estimation in a non-water 
suppressed spectrum, any value over 14Hz was re-shimmed. 
 
Fig.24 Example images showing voxel placement. Left image shows coronal 
slice, right image shows axial slice 
 
Following this PRESS was performed with the following parameters: TR 
2500ms, TE 20ms, No. of averages 512, flip angle 900, No. of data points 2048, 
spectral width 13.35ppm, dwell time 124.8µs, bandwidth 4006.41Hz. Water 
presaturation was achieved using VAPOR. The total acquisition time for one 
spectrum was 21’20”.   
 
For T1/T2 mapping a single coronal slice T1/T2 map was obtained centred on 
the hippocampus and thalamus. To obtain this map a RARE sequence was 
used with the following parameters: effective TE values 11, 33, 55, 77 and 
99ms, TR 5000, 3000, 1500, 800, 400 and 200ms, RARE factor 2, No. of 
repetitions 1, No. of echo images 5, refocusing flip angle 1800, effective 
bandwidth 44642.9Hz, FOV 20mmx20mm, spatial resolution 0.156mm/pixel, 
matrix size 128x128, slice thickness 1mm.  
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The saturation factor experiments used 4 mice and performed PRESS in the 
same way as described above, but used TR values of 2500, 5000, 10000 and 
20000 ms to check saturation factors. 
 
4.2.2. MRS Quantitation 
Analyisis of the spectroscopic data was performed using QUEST (Ratiney et 
al., 2005), part of the jMRUI software package (Stefan et al., 2009). An initial 
metabolite basis set was obtained using the routine NMRSCOPE which uses 
quantum mechanics to simulate time domain signals from metabolites under 
the pulse sequence conditions in vivo. The following metabolite signals were 
simulated - NAA, MI, phosphocholine (to represent choline-containing 
compounds), glutamate, glutamine, taurine and creatine. Additional peaks at 
1.3 and 0.9 ppm were added to the basis set, these were simulated using 
simple lorentzian lineshapes to represent the macromolecule resonances at 1.3 
and 0.9 ppm to aid with spectral fitting. Spectra were phased prior to analysis 
and any residual water peak was manually removed using the HLSVD routine 
in jMRUI. Background estimation was carried out as part of the analysis. Three 
different references were used for quantification - creatine, water and the sum 
of a selection of metabolites (creatine, MI, NAA, glutamate, phosphocholine 
and taurine). 
 
4.2.3. T1/T2 mapping Analysis 
Using ParaVision 5 (Bruker, Karlsruhe, Germany), the images acquired from 
the RARE T1/T2 sequence were used to generate T1 and T2 parametric maps. 
Areas in the hippocampus, thalamus and cortex were selected and T1 and T2 
values were obtained from each region (Fig.25) 
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Fig.25 Image from RARE T1/T2 sequence showing areas from which T1 and 
T2 values were obtained. 1 – thalamus, 2 – hippocampus, 3 - cortex 
 
4.2.4. Y Maze 
TASTPM and wild type mice in 3 age groups were used. Initial ages were 3 
months, 9 months and 15 months. Y maze testing was performed on all groups 
at 0, 2 and 4 month time points, meaning mice in 3 – 19 month age groups 
were tested at 2 month intervals. There were 4 mice per group and these 
animals were not used for MRI, as repeated anaesthesia could potentially have 
affected behaviour in the maze. 
 
Mice were placed in the centre of the Y maze and their movements were 
tracked for 8 minutes. Each arm of the maze was marked internally for 
recognition purposes. Entry into each arm of the Y maze was noted and 
counted, only full entry into an arm was counted. Exploratory behaviour was 
investigated by observing how well the mice appeared to remember where they 
had already been. In other words if a mouse had just been in arm B, then arm 
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C then logically next it should explore arm A, if the mouse does this, it is known 
as a repeating triplet. 
 
4.2.5. Statistical analysis 
2-way ANOVA (age x genotype) was carried out on all metabolite amplitudes, 
T1 and T2 values from the hippocampus, thalamus and cortex, and number of 
moves and repeating triplets from the Y maze. Analysis was performed using 
Graphpad Prism version 3.00 for Windows (GraphPad Software, San Diego, 
California, USA). 
 
ANOVA was performed on all age groups combined, but the groups were split 
to contain groups of mice of the same age tested repeatedly (3 – 7, 9 – 13 and 
15 – 19 months). 
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4.3. Results 
 
 
Fig.26 Example spectrum from a 13 month old TASTPM mouse with peak 
assignments. 1 – NAA, 2 – Glx, 3 – Creatine, 4 – Choline containing compouns, 
5 – Taurine, 6 - NAA aspartyl protons, 7 – MI, 8 – amino acid alpha protons, 9 – 
glycine coresonates with MI at 3.55ppm. Example has 3Hz line broadening 
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Fig.27 Example spectrum from a 13 month old wild type mouse with peak 
assignments. 1 – NAA, 2 – Glx, 3 – Creatine, 4 – Choline containing compouns, 
5 – Taurine, 6 - NAA aspartyl protons, 7 – MI, 8 – amino acid alpha protons, 9 – 
glycine coresonates with MI at 3.55ppm. Example has 3Hz line broadening 
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Fig.28 Example of the fit obtained using QUEST to quantify a spectrum from a 
17 month TASTPM mouse 
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Fig.29 Example of the fit obtained using QUEST to quantify a spectrum from a 
19 month wild type mouse 
 
Good quality spectra, suitable for quantitative analysis were acquired in all 
cases except one spectrum which showed low signal-to-noise for unexplained 
reasons. Examples of spectra from mice of different strains are shown in Fig.26 
and 27 A good indication of spectral quality and consistency is the metabolite 
linewidth which has been estimated for the creatine resonance in a 
representative set of 6 spectra. The linewidth at half height was 17.1 +/- 5.2 Hz, 
equivelent to 0.056 ppm. Linewidths of less than 0.1 ppm are considered 
essential for in vivo 1H MRS. The resolution to baseline between choline and 
creatine is also indicative of good spectral quality (Kreis, 2004). Though it is 
unwise to place too much emphasis on the amount of signal left in the residual 
as an indicator of quality of fit, it can be seen that the residual is featureless 
with very little structure (Fig. 28 and 29). It is easy to generate a flat residual by 
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incorporating more features into the model, but in this case we have used 
known metabolites plus two macromolecule peaks. 
 
 
4.3.1. Reference Selection for Spectroscopy 
The three different references that were used for quantification - creatine, water 
and a selection of metabolites (creatine, MI, NAA, glutamate, phosphocholine 
and taurine) were compared and contrasted, with their comparative coefficients 
of variation (Table.5)(Fig.29 and 30) 
Creatine Ratio 
 
3 - 7 months 9 - 13 months 15 - 19 months 
 
Mean SD Mean SD Mean SD 
Wild Type 16.07 5.53 18.16 5.52 22.40 8.13 
TASTPM 12.89 4.50 17.21 5.62 18.54 8.56 
 
      
Water Ref 
 3 - 7 months 9 - 13 months 15 - 19 months 
 Mean SD Mean SD Mean SD 
Wild Type 16.97 7.01 19.67 5.75 20.86 8.87 
TASTPM 13.13 5.20 20.68 9.12 18.16 9.47 
 
      
Selected Metabolites 
 3 - 7 months 9 - 13 months 15 - 19 months 
 Mean SD Mean SD Mean SD 
Wild Type 12.75 5.44 15.26 5.97 18.47 7.68 
TASTPM 11.43 6.01 14.51 6.23 15.37 8.50 
Table.5 Mean and standard deviation of coefficients of variation for different 
quantitation references. The table shows the mean CoV across all metabolites 
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Fig.30 Average coefficients of variation for the different age groups in TASTPM 
mice 
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Fig.31 Average coefficients of variation for the different age groups in wild type 
mice 
 
All the results give similar reproducibility, the preferred reference in this case is 
the selected metabolites because it avoids problems associated with using a 
separate scan for quantification referencing (as would be the case for the water 
reference), and allows estimation of all metabolites, including creatine. In 
addition the selected metabolites reference gives the lowest CoV in nearly all 
cases, although this is not statistically significant in any individual case (Fig. 30 
and 31). 
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4.3.2. Spectroscopy Results 
Creatine levels were higher in older TASTPM mice in our extract study (see in 
vitro chapter). So the results we obtained from this study are of particular 
importance. A significant effect of genotype was observed overall for creatine 
(P<0.005), as well as in the 3 – 7 (P<0.01) and 9 – 13 (P<0.05) month groups 
(Fig.32). Creatine is at a higher level in TASTPM mice, but this difference is 
most pronounced in the younger age groups, with levels being similar in middle 
age groups (13 and 15 months) and levels in TASTPM mice higher again in the 
oldest mice. 
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
3 m
on
th
5 m
on
th
7 m
on
th
9 m
on
th
11
 
m
on
th
13
 
m
on
th
15
 
m
on
th
17
 
m
on
th
19
 
m
on
th
R
at
io
 
to
 
Se
le
ct
ed
 
M
et
ab
o
lit
es
Wild Type Creatine
TASTPM Creatine
 
Fig.32 Creatine ratios to selected metabolites for all age groups, values are 
given ± S.E.M. 
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There was no difference in glutamate signal between wild type and TASTPM 
mice in our extract study. In this study, overall there was a significant effect of 
genotype (P<0.0001), age (P<0.001) and an age x genotype interaction 
(P<0.05). Glutamate levels were higher in wild type mice at all but the 13 month 
time point (Fig.33). In the 3 – 7 month group, there were significant effects of 
age (P<0.05) and genotype (P<0.0001), glutamate levels being higher in wild 
type mice. In the 9 – 13 month group there were significant effects of age 
(P<0.01), genotype (P<0.01) and an age x genotype interaction (P<0.005), 
glutamate levels appeared to be falling over time in wild type mice. In the 15 – 
19 month group there was a significant effect of genotype (P<0.001), glutamate 
levels were again higher in TASTPM mice. 
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Fig.33 Glutamate ratios to selected metabolites for all age groups, values are 
given ± S.E.M. 
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The quantification of glutamine as a separate resonance to glutamate produce 
results with poor reproducibility, coefficients of variation were very high and 
there were no statistically significant differences found (Fig.34). In some cases, 
a high glutamine signal corresponded to a low glutamate signal, whereas non-
detection of glutamine returned a high glutamate signal. For this reason it was 
decided to combine the glutamate and glutamine signals, for a combined Glx 
signal. 
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Fig.34 Glutamine ratios to selected metabolites for all age groups, values are 
given ± S.E.M. 
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Overall, there were significant effects of age (P<0.001) and genotype 
(P<0.0001) on Glx levels, with combined Glx signal higher in wild type mice at 
all but the 13 month time point (Fig.35). In the 3 – 7 month group, there were 
significant effects of age (P<0.005) and genotype (P<0.0001), Glx levels were 
higher in wild type mice at all time points. In the 9 – 13 month group there were 
significant effects of age (P<0.05), genotype (P<0.005) and an age x genotype 
interaction (P<0.05), Glx levels fell over time in the wild type mice. In the 15 – 
19 month group there was a significant effect of genotype (P<0.0005), with Glx 
levels higher in wild type mice. 
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Fig.35 Glx ratios to selected metabolites for all age groups, values are given ± 
S.E.M. 
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Overall there was a significant effect of genotype on MI levels (P<0.0001), with 
MI higher in TASTPM mice at all but the 13 month time point (Fig.36). There 
were also significant effects of genotype in the 3 – 7 and 15 – 19 month groups 
(P<0.001), MI levels in both groups were higher in TASTPM mice. There were 
no significant differences in the 9 – 13 month group, with MI levels in TASTPM 
and wild type mice getting closer with age. 
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Fig.36 MI ratios to selected metabolites for all age groups, values are given ± 
S.E.M. 
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In our extract study, we found no significant differences in the NAA levels 
between TASTPM and wild type mice, this was not in agreement with other 
MRS studies of transgenic AD mice. Overall in this study there was a significant 
effect of genotype on NAA levels (P<0.0001), with higher levels of NAA in wild 
type mice (Fig.37). In the 3 – 7 month group, there were significant effects of 
age (P<0.005) and genotype (P<0.05), with NAA levels increasing with age 
steadily in wild type mice, but climbing and then falling in TASTPM mice. In the 
9 – 13 month group there were significant effects of genotype (P<0.05) and an 
age x genotype interaction (P<0.05), with NAA levels increasing with age in 
TASTPM mice, and decreasing with age in wild type mice. In the 15 – 19 month 
group there was a significant effect of genotype (P<0.05), with NAA levels 
consistently higher in wild type mice. 
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Fig.37 NAA ratios to selected metabolites for all age groups, values are given ± 
S.E.M. 
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Overall there were significant effects of both age and genotype (P<0.0001) on 
Cho levels (Fig.38), with generally higher and more stable levels of PC in 
TASTPM mice and lower, fluctuating levels in wild type mice. In the 3 – 7 month 
group there were significant effects of age (P<0.0001), genotype (P<0.01) and 
an age x genotype interaction (P<0.05), Cho levels increased and then leveled 
off in TASTPM mice, whereas there was a steady increase but at a lower level 
in wild type mice. In the 9 – 13 month group there were significant effects of 
age (P<0.05) and genotype (P<0.001), Cho levels were stable at a higher level 
in TASTPM mice, whereas levels increased but at lower levels in wild type 
mice. In the 15 – 19 month group there was a significant effect of genotype 
(P<0.005), with consistently higher levels in TASTPM mice. 
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Fig.38 Cho ratios to selected metabolites for all age groups, values are given ± 
S.E.M. 
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Overall there was a significant effect of age (P<0.05) on taurine levels, with a 
decline over time in both strains (Fig.39). The only other significant difference 
observed was an effect of age in the 3 – 7 month group (P<0.001), with an 
apparent decline over time. 
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Fig.39 Taurine ratios to selected metabolites for all age groups, values are 
given ± S.E.M. 
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3 months 5 months 
 
Mean S.D. CoV Mean S.D. CoV 
Selected Metabolites 
      
Creatine Wild Type 0.0507 0.0020 3.9 0.0507 0.0031 6.1 
Creatine TASTPM 0.0534 0.0023 4.3 0.0522 0.0022 4.3 
Glutamate Wild Type 0.0398 0.0045 11.2 0.0372 0.0056 15.1 
Glutamate TASTPM 0.0350 0.0028 7.9 0.0308 0.0034 11.0 
Glutamine Wild Type 0.0044 0.0031 70.1 0.0032 0.0045 143.2 
Glutamine TASTPM 0.0043 0.0029 67.5 0.0025 0.0033 134.4 
Glx Wild Type 0.0443 0.0041 9.3 0.0404 0.0080 19.8 
Glx TASTPM 0.0393 0.0027 6.9 0.0333 0.0051 15.5 
MI Wild Type 0.0218 0.0028 12.8 0.0217 0.0058 26.5 
MI TASTPM 0.0231 0.0026 11.2 0.0251 0.0023 9.3 
NAA Wild Type 0.0262 0.0026 10.0 0.0301 0.0033 10.9 
NAA TASTPM 0.0237 0.0073 30.7 0.0295 0.0031 10.6 
Cho Wild Type 0.0089 0.0008 8.7 0.0097 0.0009 9.0 
Cho TASTPM 0.0087 0.0008 8.7 0.0115 0.0014 11.9 
Taurine Wild Type 0.0304 0.0029 9.6 0.0269 0.0050 18.4 
Taurine TASTPM 0.0317 0.0047 14.8 0.0242 0.0042 17.3 
 
7 months 9 months 
 
Mean S.D. CoV Mean S.D. CoV 
Selected Metabolites 
      
Creatine Wild Type 0.0512 0.0047 9.2 0.0464 0.0023 5.0 
Creatine TASTPM 0.0557 0.0041 7.4 0.0526 0.0018 3.5 
Glutamate Wild Type 0.0367 0.0058 15.8 0.0444 0.0065 14.6 
Glutamate TASTPM 0.0277 0.0058 20.9 0.0310 0.0060 19.3 
Glutamine Wild Type 0.0028 0.0048 170.9 0.0057 0.0040 71.0 
Glutamine TASTPM 0.0022 0.0023 104.2 0.0051 0.0043 85.3 
Glx Wild Type 0.0395 0.0055 13.8 0.0501 0.0088 17.5 
Glx TASTPM 0.0298 0.0049 16.4 0.0361 0.0055 15.3 
MI Wild Type 0.0193 0.0037 19.3 0.0192 0.0017 8.8 
MI TASTPM 0.0258 0.0027 10.7 0.0246 0.0060 24.4 
NAA Wild Type 0.0315 0.0033 10.5 0.0323 0.0040 12.2 
NAA TASTPM 0.0272 0.0021 7.6 0.0261 0.0036 13.9 
Cho Wild Type 0.0103 0.0012 11.5 0.0079 0.0019 23.5 
Cho TASTPM 0.0112 0.0006 5.6 0.0110 0.0024 22.3 
Taurine Wild Type 0.0270 0.0019 7.0 0.0275 0.0050 18.1 
Taurine TASTPM 0.0274 0.0023 8.5 0.0274 0.0071 26.0 
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11 months 13 months 
 
Mean S.D. CoV Mean S.D. CoV 
Selected Metabolites 
      
Creatine Wild Type 0.0521 0.0050 9.6 0.0528 0.0028 5.3 
Creatine TASTPM 0.0529 0.0022 4.2 0.0516 0.0034 6.6 
Glutamate Wild Type 0.0359 0.0065 18.2 0.0298 0.0052 17.4 
Glutamate TASTPM 0.0328 0.0043 13.0 0.0321 0.0056 17.4 
Glutamine Wild Type 0.0052 0.0063 120.9 0.0055 0.0059 107.0 
Glutamine TASTPM 0.0038 0.0047 126.4 0.0030 0.0049 165.8 
Glx Wild Type 0.0411 0.0063 15.4 0.0353 0.0067 18.9 
Glx TASTPM 0.0365 0.0078 21.3 0.0351 0.0046 13.0 
MI Wild Type 0.0207 0.0060 29.0 0.0243 0.0037 15.1 
MI TASTPM 0.0233 0.0051 22.1 0.0241 0.0041 17.0 
NAA Wild Type 0.0304 0.0040 13.2 0.0272 0.0034 12.6 
NAA TASTPM 0.0277 0.0020 7.3 0.0286 0.0029 10.2 
Cho Wild Type 0.0093 0.0016 17.2 0.0109 0.0014 13.2 
Cho TASTPM 0.0116 0.0010 8.2 0.0116 0.0010 8.4 
Taurine Wild Type 0.0268 0.0036 13.4 0.0273 0.0048 17.6 
Taurine TASTPM 0.0240 0.0036 15.1 0.0250 0.0037 14.8 
 
15 months 17 months 
 
Mean S.D. CoV Mean S.D. CoV 
Selected Metabolites 
      
Creatine Wild Type 0.0518 0.0067 12.9 0.0512 0.0037 7.3 
Creatine TASTPM 0.0536 0.0053 9.9 0.0530 0.0048 9.0 
Glutamate Wild Type 0.0370 0.0088 23.8 0.0325 0.0055 16.9 
Glutamate TASTPM 0.0291 0.0057 19.7 0.0272 0.0082 30.2 
Glutamine Wild Type 0.0067 0.0055 82.8 0.0066 0.0061 93.2 
Glutamine TASTPM 0.0069 0.0067 96.5 0.0044 0.0047 107.1 
Glx Wild Type 0.0437 0.0104 23.8 0.0390 0.0063 16.1 
Glx TASTPM 0.0360 0.0029 8.2 0.0316 0.0062 19.7 
MI Wild Type 0.0193 0.0069 35.7 0.0225 0.0073 32.4 
MI TASTPM 0.0269 0.0042 15.7 0.0292 0.0019 6.6 
NAA Wild Type 0.0306 0.0067 21.9 0.0281 0.0022 7.8 
NAA TASTPM 0.0233 0.0079 33.8 0.0265 0.0017 6.6 
Cho Wild Type 0.0091 0.0022 24.1 0.0105 0.0012 11.9 
Cho TASTPM 0.0109 0.0018 16.3 0.0116 0.0017 14.4 
Taurine Wild Type 0.0263 0.0066 25.1 0.0273 0.0045 16.5 
Taurine TASTPM 0.0272 0.0031 11.4 0.0249 0.0040 16.1 
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19 months 
 
Mean S.D. CoV 
Selected Metabolites 
   
Creatine Wild Type 0.0516 0.0038 7.5 
Creatine TASTPM 0.0531 0.0034 6.4 
Glutamate Wild Type 0.0336 0.0046 13.7 
Glutamate TASTPM 0.0250 0.0029 11.6 
Glutamine Wild Type 0.0072 0.0118 163.5 
Glutamine TASTPM 0.0035 0.0078 223.6 
Glx Wild Type 0.0408 0.0081 19.9 
Glx TASTPM 0.0285 0.0058 20.2 
MI Wild Type 0.0217 0.0062 28.8 
MI TASTPM 0.0283 0.0050 17.8 
NAA Wild Type 0.0298 0.0072 24.1 
NAA TASTPM 0.0264 0.0028 10.7 
Cho Wild Type 0.0100 0.0012 12.0 
Cho TASTPM 0.0118 0.0006 4.8 
Taurine Wild Type 0.0247 0.0037 14.9 
Taurine TASTPM 0.0271 0.0033 12.1 
Table.6 Mean, standard deviation and coefficients of variance for all 
metabolites at all time points 
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4.3.3. T1 mapping 
Overall, there was a significant effect of genotype on T1 in the cortex 
(P<0.0001), hippocampus (P<0.0001) (Fig.40) and thalamus (Fig.41) (P<0.05). 
In all cases, the T1 times from the brains of the TASTPM mice were shorter 
than the wild type mice. There was also a significant effect of age in the 
hippocampus (P<0.05). In the 3 – 7 month group there was a significant effect 
of genotype in the cortex and the hippocampus (P<0.05) but not in the 
thalamus, again, where significant effects were seen, TASTPM T1 times were 
shorter. 
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Fig.40 T1 values in the hippocampus and cortex for mice of both strains and all 
age groups, values are mean ± S.E.M. 
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Fig.41 T1 values in the thalamus for mice of both strains and all age groups, 
values are mean ± S.E.M. 
 
In the 9 – 13 month group there was a significant effect of genotype in the 
hippocampus (P<0.0001) with TASTPM T1 times again shorter. No other 
significant effects were observed. In the 15 – 19 month group there was a 
significant effect of genotype in the cortex (P<0.01), hippocampus (P<0.0005) 
and thalamus (P<0.05), TASTPM T1 times were once again shorter. 
 
T1 has an almost linear dependence on the water content of tissue (Fatouros 
and Marmarou, 1999), so these data could be interpreted as showing a slight 
reduction in brain water in TASTPM mice.  
 
4.3.4. T2 mapping 
Overall there was a significant effect of genotype on T2 in the hippocampus 
(P<0.01) and cortex (P<0.001), with TASTPM values slightly lower (Fig.42). 
There was also a significant effect of age in the thalamus (Fig.43) (P<0.001), 
with T2 decreasing over time, and a significant age x genotype interaction in 
the hippocampus (P<0.05). 
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Fig.42 T2 values in the hippocampus and cortex for mice of both strains and all 
age groups, values are mean ± S.E.M. 
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Fig.43 T2 values in the thalamus for mice of both strains and all age groups, 
values are mean ± S.E.M. 
 
In the 3 – 7 month group there was a significant effect of age (P<0.001), 
genotype (P<0.001) and an age x genotype (P<0.05) interaction in the cortex, 
where T2 times fell with age, but to a greater degree in the TASTPM mice. 
There was a significant effect of genotype in the hippocampus (P<0.05), with 
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T2 times shorter in TASTPM. In the thalamus, age was a significant factor 
(P<0.05), again showing a decline with age. 
 
In the 9 – 13 month group there were significant effects of age and genotype, 
as well as a age x genotype interaction on T2 times in the hippocampus 
(P<0.05), T2 times appeared stable in the wild type mice, whereas T2 values 
decreased with age in the TASTPM mice. No significant effects were seen in 
the cortex or thalamus. 
 
In the 15 – 19 month group there was a significant age x genotype interaction in 
the hippocampus (P<0.05), with T2 times decreasing slightly with age in the 
wild type mice, and increasing in the TASTPM mice. No significant effects were 
seen in the cortex or thalamus. 
 
4.3.5. Y maze 
Overall, Y maze testing showed a significant effect of genotype (P<0.0001), 
with older TASTPM making fewer repeating triplets than wild type (Fig.44), as 
well as a significant effect of age (P<0.01). In the case of total number of 
moves in the maze, a significant effect of age was seen overall (P<0.01) 
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Fig.44 Graph showing repeating triplet percentages for both strains of mice of 
all age groups, values shown are ± S.E.M 
 
In the 3 – 7 month age group there was a significant effect of genotype on 
repeating triplets (P<0.05), with TASTPM again having fewer. There was a 
significant effect of age on total moves (P<0.05) 
 
In the 9 – 13 month age group there was a significant effect of age (P<0.05). 
There was no significant difference detected in total moves. 
 
In the 15 – 19 month age group there was a significant effect of genotype 
(P<0.001), with TASTPM again having fewer repeating triplets. There was no 
significant difference detected in total moves. 
 
4.3.6 Saturation Factors 
With the exception of NAA, at TR 2500 ms all metabolites are over 85% relaxed 
(Table.7). The difference between spectra at TR 2500 and 20000 ms is not 
great for any metabolite resonance (Fig.45) 
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Metabolite Mean S.E.M. 
NAA 0.74 0.082 
Glx 0.98 0.228 
Cr1 0.87 0.029 
Cho 0.86 0.029 
Taurine 0.93 0.132 
Alpha 0.90 0.128 
Cr2 1.07 0.057 
Table.7 Mean and S.E.M. of saturation factors between 2500 and 20000 ms 
TR for major metabolites 
 
Fig.45 Comparison of spectra of TR 2500 ms (top), 20000 ms (middle) and the 
difference between the two 
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4.4. Discussion 
Firstly, we saw a significant difference in NAA levels between TASTPM and 
wild type mice. NAA concentration was lower in TASTPM mice at all but the 13 
month time point. This is in agreement with other in vivo studies on transgenic 
AD mice (Dedeoglu et al., 2004; Marjanska et al., 2005; von Kienlin et al., 
2005), all of which observed decreased NAA/Cr ratios in AD mice compared to 
their wild type base strain. The lower level of NAA observed indicates that there 
is disruption, dysfunction or loss of neurons occurring (Demougeot et al., 2004). 
There is known to be some neurodegeneration in TASTPM mice in the form of 
the thalamic lesions, but this only occurs after 7 months. It is at 7 months that 
the difference in NAA concentration between the two strains starts to become 
most apparent. This may be a consequence of the formation of the thalamic 
lesions. It is also possible that the difference is caused by neuronal disruption, 
as opposed to frank neurodegeneration. Normal neuronal function may be 
affected by Aβ accumulation, without detectable neuronal death, reduced NAA 
has been observed in similar situations (Demougeot et al., 2004). As there is a 
difference in NAA in mice of different age groups which appears independent of 
amyloid deposition, the difference observed may be a marker of disease, 
without being a marker for disease progression in this model. 
 
The NAA differences observed are not in agreement with the data from our 
extract study. We saw no difference in NAA between TASTPM and wild type in 
the extract study. A possible reason for this difference is that we used whole 
brains in our extract study, whereas a specific voxel was centred over specific 
regions of interest in this study. The use of the whole brain may have masked 
regional metabolic differences which this study has picked up due to the more 
focused area of interest. 
 
Creatine levels were significantly different between the two strains of mice, 
being slightly higher in TASTPM mice. In our extract study the creatine 
concentration was higher only in older TASTPM mice, however in this study 
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creatine concentrations are higher in younger TASTPM mice as well. The 
difference does not appear as pronounced as in the extract study. The reason 
for this discrepancy may be the same as for NAA, in this case a whole brain 
creatine increase may occur which is less pronounced in the regions scanned 
in this study. The significant difference would still indicate that care must be 
taken when using creatine as a reference metabolite in these (and possibly 
other transgenic AD) mice. 
 
Reduced glutamate and Glx concentrations were observed in TASTPM mice at 
all except the 13 month time point. This is in agreement with other in vivo 
studies of transgenic AD mice (Dedeoglu et al., 2004; Marjanska et al., 2005; 
von Kienlin et al., 2005). All these studies observed reduced glutamate/Cr 
ratios. As glutamate is a metabolic indicator, the reduced levels in TASTPM 
mice are likely a marker of neuronal hypometabolism in these mice, a symptom 
that has also been observed in human AD (Valla et al., 2001; Zhu et al., 2004; 
Moreira et al., 2007). As reduced glutamate levels can be observed at 3 
months, when amyloid plaques are barely detectable, this effect is likely 
independent of amyloid deposition. There is a weak age x genotype interaction 
for glutamate (not Glx) signal, this may be more due to the levels intersecting at 
13 months, as the difference appears fairly uniform other than at this time point. 
It is likely that glutamate and Glx are markers of the presence of amyloid in 
TASTPM mice, without being sensitive to increasing amyloid deposition. 
 
In our extract study we found no difference in glutamate signal between 
TASTPM and wild type mice. We did find a decrease in succinate concentration 
in the brains of TASTPM mice, as succinate coresonates with glutamate in vivo, 
it is possible that this partially explains the difference observed in vivo. Again, 
the more focused nature of this study may be detecting locally decreased 
glutamate signal which is not detectable by whole brain measurement. It is also 
possible that there is a difference in glutamate storage between the two strains, 
since not all of the cerebral glutamate pool is detectable in vivo (Kauppinen and 
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Williams, 1991; Kauppinen et al., 1994), thus it is possible that more glutamate 
is being stored intracellularly in the TASTPM mice, making it undetectable by in 
vivo spectroscopy, but detectable by in vitro spectroscopy on extracts. 
 
Higher MI concentration was observed in TASTPM mice at all except the 13 
month time point. This study found increased MI/Cr ratio in APP-PS1 mice. The 
presence of higher MI in younger TASTPM mice (before extensive amyloid 
deposition) suggests that MI levels are independent of amyloid plaque 
formation. The elevated levels of MI observed in TASTPM mice are in 
agreement with a previous in vivo study showing increased MI in transgenic 
(APP-PS1) AD mice (Marjanska et al., 2005). However, in two other studies of 
transgenic AD mice by 1H MRS, no increase in MI was reported (Dedeoglu et 
al., 2004; von Kienlin et al., 2005). One study found an increase in taurine 
levels and postulated that this may be the equivalent of the MI increase seen in 
human AD (Dedeoglu et al., 2004). The increase in MI could be indicative of 
glial cell proliferation or microglial activation in these mice. Activated microglia 
have been found to be associated with the amyloid plaques in TASTPM mice 
(Howlett et al., 2004). The TASTPM mice and APP-PS1 mice contain the same 
double mutant APPswe (K671N; M671L) mutation (Richardson et al., 2003; 
Marjanska et al., 2005). The PS1 mutations incorporated are slightly different, 
the TASTPM contains the M146V variant (Howlett et al., 2004), the APP-PS1 
contains the M146L variant (Marjanska et al., 2005). The functions of MI in 
osmoregulation and membrane metabolism mean that higher MI levels may 
cause disruption of normal function (Beacher et al., 2005).  MI is also a 
precursor in the formation inositol trisphosphate and therefore can affect 
neuronal calcium signalling (Berridge, 1993). Calcium signalling modulates 
aspects of brain development and function, including neurotransmission, 
learning and memory (Berridge et al., 2000). The presence of elevated MI may 
be causing some of the problems, as opposed to being merely a marker. 
However, the fact that there was no age-dependence of the difference in MI 
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suggests that it may be a disease marker but would not act as a biomarker of 
disease progression in this model. 
 
 
In the case of MI, the results of the in vivo and in vitro studies are very similar, 
thus the increased MI may be present throughout the whole brain, as opposed 
to areas specifically affected by AD. 
 
Higher levels of Cho were observed in TASTPM mice compared to wild type. 
Cho levels were also more stable over time in TASTPM mice. This could be 
indicative of differences in phospholipid metabolism or cell membrane 
composition between the two strains. Perturbations in phospholipid metabolism 
have also been observed in human AD (Kuo et al., 1998; Notkola et al., 1998; 
Roher et al., 1999; Sparks et al., 2000). Differences in lipid functional groups 
were observed in the organic extract section of this thesis.  
 
The differences in taurine levels between the two strains are minimal and not 
significant, the only significant factor is age, with taurine levels at 3 months 
being high in both strains and then declining slightly. 
 
The saturation factors that we obtained showed that most metabolites were 
over 85% fully relaxed at TR 2500 ms, thus any change in T1 with disease or 
age will not have a great effect on metabolite signal intensity and T1 can be 
ruled out as underlying any apparent metabolite changes. 
 
The T1 data indicate slightly shorter T1 times in TASTPM mice, the difference 
is only about 100ms, but it is significant. It is therefore possible that the 
presence of amyloid in the brains of TASTPM mice is disrupting normal osmotic 
function. The effect is present in younger mice but becomes more pronounced 
in older mice so may be linked to increasing amyloid deposition. Our hypothesis 
that osmotic changes in the older TASTPM mice may lead to overestimation of 
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some metabolites does not appear to be true, as the T1 values are reduced at 
a much earlier time point than the point at which we saw increased metabolite 
levels in vitro. T1 has an almost linear dependence on the water content of 
tissue (Fatouros and Marmarou, 1999), so these data could be interpreted as 
showing a slight reduction in brain water in TASTPM mice. T2 shows 
proportionally similar effects to T1, which is likely also to reflect a similar 
dependency on total water content. 
 
The Y maze data show the most significant difference in exploratory behaviour 
to be in the oldest age group (15 – 19 months) when amyloid deposition is 
extensive. The metabolites showing significant differences do not become more 
significant over time, so cannot be said to be dependent upon amyloid 
deposition. The behavioural differences may be dependent upon amyloid 
deposition and thus may be a marker of disease progression.  
 
In this study several metabolitic differences have been observed between 
TASTPM and wild type mice (NAA, glutamate, MI, Cho and creatine), these 
may be markers of pathology but do not appear sensitive to disease 
progression or amyloid deposition. The behavioural differences may be 
sensitive to disease progression, more extensive study is needed, using 
different behavioural tests to confirm this. If there is sensitivity to disease 
progression behavioral differences may be useful in testing amyloid-lowering 
therapies in this mouse model. 
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Chapter 5. Pilot Study for Evaluation of TASTPM and Wild Type Brain 
Sections using MALDI MS Imaging and Laser Capture Microscopy 
 
5.1. Introduction 
 
TASTPM mice are known to have increasing deposits of Aβ in the brain from 6 
months onward (Howlett et al., 2004). MALDI MS Imaging is a useful tool for 
profiling protein expression in tissues, and is also used widely for analysis of 
small molecules and peptides. The ability to observe protein profiles in the 
brains of TASTPM mice and their wild type base strain could be used to identify 
potential protein biomarkers in the TASTPM mice, as well as Aβ. Such 
biomarkers could be invaluable in furthering our understanding of the 
pathogenesis of AD, as well as having uses in preclinical efficacy trials. 
 
This chapter will focus on several aspects of MALDI MS Imaging. The first 
aspect will be development of a protocol for the analysis of formalin-fixed tissue 
sections by MALDI MS Imaging, using TASTPM brain sections. 
 
The second aspect will describe the optimisation of the matrix application 
procedure, comparing manual spraying with automated matrix application using 
an ImagePrep device. 
 
The final section will focus on the use of MALDI MS Imaging to look for 
differences in regional protein expression between TASTPM and wild type 
mouse brains, followed by isolation of any differences and attempted 
identification. 
 
Efforts are being made to enable the use of MALDI MS imaging on formalin-
fixed tissue sections (Lemaire et al., 2007; Stauber et al., 2008). Alternatives to 
formalin-fixation for long term storage are also being investigated (Chaurand et 
al., 2008). If a method could be found to obtain useful information on protein 
profiles from formalin-fixed paraffin-embedded tissue sections, this could be 
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useful to histologists as the extensive libraries of fixed tissues could be 
analysed in a completely different way than is currently available. 
 
The initial work carried out was to attempt to develop a protocol for analysing 
fixed sections using MALDI MS Imaging. 
 
Before embarking on method development with fixed tissue, experiments were 
performed on frozen tissue sections. Firstly, MALDI imaging of amyloid peptide 
solutions that had been spotted onto tissue sections and allowed to dry was 
undertaken to confirm their detection and provide estimates of the limits of 
detection. This was followed by tryptic digests of these spots to confirm the 
detection of amyloid fragments. MALDI MS imaging of endogenous TASTPM 
amyloid deposits was then undertaken, followed by trypsin digests of TASTPM 
brain sections and subsequent MALDI MS imaging. These proof of concept 
experiments on frozen tissue sections were successful following four repeats 
and so the attention was then transferred to fixed tissue sections.  
 
Formalin fixed TASTPM brain sections were dewaxed and trypsin digests 
performed in order to break the protein crosslinks formed during the fixing 
process. MALDI MS imaging was then performed to look for amyloid fragments 
in the dewaxed brain sections. The successful detection of any amyloid 
fragments by this approach would indicate that further study of other formalin-
fixed tissues might be carried out in ways not previously thought possible, 
looking for individual peptide signals previously invisible to MS due to protein 
crosslinks. 
 
Matrix can be manually applied using a spray device, or in an automated 
system, one example an automated device is the ImagePrep (Bruker 
Daltonics). Matrix thickness and tissue wetness are both crucial factors in the 
preparation of samples for MALDI MS analysis. A comparison of the two 
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methods of matrix application was carried out to determine the optimum 
conditions for sample preparation.  
 
Coronal sections of frozen TASTPM and wild type mouse brains were used as 
test samples. The areas chosen for study contain the hippocampus and the 
thalamus. The hippocampus was selected as it is one of the first areas affected 
in human AD, the thalamus was included due to the presence of thalamic 
hypointensities (THIs) in TASTPM mice (Evans et al., 2007). THI regions have 
been observed in other transgenic AD mice, such as APP/PS1 (Dhenain et al., 
2009). The images obtained are presented and discussed below. 
 
During the course of matrix application comparison an unknown peptide ion of 
apparent molecular weight (m/z) 4811 Daltons was detected localised to the 
THI regions. Identification of this unknown peptide may provide insight into the 
underlying pathology causing the formation of the THIs. Further study was 
carried out using laser capture microscopy (LCM) to dissect out the THI regions 
and attempt to isolate and identify the unknown peptide using MALDI and liquid 
chromatography-MS 
 
5.2. Methods 
 
5.2.1. Section Preparation for MALDI Imaging 
Frozen mouse brains were mounted onto a cryostat sample disc using 
carboxymethylcellulose (2%w/v) medium. After wiping down all surfaces in the 
cryostat with ethanol to remove any contamination, 12µm sections of brain 
were cut and thaw mounted onto indium tin oxide (ITO) coated glass slides 
(Bruker Daltonics) which had been kept inside the cryostat at -20oC whilst the 
sectioning was taking place. The tissue section was touched onto the ITO 
coated surface of the slide and then from underneath the slide the finger is 
touched onto the slide to gently warm up the slide and aid the mounting 
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process. Any sections unused on the day of sectioning were stored in a slide 
container in the freezer at approx. -20oC.  
 
5.2.2. Amyloid Spots on Tissue 
In all cases 1µl of amyloid solution (dissolved in deionised water) was spotted 
onto the tissue, at varying concentrations, concentrations are indicated in the 
images for the different experiments. 
 
5.2.3. Tissue Washing 
Mouse brain sections were each pipette washed five times with 1ml 70% 
ethanol, followed by five washes with 1ml 100% ethanol to remove lipids. The 
sections were then allowed to dry in the fume cupboard. 
 
5.2.4. Tissue Dewaxing 
Formalin-fixed paraffin-embedded sections were cut onto ITO coated slides. 
Each slide was then immersed for 5 minutes in Histoclear (x2), 100% 
methylated spirit (x2), 90% methylated spirit, 70% methylated spirit and finally 
distilled water to remove the paraffin wax. 
 
5.2.5. Trypsin Digests 
Trypsin dilutions were made up in 100mM ammonium bicarbonate to 500ng/µl. 
Trypsin solution was spotted onto brain sections, sections were then placed in 
an incubator at 37oC and 100% humidity for the desired time (either 1 hour or 
24 hours). In cases of digestion of applied Aβ 1-40, a 1µl spot of trypsin 
solution was applied on top of the Aβ spot after it had been allowed to dry, in 
cases of trypsin digest without applied amyloid, trypsin solution was applied to 
the entire brain section in question. 
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5.2.6. Matrix Application 
The matrix used was 7mg/ml alpha-cyano-4hydroxycinnamic acid in 50% 
acetonitrile and 0.2% trifluoroacetic acid (TFA). This solution was prepared and 
sonicated for 30 minutes to ensure the matrix was fully dissolved 
 
The manual spray application (performed in a fume cupboard) involved 
spraying small amounts of the matrix onto the tissue multiple times. Care was 
taken during each application of matrix to not allow the tissue to get too wet. 
Otherwise this could lead to delocalisation of the components of interest. The 
sections were allowed to air dry between each application of matrix. Matrix 
application continued until an even coating on the tissue was achieved. 
 
For automated matrix application, the slide with sections mounted onto it was 
placed in the ImagePrep (Bruker Daltonics) matrix application device, ensuring 
that the light sensor was not covered. The matrix was loaded into the machine 
and the sequence was started, spray was automated and tissue wetness/matrix 
thickness was monitored by passage of light through the slide onto the light 
sensor beneath. This sensor allowed the machine to sense when matrix was to 
be reapplied and when sufficient matrix had been applied.  
 
5.2.7. MALDI Imaging 
Before matrix application, very small droplets of liquid paper were placed onto 
the glass slide containing the sections of interest to act as “teach marks” as part 
of the sample alignment procedure for the mass spectrometer. An optical image 
of the contents of the slide was obtained using a scanner. After matrix 
application, the slide was mounted in a specially designed slide holder, the 
location of the teach marks was then recorded to be referenced to a grid for 
sample alignment. The sample was then placed in a Bruker Ultraflex III MALDI 
TOF/TOF mass spectrometer, software used was Compass 1.2 which includes 
FlexControl v3.0., FlexImaging v1.1.9.0 and FlexAnalysis v3.0.5.  
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FlexImaging was used to align the slide with the optical image using the teach 
marks. This software allows us to observe the slide containing the sections to 
be analysed at magnification (x20 – x40). The software also contains a grid 
system which can be compared to the recorded locations of the teach marks. 
The teach marks are used to triangulate the exact location of the sections on 
the slide, so that the MALDI image obtained will be properly aligned with the 
optical image. 
 
The preferred method for imaging the tissue sections used the following 
parameters; mass range 3000-20000Da, laser power 51%, detector gain 6.5x, 
Ion source 1 voltage 25kV, Ion source 2 voltage 23.3kV, lens voltage 6.5kV, 
pulsed ion extraction delay 100ms. The desired areas required for analysis 
were selected using the FlexImaging software. This software allows 
observation of the optical image and selection of areas of interest to acquire 
MALDI data to construct an image. Ahead of the automated data acquisition by 
the mass spectrometer, the method was tested and adjustments to laser power 
and attenuation were made in order to get good resolution of mass peaks 
without the noise associated with too much laser power. The refined method 
was then saved in the FlexControl software prior to commencement of the 
analysis. The method was refined before each data acquisition from each new 
sample. Data was acquired in a dot matrix fashion from the sample, individual 
points were 200µm in diameter. Sample analysis and data acquisition took 
between 1 and 24 hours depending on the size and number of sections being 
imaged.  
 
Spectral analysis of the captured images was done using the FlexAnalysis 
software. This software takes the mass spectra gathered from each point and 
overlays them on the optical image, creating a MALDI image. We can then 
refine the image to pick out a particular mass or a range of masses in order to 
investigate the distribution of molecules of interest. We can also use the 
software to search for molecules, as we can highlight an area and get the 
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overall mass spectrum from that area, then look at the distribution of any major 
peaks we find. The MALDI Images shown in this thesis are created using mass 
ranges, from the mass of interest ±1 Dalton. 
 
Other studies of peptides specific to TASTPM mice performed as part of the 
investigation consisted of the isolation of areas of interest from selected brain 
sections using LCM. Captured areas were then analysed, first by MALDI, then 
using other analytical techniques (e.g. nanoLC-MS) in an attempt to identify the 
peptide(s) of interest. 
 
5.2.8. Laser Capture Microscopy – Slide Preparation 
Frozen mouse brains were mounted onto a cryostat mounting disc using 
carboxymethylcellulose (2%w/v) medium. After wiping down all surfaces in the 
cryostat with ethanol to minimise contamination, 8µm sections were cut and 
mounted onto room temperature uncoated glass slides, a maximum of 2 
sections were collected per slide. The slides were immediately placed in a slide 
box on dry ice and not allowed to air dry. Four slides at a time were removed 
from the dry ice and allowed to thaw on a kimwipe for no more than 30 
seconds. The slides were then immersed for 30 seconds in 75% ethanol, 2x 
distilled water, 75% ethanol, 95% ethanol, 100% ethanol and finally placed in 
xylene for 5 minutes. Slides were then placed in a dessicator containing fresh 
silica gel dessicant until ready for LCM. All washing solutions were changed 
after each wash.  
 
5.2.9. Manual Laser Capture Microscopy 
The slide containing the sample was placed on the laser capture microscope 
and the area containing the desired region was located. A fresh cap was placed 
on the arm and lowered onto the sample. The desired area was collected onto 
the cap by LCM, manoeuvring the table to allow collection. Once the desired 
area from one slide was collected, a fresh slide was put in place and the 
process repeated. Caps were stored in a -20oC freezer until ready to use. 
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5.2.10. Automated Laser Capture Microscopy 
Slides were loaded into a Veritas Microdissection Instrument (Arcturus 
Bioscience Inc.), 3 at a time. The areas of interest were located and highlighted 
using the Veritas software (Fig.46). The laser was focused using pulse length, 
laser power and intensity in order to maximise capture. Following laser 
focussing, capture of desired areas was initiated. Between each section, laser 
focus was adjusted to retain optimum tissue adhesion to caps. No more than 6 
sections worth of sample was collected onto each cap, again to maximise 
adhesion. Caps were stored in the -20oC freezer until ready to use. 
     
 
Fig.46 Optical image of THI regions in the LCM instrument, before capture, 
marked for capture, after capture. Magnification x100 
 
5.2.11. Preparation For Analysis 
To the surface of the LCM caps containing the sample, 1µl of a solution of 
formic acid:water:isopropanol (1:3:2) was added, agitated around the surface 
and then immediately removed into a vial prior to analysis. For MALDI analysis 
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1µl was added to 1µl of matrix (7mg/ml alpha-cyano-4hydroxycinnamic acid in 
50% acetonitrile and 0.2% trifluoroacetic acid), mixed and spotted onto a 
MALDI target. Analysis was carried out once the spot was dry. 
 
5.2.12. Nano-LC/MS 
An Orbitrap XL mass spectrometer (Thermo Fisher Scientific, San Jose, CA), 
coupled to a nanoAcquity uPLC system (Waters) was used for the analysis. 
Nano-LC was performed using a 0.1 mm X 150 mm Cadenza C18 (Imtakt) 
analytical column maintained at 40C, along with a Symmetry C18 5um 180um 
X 20mm trapping column (Waters). The sample was injected in 5µl aliquots. 
Buffer A consisted of 0.1% formic acid (Aristar grade) in Water (Optima LC/MS 
grade) (Fisher), buffer B consisted of 0.1% formic acid (Aristar grade) in 
Acetonitrile (Optima LC/MS grade) (Fisher). Vented column trapping was 
carried out using buffer A for 5 minutes at 4µl/min following sample loading. 
The flow rate was then adjusted to 0.3 ul/min. A series of nano-flow gradients 
were used, the profile of which was (i) 5 minutes at 98% A; (ii) 40 minutes at 
60% A; (iii) 2 minutes at 5% A; (iv) 3 minutes at 5% A; (v) 2 minutes at 98% A, 
and finally (vi) 18 minutes at 98% A. A blank run was performed between each 
sample using buffer A and the data were searched in the same manner as the 
sample runs, with no proteins found in any blanks. 
 
For the mass spectrometry, one scan cycle included an initial scan (m/z 300-
1800) at a resolution of 60000 followed by 5 collision-induced dissociation (CID) 
scans at resolution 15000 to perform MS/MS on the 5 most intense ion signals 
from the first scan. The activation time was 30ms, the isolation width was 
2amu, the normalised activation energy was 30% and the activation q was 
0.25.  
 
Data analysis was performed using MASCOT. RAW files were searched using 
MASCOT running in Thermo Proteome Discoverer 1.0 processing software. MS 
data was searched using MASCOT against the psr_all non-redundant 
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database, taxonomy Rodentia. Max number missed cleavages 3, 15ppm 
precursor mass tolerance, 0.8 Da fragment mass tolerance. carbamidomethyl 
ysteine as a fixed modification and N-term acetylation and oxidised methionine 
were used as dynamic modifications. Resulting protein hits were filtered to 
remove any protein containing only 1 peptide hit and any keratin related 
proteins. 
 
5.3. Results 
Detection of amyloid fragments was based on mass from fragments observed 
previously from trypsin digestion (Kheterpal et al., 2001). Fragments observed 
were 17-40, 17-28, 1-16 and 6-16. 
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5.3.1. Protocol development for analysis of formalin-fixed tissues 
5.3.1.1. Aβ 1-40 spotted on to frozen sections, followed by 1 hour trypsin 
digest (500ng/µl) 
Following trypsin digest, Aβ peptide 1-40 and fragments 17-40 (Fig.47) along 
with 17-28, 1-16 and 6-16 were observed on tissue sections.  
 
  
Fig.47 MALDI Imaging results from frozen brain sections from TASTPM mice. 
Treatment of sections: T – trypsin (500ng/µl) only, 1 - 100µg/ml Aβ 1-40 + 
trypsin (500ng/µl) , 2 – 1mg/ml Aβ 1-40 only, 3 – 1mg/ml Aβ 1-40 + trypsin 
(500ng/µl). Scaling bars indicate intensity of signal, from low intensity (blue) to 
high intensity (white). Magnification x 5 
 
From these images Aβ 1-40 was detected when spotted onto the section at 
1mg/ml in the absence of trypsin. Aβ 17-40 can be detected following 1 hour 
trypsin digest of both 1mg/ml and 100µg/ml Aβ 1-40. Where some Aβ 1-40 can 
be seen around the edges of the trypsin digest at 1mg/ml, all Aβ 1-40 was 
digested by the trypsin at 100µg/ml. Aβ 17-40 can also be detected on the 
section where only trypsin was added, indicating that endogenous amyloid is 
being digested in this case. 
 
distribution of Aβ 1-40 distribution of Aβ 17-40 
T 
T 
1 1 
2 2 
3 3 
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5.3.1.2. Aβ 1-40 spotted on to frozen sections, followed by 24 hour trypsin 
digest (500ng/µl) 
Aβ peptide fragments 1-40, 17-40, 17-28, and 1-16 were observed on tissue 
sections following digest (Fig.48). 
 
  
  
Fig.48 MALDI Imaging results from frozen brain sections from TASTPM mice. 
Treatment of sections: 1 - 1mg/ml Aβ 1-40 + trypsin (500ng/µl), 2 - 1mg/ml Aβ 
1-40 only, 3 – 100µg/ml Aβ 1-40 + trypsin (500ng/µl), T  – trypsin only 
(500ng/µl). Scaling bars indicate intensity of signal, from low intensity (blue) to 
high intensity (white). Magnification x 5 
 
From these images Aβ 1-40 was almost completely digested at 1mg/ml and 
100µg/ml in a 24 hour trypsin digest. On section 1 where Aβ 1-40 is present 
distribution of Aβ 1-40 distribution of Aβ 17-40 
distribution of Aβ 1-16 distribution of Aβ 17-28 
1 1 
1 1 
2 2 
2 2 
3 3 
3 3 
T T 
T T 
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around the edges of the spot, this is likely where the trypsin spot did not entirely 
cover the spot of applied Aβ 1-40. Aβ 17-40 is present in all the sections where 
trypsin was added, whereas Aβ 1-16 is only weakly detected on the 100µg/ml 
Aβ1-40 section, indicating that it has been further digested by the trypsin over 
24 hours. Aβ 17-28 was observed in the images, including the section to which 
no trypsin was added, overall signal in this case was weak, so this may be an 
artefact. Aβ 1-16 and 17-40 were strongly detected on the sections with just 
trypsin added, indicating digestion of endogenous amyloid.  
 
Following this work, the aim was to show that Aβ peptide and fragments can be 
observed by MALDI on dewaxed formalin-fixed tissue sections, as well as 
performing trypsin digests on the dewaxed sections without adding Aβ. 
 
5.3.1.3. Aβ 1-40 spotted on to dewaxed sections, followed by 1 hour 
trypsin digest (500ng/µl) 
Aβ peptide fragments 1-40, 17-40, 1-16 and 6-16 were observed on tissue 
sections following digest (Fig.49). 
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Fig.49 MALDI Imaging results from dewaxed formalin-fixed TASTPM brain 
sections. Treatment of sections: 1 - 1mg/ml Aβ 1-40 + trypsin (500ng/µl), 2  -
1mg/ml Aβ 1-40 only, 3 - 100µg/ml Aβ 1-40 + trypsin (500ng/µl), T - trypsin 
(500ng/µl) only. Scaling bars indicate intensity of signal, from low intensity 
(blue) to high intensity (white). Magnification x 5 
 
From these sections it can be seen that Aβ 1-40 is only detectable on the 
section where no trypsin was added, indicating that all Aβ 1-40 was digested on 
the other sections. Aβ 17-40, 1-16 and 6-16 were all detected on the section 
with the 1mg/ml Aβ solution added, with just 17-40 detectable with the 
100µg/ml Aβ solution. Encouragingly, it appears that Aβ 17-40 was detected on 
the section treated with trypsin only, indicating that crosslinked Aβ has been 
digested by the trypsin, allowing it’s detection by MALDI. 
 
5.3.1.4. Aβ 1-40 spotted on to dewaxed sections, followed by 24 hour 
trypsin digest (500ng/µl) 
Aβ peptide fragments 1-40, 17-40 and 1-16 were observed on tissue sections 
following digest (Fig.50). 
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Fig.50 MALDI Imaging results from dewaxed formalin-fixed TASTPM brain 
sections. Treatment of sections: 1 - 1mg/ml Aβ 1-40 + trypsin, 2 - 1mg/ml Aβ 1-
40 only, 3 - 100µg/ml Aβ 1-40 + trypsin, T - trypsin, trypsin only. Scaling bars 
indicate intensity of signal, from low intensity (blue) to high intensity (white). 
Magnification x 5 
 
From these sections it can be seen that Aβ 1-40, as well as 17-40 and 1-16 
were detected on the section treated with 1mg/ml Aβ solution plus trypsin, the 
Aβ 1-40 detected is likely as a result of the trypsin solution spot not entirely 
covering the spot of applied Aβ 1-40. Aβ 17-40 is the only fragment detected on 
the section treated with 100µg/ml Aβ solution plus trypsin, indicating Aβ 1-16 
may have been further digested. Aβ 17-40 has been detected in large amounts 
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on the section only treated with trypsin, suggesting digestion of endogenous Aβ 
within the tissue.  
 
The detection of Aβ fragments on dewaxed sections treated with trypsin in 
these experiments indicates that there is potential in this method for digesting 
protein crosslinks in formalin-fixed tissues, allowing proteomic analysis by 
MALDI MS Imaging. The following sections describe our attempts to refine 
these methods. 
 
5.3.2. Refinement of protocol, optimisation of trypsin concentrations and 
limits of amyloid detection 
5.3.2.1. Aβ 1-40 (1mg/ml) spotted on to frozen TASTPM brain sections 
sections, followed by 1 hour trypsin digest 
1 mg/ml Aβ was spotted on to frozen TASTPM brain sections, followed by 
digestion with varying concentrations of trypsin. Aβ peptide fragments 1-40, 17-
40 and 1-16 were observed on tissue sections following digest (Fig.51). 
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Fig.51 MALDI Imaging results from frozen brain sections from TASTPM mice. 
Trypsin concentrations on sections 1 - 500ng/µl, 2 -  50ng/µl, 3 - 500pg/µl, 4 -  
5ng/µl. Scaling bars indicate intensity of signal, from low intensity (blue) to high 
intensity (white). Magnification x 5 
 
From these images, the only trypsin concentration where both Aβ 17-40 and 1-
16 can be detected is 50ng/ml, in which the original peptide is also detected, 
but it appears that this is due to the trypsin spot not fully covering the applied 
Aβ 1-40 spot. The 500ng/ml trypsin appears to have fully digested the applied 
Aβ 1-40 and digested the endogenous amyloid around the spot, causing 
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detection of Aβ 1-16 from endogenous amyloid. Due to detection of Aβ 17-40 1-
16 it appears that for 1 hour trypsin digests 50ng/ml trypsin solution is the 
optimum concentration of the four tested. 
 
 
 
5.3.2.2. Different Aβ 1-40 concentrations spotted onto frozen TASTPM 
brain sections along with trypsin digests 
Aβ concentrations of 1mg/ml, 200µg/ml, 40µg/ml and 8µg/ml were spotted onto 
frozen TASTPM brain sections, on the same slide, 24 hour trypsin digests were 
carried out using trypsin at 20ng/µl. Aβ 1-40 was detectable at 200µg/ml, but 
not at 40µg/ml. On trypsin digests of the 1mg/ml spot, fragments 1-40, 6-16, 
17-28 were visible. Thus the limit of detection in a spot approximately 1mm in 
diameter is 200ng (1µl of 200µg/ml in the spot). For trypsin digests it seems 
more than this amount is needed for subsequent fragment detection. 
 
5.3.2.3. Aβ 1-40 spotted on to dewaxed sections, followed by both 1 hour 
and 24 hour trypsin digests 
In the 1 hour digest, Aβ 1-40, as well as fragments 17-40, 17-28, 1-16 and 6-16 
were observed on tissue sections (Fig.52) 
In the 24 hour digest, Aβ 1-40, as well as fragments 17-40, 17-28, 1-16 and 6-
16 were observed on tissue sections (Fig.53) 
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Fig.52 MALDI Imaging results from dewaxed formalin-fixed TASTPM brain 
sections, 1 hour trypsin digest. Treatment of sections 1 - 1mg/ml Aβ 1-40 + 
trypsin (40ng/µl), 2 (top spot, second section from the left) - 200µg/ml Aβ 1-
40 + trypsin (40ng/µl), 3 (bottom spot, second section from the left) – 
40µg/ml Aβ 1-40 + trypsin (40ng/µl), 4 (Both right hand sections) – trypsin 
(40ng/µl) only. Scaling bars indicate intensity of signal, from low intensity (blue) 
to high intensity (white). Magnification x 5 
 
From these images, after 1 hour trypsin digests, all the Aβ fragments 
mentioned above are detectable on the 1 mg/ml Aβ spot. Aβ 1-40, 17-40 and 1-
16 can just be detected on the 200µg/ml Aβ spot. Nothing can be detected on 
the 40µg/ml Aβ spot, unfortunately the same is the case for the two sections 
which just had trypsin added to them, indicating digestion of endogenous, 
crosslinked Aβ has not occurred.  
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Fig.53 MALDI Imaging results from dewaxed formalin-fixed TASTPM brain 
sections, 24 hour trypsin digest. Treatment of sections 1 - 1mg/ml Aβ 1-40 + 
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trypsin (40ng/µl), 2 (top spot, second section from the left) - 200µg/ml Aβ 1-
40 + trypsin (40ng/µl), 3 (bottom spot, second section from the left) – 
40µg/ml Aβ 1-40 + trypsin (40ng/µl), 4 (Both right hand sections) – trypsin 
(40ng/µl) only. Scaling bars indicate intensity of signal, from low intensity (blue) 
to high intensity (white). Magnification x 5 
 
From these sections it can be seen that after 24 hour trypsin digests, all the 
amyloid fragments mentioned are detectable on the 1mg/ml Aβ 1-40 spot. Aβ 
1-40 and17-40 can just be detected on the 200µg/ml Aβ 1-40 spot. Nothing can 
be detected on the 40µg/ml Aβ 1-40 spot, unfortunately the same is the case 
for the two sections which just had trypsin added to them, again indicating 
digestion of endogenous, crosslinked Aβ has not occurred. 
 
5.3.3. Matrix application comparison 
Manual spray was compared to automated (ImagePrep) matrix application. 
During this experiment the initial detection of the unknown ion m/z 4811 in THI 
regions of TASTPM brains was made. In the case of the unknown peptide, the 
ImagePrep was found to give better signal localisation (Fig.54) but less overall 
signal (Fig.52).  Maximum intensity of the unknown peptide was found to be 
4800 for ImagePrep matrix application, whereas the maximum intensity for 
manual matrix application was 15000 (Fig.55). 
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Fig.54 Images showing distribution of unknown ion m/z 4811 in TASTPM brain 
sections containing thalamic hypointensity regions. ImagePrep (top), manual 
spray (bottom). Scaling bars indicate intensity of signal, from low intensity 
(blue) to high intensity (white). Magnification x 5 
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Fig.55 Mass spectra from THI regions showing intensity of signal for unknown 
peptide 4811. ImagePrep (top), manual spray (bottom). 
 
From these images and spectra, it appears that manual spraying has allowed 
for stronger detection of the peptide in question, whereas the ImagePrep 
 163
seems to suffer from less delocalisation, with the peptide signal confined to 
smaller areas.  
 
When the overall spectra from the experiments are examined (Fig.56), the 
situation is very different, while no information is available about localisation of 
molecules, it can be clearly seen that, in this instance, not only can many more 
different molecules be detected by the manual spray technique, but overall 
signal strength is also better. 
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Fig.56 Overall spectra from ImagePrep (top) and manual spray (bottom) 
comparison 
 
Following this experiment, focus shifted to analysis of the distribution and signal 
intensity of the unknown peptide m/z 4811 in TASTPM and wild type mouse 
brains. 
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5.3.4. Analysis of TASTPM and Wild Type brain sections in order to image 
the distribution of the unknown peptide identified above 
5.3.4.1. 12 month TASTPM brain sections imaged to look for distribution 
of unknown ion 
The unknown ion 4811 was found to be localised to the THIs, another ion m/z 
7635 was also found localised to the THIs (Fig 57). The highest intensity peak 
of the 4811 ion was 14000 (Fig.58), the highest intensity of the 7636 peak was 
400. 
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Fig.57 MALDI Images of 12 month old TASTPM brain sections showing an 
optical image with the THIs depicted as white spots, and the distribution of the 
4811 ion (coloured spots) and its localisation to the THI regions. Another ion 
found localised to the THI regions, though apparently in much lesser 
concentration, m/z 7635 is also shown. Scaling bars indicate intensity of signal, 
from low intensity (blue) to high intensity (white). Magnification x 5 
 
Distribution of THIs distribution of 4811 ion 
distribution of 7635 ion 
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Fig.58 Zoom of relevant section of mass spectrum showing highest intensity of 
unknown ion 4811 
 
5.3.4.2. 18 month TASTPM brain sections Imaged to look for distribution 
of unknown ion 
The unknown ion 4811 was found to be localised to the THIs, another ion m/z 
7635 was also found localised to the THIs (Fig 59). The highest intensity peak 
of the 4811 ion was 20000 (Fig.60), the highest intensity of the 7636 peak was 
750 
 168
 
 
Fig.59 MALDI Images of 18 month old TASTPM brain sections showing an 
optical image with the THIs depicted as white spots, also the distribution of the 
4811 and 7635 ions and their localisation to the THI regions. Scaling bars 
indicate intensity of signal, from low intensity (blue) to high intensity (white). 
Magnification x 5 
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Fig.60 Zoom of relevant section of mass spectrum showing highest intensity of 
unknown ion 4811 
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Fig.61 Graph showing maximum peak intensities for detection of 4811 peptide 
in TASTPM and wild type mice 
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5.3.4.3. 12 month Wild Type brain sections Imaged to look for distribution 
of unknown ion 
Small THIs were found in the thalamus, 4811 peptide was found to be present 
(Fig. 62), the highest intensity peak was 300 (Fig. 63). 
 
 
Fig.62 MALDI Images of 12 month old wild type brain sections showing an 
optical image with the small THIs depicted as white spots, also the distribution 
of the 4811 ion and its localisation to the THI regions. Scaling bars indicate 
intensity of signal, from low intensity (blue) to high intensity (white). 
Magnification x 5 
Distribution of THIs Distribution of 4811 ion 
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Fig.63 Zoom of relevant section of mass spectrum showing highest intensity of 
unknown ion 4811 
 
5.3.4.4. 18 month Wild Type brain sections Imaged to look for distribution 
of unknown ion 
Small THIs were found in the thalamus, 4811 peptide was found to be present 
(Fig.64), the highest intensity peak was 600 (Fig.65). 
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Fig.64 MALDI Images of 18 month old wild type brain sections showing an 
optical image with the small THIs depicted as white spots, also the distribution 
of the 4811 ion and its localisation to the THI regions. Scaling bars indicate 
intensity of signal, from low intensity (blue) to high intensity (white). 
Magnification x 5 
 
Distribution of THIs Distribution of 4811 ion 
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Fig.65 Zoom of relevant section of mass spectrum showing highest intensity of 
unknown ion 4811 
 
5.3.5. Direct comparison of TASTPM and wild type brain sections on the 
same slide 
5.3.5.1. 12 month TASTPM and Wild Type sections on same slide for 
comparison 
Coronal sections of brains from both TASTPM and wild type mice were MALDI 
imaged on the same slide for direct comparison. Both the 4811 and 7635 
peptides were seen in TASTPM sections, neither was detected in wild type 
sections (Fig.66) 
 
 
 
Fig.66 MALDI Images of 12 month old TASTPM (bottom 3) and wild type (top 
3) brain sections showing an optical image with the THIs (where present) 
Distribution of THIs Distribution of 4811 ion 
Distribution of 7635 ion 
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depicted as white spots, also the distribution of the 4811 and 7635 ions and 
their localisation to the THI regions. Scaling bars indicate intensity of signal, 
from low intensity (blue) to high intensity (white). Magnification x 5 
 
5.3.5.2. 18 month TASTPM and Wild Type sections on same slide for 
comparison 
Coronal sections of brains from both TASTPM and wild type mice were MALDI 
imaged on the same slide for direct comparison. Both the 4811 and 7635 
peptides were seen in TASTPM sections, neither were detected in wild type 
sections (Fig.67) 
 
 
 
Fig.67 MALDI Images of 18 month old TASTPM (bottom 3) and wild type (top 
3) brain sections showing an optical image with the THIs (where present) 
Distribution of THIs Distribution of 4811 ion 
Distribution of Aβ 1-40 
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depicted as white spots, also the distribution of the 4811 ion and its localisation 
to the THI regions. Also shown is a visualisation of amyloid plaques detected by 
the presence of Aβ 1-40 in the TASTPM sections. Scaling bars indicate 
intensity of signal, from low intensity (blue) to high intensity (white). 
Magnification x 5 
 
From the findings above, the 4811 peptide (and the 7635) are well localised to 
the THI regions, as well as giving a stronger signal the more developed the THI 
regions are. It is possible that one or both are linked to the underlying 
processes which cause the development of these lesions. Identification of the 
unknown peptides could provide valuable information about not only the THI 
regions, but of amyloid pathology in general.  
 
In an effort to identify the 4811 and 7635 peptides, LCM was used to isolate 
and dissect out the THI regions, extraction procedures were then used to 
dissolve the contents and LC-MS was performed to attempt to identify the 
components. LC-MS was used as it is much more sensitive than MALDI so the 
chances of identifying a very small amount of a molecule are much greater. 
 
5.3.6. Further analysis of components of THI regions isolated by LCM 
5.3.6.1. MALDI Analysis of LCM samples 
MALDI analysis of the THI regions isolated by LCM was able to identify Aβ 1-
38, 1-40 and 1-42 along with the unknown peptide 4811. MS/MS was 
attempted on the 4811 fragment but no signal was detected. A tryptic digest of 
the sample was performed and whilst fragments of the amyloid peptides were 
observed and identified, nothing was observed or identified as a fragment of the 
4811 peptide. 
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5.3.6.2. LC/MS Analysis of LCM samples 
LC/MS analysis of THI regions isolated from TASTPM brain sections by LCM 
allowed identification of a number of proteins localised within the THI regions. 
These were APP, Glial fibrillary acidic protein, myelin basic protein 
apolipoprotein E precursor and secretogranin. The unknown peptide 4811 was 
found to be doubly charged and thus have an actual mass of 9622Da, however 
it could not be identified. The unknown peptide with mass 7635Da could not be 
identified either. 
 
 
5.4. Discussion 
The visualisation of amyloid plaques in brain sections from transgenic AD mice 
by MALDI MS Imaging has been reported before (Rohner et al., 2005; Stoeckli 
et al., 2006), but this is the first report in TASTPM mice. One of the aims of this 
research was to visualise the distribution of Aβ 1-40 and Aβ 1-42 in plaques in 
transgenic mouse brains. One finding of previous studies was that Aβ 1-40 was 
diffusely spread in different areas of the brain, whereas Aβ 1-42 was more 
confined to the centre of the denser plaques.  
 
Tryptic digests of applied and endogenous amyloid peptides followed by MALDI 
MS Imaging has not been reported before. It was also observed that, in the 
case of frozen sections with applied amyloid peptide the endogenous amyloid 
peptide is detectable but because it is present at lower concentrations than the 
applied amyloid peptide, it is difficult to visualise in an image. However, 
following trypsin digestion, (especially for 24 hours), endogenous amyloid 
fragments were easily observable on tissue sections treated with trypsin only, in 
some cases overall signal was stronger than on sections where amyloid had 
been applied. The trypsin digestion thus appears to make more amyloid 
fragments available for detection by MALDI than undigested amyloid on 
untreated sections. It is possible that, due to the aggregated nature of amyloid 
plaques, not all amyloid peptides are available for ionisation by the MALDI 
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laser. Thus, when the aggregated structure is broken down by the trypsin 
digest, the resulting fragments are much more easily ionised, resulting in a 
much stronger MALDI signal. 
 
In the case of the dewaxed formalin-fixed sections, it was observed that 
following dewaxing, ions were generated and detected from the tissues. 
Applied amyloid peptide was detected, along with amyloid fragments following 
tryptic digests. The tryptic digests of the dewaxed sections without any amyloid 
applied showed some encouraging results. In the initial 1 and 24 hour trypsin 
digests (Figs.46 and 47), Aβ 17-40 fragment could be detected on the dewaxed 
sections. However this was not found when the experiment was repeated. The 
initial detection of Aβ 17-40 from the tryptic digests of the dewaxed sections 
suggests that the method could be used to generate information from fixed 
sections. Further refinement of the techniques is required to ensure 
reproducibility. Varying the trypsin concentration, the solutes used, the method 
of application and incubation are all parameters that need refining. Several pilot 
studies have been carried out (Lemaire et al., 2007; Ronci et al., 2008). 
Attaining a suitable, reliable and robust method would allow the analysis of 
extensive libraries of tissue samples, which are a source of vast quantities of 
clinical and biological information for proteomic investigation. 
 
In the comparison between manual spray matrix application and the ImagePrep 
automated system, results from the 4811 peptide indicated that overall signal 
intensity was better with the manual spray method. A potential problem with 
manual spray can be delocalisation of peptides/proteins of interest, caused by 
over-wetting of the tissue during matrix application. This gives rise to apparent 
signal from areas where none of the detected molecule is present. In the same 
example, the ImagePrep gave much less compound delocalisation than manual 
spraying. Looking at the overall picture showed that as well as better overall 
signal strength, many different compounds were detected with the manual 
spray method than with the ImagePrep. Thus, according to our data, if signal 
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detection is more important than exact location, manual spray matrix 
application is preferable. Whereas, if exact localisation of signal is paramount, 
ImagePrep application is the preferred. 
 
It was during this comparison, that the initial discovery took place of the 
unknown peptide which was highly localised in the THI regions. 
Further study of THI regions from TASTPM and wild type animals of different 
ages confirmed the co-localisation of the THIs and the unknown peptide. 
Furthermore, as THI size and number increased, so did the intensity of the MS 
peak for the unknown peptide. In older wild type mice, where THIs (if present) 
were small, the intensity of the peak for the unknown peptide was between 300 
and 600. In the TASTPM mice at 12 months, where THIs were larger and more 
numerous, peak intensity reached 14000. In the 18 month TASTPM mice, 
where THIs were even more developed and numerous, maximum peak 
intensity reached 20000 (Fig.58).  
 
The importance and role of this unknown peptide is of significant interest, as 
the THIs represent a neurodegenerative process which involves amyloid 
plaques, neuroinflammatory mediators (astrocytes and macrophages) and iron 
accumulation (Evans et al., 2007; Howlett et al., 2008), all of which occur in 
human AD. Many mouse models of AD do not show any neurodegeneration, 
thus any data from this model on the underlying pathology could be valuable in 
furthering our understanding of human AD. It should be noted that, although the 
pathology has similarities with human AD, it is by no means identical. Human 
AD is much more complex than simply amyloid plaques, as outlined in the 
introduction to this thesis, there are many other factors which have an effect. 
The human mutant genes which are expressed in the TASTPM mouse cause 
early onset AD, which can be very different to sporadic AD and only causes 
less than 1% of cases. Due to this any information gleaned from studying the 
THIs should be interpreted with caution. 
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Following THI isolation using LCM, LC/MS revealed the identities of several 
different proteins present in the THI regions. These included APP and the 
different Aβ peptides as expected, as the THIs are associated with amyloid 
plaques. Glial fibrillary acidic protein is a glial cell marker and may be increased 
as a consequence of glial cell proliferation due to neurodegeneration. Myelin 
basic protein is also to be expected, as some neurons will be contained in the 
THI regions, despite the overall neurodegeneration. The presence of 
apolipoprotein E precursor is interesting, as the ε4 allele is known to be a risk 
factor for late onset AD in humans (Strittmatter et al., 1993). The fact that we 
see this protein may mean that some perturbation of lipid metabolism is 
involved in the formation of the THIs, as apolipoprotein E is known to be 
involved in triglyceride and cholesterol homeostasis (Davignon et al., 1988a). 
The detection of secretogranin is likely not significant as it performs multiple 
roles throughout the CNS. 
 
In summary, this study has shown several potential applications of MALDI MS 
Imaging in proteomics research which may become increasingly prevalent as 
the technology becomes more widely available. Whether the study is to 
determine the distribution of endogenous components, investigating old tissue 
libraries in novel ways or for the discovery of novel biomarkers of pathology, 
MALDI Imaging has the potential to be a very useful tool in years to come. 
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Chapter 6. Final Discussion 
 
 
During the course of this thesis, the brain of the TASTPM mouse has been 
investigated using 1H MRS and MALDI Imaging. The experiments undertaken 
were carried out with several aims in mind.  
 
The first was to continue the search for a reliable biomarker of disease 
progression in AD (or at least the TASTPM mouse), which, if found could be 
useful in the diagnosis and monitoring of the disease. 
 
The second was to evaluate the TASTPM mouse as a model for AD, and to 
compare MRS results with results from other models of AD. Any reproducible 
differences observed could potentially be exploited in preclinical testing, aiding 
the drug discovery process. 
 
 
The third was to investigate any regional proteomic differences in TASTPM 
mice using MALDI Imaging. Any differences would have the potential to further 
our understanding of the underlying pathology behind AD. 
 
In the search for a biomarker, a marker of disease progression was elusive. We 
found age x genotype interactions in vitro with choline and in vivo with 
glutamate, but neither of these interactions was present in both studies. It is 
possible they might be used to plot disease progression in association with 
other measurable factors, but levels fluctuated over time in both cases, 
meaning using them separately to accurately map what stage of pathology a 
TASTPM mouse is in would be impossible. Thus, though we found parallels 
both with human AD and previous animal studies, the search for an AD specific 
biomarker goes on. 
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In our evaluation of the suitability of TASTPM mice as a model of AD we found 
a number of cerebral metabolic differences between TASTPM mice and the 
wild type base strain. These might be used as biomarkers of pathology in 
further study of the TASTPM mice. 
 
 
In vitro we found whole brain differences in levels of MI, succinate, choline, 
creatine and several lipid functional groups. In all cases except choline there 
was no statistically significant change with age in the disease group during the 
time when amyloid plaques are being formed. Therefore MI, succinate, creatine 
and the observed lipid functional groups may be markers of AD in this model, 
without being linked to disease progression. It is possible choline levels are 
related to disease progression, but the fluctuating levels observed would make 
it difficult to accurately estimate disease progression from choline levels alone. 
There were possible similarities with human AD, where increased MI has also 
been observed (Kantarci et al., 2000; Dixon et al., 2002; Ackl et al., 2005; Zhu 
et al., 2006) and linked with gliosis and membrane dysfunction (Lazeyras et al., 
1998). Decreased succinate may be indicative of impaired neuronal energy 
metabolism, another effect seen in human AD (Valla et al., 2001; Zhu et al., 
2004; Moreira et al., 2007). The increased creatine levels observed, while not 
linked with human AD, have been shown to correlate with cognitive decline in 
older humans (Ferguson et al., 2002). The cholinergic differences, along with 
differences in lipid functional groups could indicate perturbation of phospholipid 
metabolism or membrane changes, altered phospholipid metabolism has also 
been observed in human AD (Kuo et al., 1998; Roher et al., 1999; Sparks et al., 
2000). 
 
In vivo we observed differences in NAA, glutamate, Glx, MI, PC, T1 values and 
exploratory behaviour. Differences were compared with previous in vivo work in 
other transgenic AD mice, along with our own in vitro work. Lower NAA levels in 
TASTPM mice are indicative of neuronal damage/death (Demougeot et al., 
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2004), possibly a consequence of the formation of THIs. Lower NAA levels 
have been linked to neurodegeneration and have been observed in many 
cases in human AD (Kantarci et al., 2000; Dixon et al., 2002; Chantal et al., 
2004; Ackl et al., 2005). Decreased glutamate and Glx may indicate neuronal 
metabolic deficiency, a symptom of AD (Valla et al., 2001; Zhu et al., 2004; 
Moreira et al., 2007). Changes in MI levels and choline containing compounds 
were discussed above.  
 
The observed changes in NAA, glutamate and MI are in agreement with other 
in vivo studies on different transgenic AD mice (Dedeoglu et al., 2004; 
Marjanska et al., 2005; von Kienlin et al., 2005), with all in agreement regarding 
reduced NAA and glutamate, but only one of these other mouse models 
showed increasing MI (the APP-PS1 mouse),- (Marjanska et al., 2005). The 
differences observed with choline levels were not seen in other studies, the 
possible link to altered lipid homeostasis (along with evidence from in vitro 
changes in lipid functional groups) shows TASTPM mice may exhibit another 
hallmark of human AD not exhibited by the other mouse models. 
 
The metabolic differences observed in vitro and in vivo showed similarities, 
such as MI and choline differences, but also several differences, such as no 
changes in glutamate or NAA in vitro. A possible explanation for this lies in the 
use of whole brain extracts for the in vitro study, as opposed to a voxel focused 
on areas known to suffer pathological changes. Localised metabolic differences 
may have been masked by the use of whole brains in the extract study.  
 
Shorter T1 values in TASTPM mice may be due to alterations in brain water 
content (Bell et al., 1987; Besson et al., 1989). The alterations may be due to 
large amounts of amyloid disrupting normal brain osmoregulation, the effect 
becomes more pronounced with age, so may be linked to increasing amyloid 
deposition. 
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The changes in exploratory behaviour observed became most pronounced in 
older mice, meaning this effect may be in some way dependent on amyloid 
deposition. It may also be due to the increasing size of the THI regions, 
meaning administration of an amyloid lowering agent would have no effect on 
behaviour. 
 
The most striking findings of the MALDI investigation are the presence of the 
two unknown peptides localised to the THI regions in the TASTPM (and older 
wild type) mice. Efforts to identify these peptides are ongoing and, if 
identification can be achieved it may provide valuable information concerning 
the underlying pathology behind these lesions, 
 
Thus, we have advanced our knowledge of the TASTPM mouse and shown 
parallels between the TASTPM mouse other transgenic mouse models and 
human AD. The differences observed in vivo are most promising, as they would 
allow repeat investigation of the same mouse over a course of therapeutic 
intervention. Further study using amyloid lowering agents would allow 
observation of whether normalisation back to wild type values occurs in any of 
the metabolites, T1 or behavioural differences. If this was to occur then the 
TASTPM may be a useful tool in preclinical screening of amyloid-lowering 
agents. 
 
The comparison of in vivo MRS data between TASTPM and other strains of 
transgenic AD model must be done carefully, as in all the mice tested the 
protocols used varied, as did the MR scanners and peripheral equipment, as 
well as the ages of the mice. MRS voxel placement and size was different in all 
mice, for example. Thus the only way to be fully confident of comparisons 
would be to use the same equipment and the same protocols to obtain data 
from mice from the different strains, all of the same age, something which was 
beyond the scope of this thesis. 
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Another limitation of the study is that we found quite large discrepancies 
between the MRS data from in vitro and in vivo scans from brains of the same 
strains of mice. While this may be due to the more focused nature of the in vivo 
scans, it may also be that these mice do not have fully stable or predictable 
levels of the various metabolites investigated over their lifespans. If this were 
the case then attempting to observe brain metabolites by MRS as a way of 
measuring the action of amyloid-lowering agents would be problematic at best. 
One way to test this would be to carry out further extract studies on dissected 
brains of TASTPM mice to see if we detect regional differences, as have been 
performed on other transgenic AD mice (Salek et al., 2010). If we see similar 
changes to the in vivo work in areas such as the hippocampus and thalamus 
then we can be more confident of the robustness of the TASTPM mouse as a 
model for preclinical testing. 
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